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Abstract

SYNTHETIC CANNABINOIDS VERSUS DELTA-9-TETRAHYDROCANNABINOL:
ABUSE-RELATED CONSEQUENCES OF ENHANCED EFFICACY AT THE
CANNABINOID 1 RECEPTOR
By Travis Grim, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2015
Major Director: Aron H. Lichtman, Ph.D., Department of Pharmacology and Toxicology

In the past ten years, synthetic cannabinoids (SC) have emerged as drugs of abuse. The
first generation of these were research chemicals used to elucidate the existence and function of
the cannabinoid receptor 1 (CB1). Unlike 9-tetrahydrocannabinol (THC), many SCs are
associated with serious health complications and death. One way in which THC and SCs differ
lies with their enhanced potency and efficacy at the CB1 receptor. Accordingly, much lower
concentrations of SCs are needed to elicit their THC-like effects, and many of these ligands are
able to stimulate far more activity per receptor than THC. No current methods exist to measure
efficacy at the CB1 receptor in vivo, and the abuse-related properties of SC cannabinoids are not
well explored. Here, we utilized CB1 wild type (WT), heterozygous (HET), and knockout (KO)
mice, which possess 100%, 50%, and 0% of normal CB1 expression. By employing CB1 ligands
which differ in efficacy we have developed a method to explore the relationship between
efficacy and the ability to produce cannabimimetic (catalepsy, hypothermia, and antinociception)
xi

effects when CB1 expression was reduced by half. Additionally, the intracranial self-stimulation
procedure (ICSS) was utilized to investigate the effects of enhanced efficacy at CB1 upon reward
processes using representative SC CP55,940. As predicted, the potency shift between WT and
HET mice inversely correlated with the efficacy of the test drug for both hypothermia and
antinociception, but not catalepsy. This efficacy stratification was correlated with the agoniststimulated [35S]GTPS binding assay, demonstrating this model as an effective tool to ascertain
in vivo efficacy differences at CB1. In ICSS, CP55,940 elicited only rate-decreasing effects
acutely, although tolerance developed following repeated dosing. No evidence for spontaneous
or rimonabant-precipitated withdrawal was observed. Together, these data indicate that highly
efficacious cannabinoid ligands require few receptors to produce cannabimimetic effects, and
that the model provides an effective means to quickly ascertain differences in efficacy. SCs
continue to be a public health concern, and as they emerge their similarities to known
cannabimimetic agents can be examined both in terms of efficacy and abuse-related effects.
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Chapter 1: Introduction

1.1

Development and synthesis of cannabinoids as research tools
Written records and archeological evidence document that Homo sapiens have utilized

the Cannabis sativa and Cannabis indica plants for recreational and medicinal purposes for at
least 5000 years (Adrian, 2015). These uses of cannabinoids continue to the present day.
Although inhalation of smoked cannabis or oral consumption produces well-described effects,
including somnolescence (Belendiuk et al, 2015; Tart, 1970), euphoria as well as dysphoria,
visual and auditory distortions of perception, elevated heart rate (Isbell et al, 1967; Weil et al,
1968), increased blood pressure, and impaired cognition (Waskow et al, 1970), the mechanisms
by which cannabis (or marijuana) exerted its psychoactive effects were largely unknown until its
chief primary psychoactive constituent, 9-tetrahydrocannabinol (THC), was discovered. THC
was first isolated in an impure form and its structure postulated more than seven decades ago
(Wollner et al, 1942). In 1964, THC was again isolated from Cannabis sativa in a more pure
preparation (Gaoni and Mechoulam, 1964). Subsequent work by Mechoulam showed THC
extracted from marijuana and marijuana itself engendered similar psychoactive effects in humans
(Mechoulam and Gaoni, 1967), and further examination of the composition of Cannabis sativa
identified THC as a major component of marijuana (Mechoulam, 1970). The phytocannabinoid
cannabidiol was also discovered at this time (Mechoulam et al, 1970; Mechoulam and Shvo,
1963), but unlike THC, it did not possess high affinity for CB1 or CB2 (Showalter et al, 1996),
1

lacked cannabimimetic activity (Bloom et al, 1978; Chesher et al, 1973; Pertwee, 1972), and
failed to substitute for THC’s discriminative stimulus (Bueno et al, 1976; Järbe et al, 1977).
Although these studies taken together implicated THC as the primary psychoactive ingredient of
marijuana, they raised the following question: how was THC evoking its pharmacological
effects?
Initial studies proposed various mechanisms to explain the pharmacological effects of
THC such as plasma membrane perturbation or enzymatic interactions (Laurent and Roy, 1975;
Roth and Williams, 1979). However, the concentrations of THC needed to achieve these effects
were in the mid to upper micromolar range and far exceed the low or sub mg/kg doses sufficient
to produce psychoactive effects in humans (Mechoulam and Gaoni, 1967). Promising
mechanistic experiments conducted by Howlett and colleagues identified THC as a potent
inhibitor of adenylyl cyclase. The findings that pharmacological blockade of a variety of
receptors, including secretin, alpha adrenergic, serotonergic, and mu-opioid receptor antagonists
(Howlett, 1984) did not prevent THC-induced inhibition of adenylyl cyclase suggest that a
discrete cannabinoid receptor might exist and that it likely did not exert its pharmacological
effects through the proposed disturbance of plasma membranes (Howlett and Fleming, 1984).
Early radioligand displacement studies employing [3H]trimethylammonium-8tetrahydrocannabinol ([3H]TMA) and unlabeled THC in rat brain homogenates strongly
suggested discrete binding sites in a stereoselective manner, though potent displacement by
cannabinoids with weak affinity for THC binding sites called into question the binding
specificity of [3H]TMA and precluded definitive identification of a discrete cannabinoid receptor
(Nye et al, 1985). Fortunately, a series of potent cannabinoid ligands synthesized by Pfizer
utilizing a bicyclic backbone structure provided highly useful tools for structure activity
2

relationship (SAR) and radioligand binding studies. A notable compound produced from these
efforts was CP55,940, which was shown to behave similar to THC in inhibition of adenylyl
cyclase (Howlett et al, 1988). This compound was subsequently radiolabeled with tritium and
used to characterize the putative cannabinoid receptor(s) (Devane et al, 1988). [3H]CP55,940
was utilized in autoradiography studies to characterize the distribution of cannabinoid receptor
binding sites in the CNS (Herkenham et al, 1990). Proof of the existence of specific cannabinoid
receptors culminated with the cloning of the CB1 (Matsuda et al, 1990) and CB2 (Munro et al,
1993) receptors, conclusively providing the sites of action by which cannabinoids exert their
effects. The discovery of cannabinoid receptors would not have been possible without the
synthesis of novel cannabinoids.
Other cannabinoids were developed for basic research as well as for potential therapeutic
development. The classical cannabinoids possess the tricyclic structure characteristic of THC and
include compounds such as HU series (Mechoulam et al, 1990). The alkylindole class of
cannabinoids, including the JWH series (Aung et al, 2000) and the widely adopted WIN55,212-2
(Kuster et al, 1993), contained a great variety of backbone structures capable of binding and
activating the CB1 receptor. Similar to THC, many of these synthetic cannabinoids (SC) bound
CB1 and CB2 (e.g. CP55,950; (Thomas et al, 1998), but the advent of the highly CB1 selective
antagonist SR141716A (or rimonabant) (Rinaldi-Carmona, 1994) revealed CB1 in humans was
the mechanism by which marijuana evoked its psychoactive effects (Huestis et al, 2001).
Rimonabant also antagonized the in vivo subjective effects of CP55,940, WIN55,212-2, and
THC in rats trained to discriminate THC from vehicle in the drug discrimination assay (Järbe and
Henriksson, 1974; McMahon and Koek, 2007; Wiley et al, 1995) suggesting a similar
mechanism of action between rodents and man. Finally, radiolabeled [3H]SR141716A was used
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to validate further that the majority of cannabinoid receptors in brain autoradiographs was CB1
(Rinaldi-Carmona et al, 1996), cementing the CB1 as the major cannabinoid receptor in the
central nervous system. Cannabinoid ligands proved to be a promising molecules for numerous
potential therapeutic indications, such as neuropathic pain, weight loss, and anxiolysis; thus, the
push to synthesize and optimize new cannabinoids for these purposes continued. The
cannabinoid field began to amass knowledge of hundreds of CB1 ligands, and the SAR became
very well understood for numerous scaffolds. Unwittingly, scientific publications that described
the chemical synthesis of these drugs and their pharmacology set the stage for CB1 agonists to be
utilized for illicit purposes.
1.2

Pharmacological actions of marijuana, THC, and synthetic cannabinoids
Later efforts provided a more thorough investigation of the pharmacological effects of

both marijuana and isolated THC in man and laboratory animals. Cardiovascular effects
measured included elevated heart rate and increased blood pressure in human subjects (Isbell et
al, 1967; Kochar and Hosko, 1973; Tashkin et al, 1973; Weil et al, 1968). The psychotropic
effects in humans included subjective high (Weil et al, 1968), euphoria (Isbell et al, 1967),
relaxation (Tart, 1970), memory impairments (Clark et al, 1970; Tinklenberg et al, 1970),
disruption of cognitive tasks (Weil et al, 1968), and changes in temporal perception (Clark et al,
1970; Tinklenberg et al, 1970). Both anxiogenic (Zuardi et al, 1982) and anxiolytic (Fabre and
McLendon, 1981) effects were also observed. In animal subjects, the subjective effects of
cannabinoids were assessed utilizing the drug discrimination procedure, finding that generally,
most cannabinoids substituted for THC and vice versa (Hruba et al, 2012; Järbe et al, 2014;
McMahon, 2006; Wiley et al, 1995, 2013, 2014). In vivo, cannabinoids in rodents generally elicit
hypolocomotion, hypothermia, catalepsy, and antinociception (Compton et al, 1992; Fan et al,
4

1994; Little et al, 1988a; McLaughlin et al, 2013), a constellation of effects generally referred to
as the cannabinoid tetrad. Memory impairments (Ferrari et al, 1999; Heyser et al, 1993;
Nakamura et al, 1991), anti-allodynic properties (Conti et al, 2002; Herzberg et al, 1997), and
anxiety-related properties (Genn et al, 2004; Haller et al, 2002) were also commonly observed.
Abuse-related behaviors represented a notable discrepancy between humans and laboratory
animals.
1.3

Emergence of synthetic cannabinoids as drugs of abuse
With the growing scientific literature describing the synthesis of research compounds that

bound CB1 and produced cannabis-like effects, it should not be altogether surprising that many
of these ligands eventually appeared as drugs of abuse. Indeed, John W. Huffman, the progenitor
of the JWH cannabinoid series, was quoted in a Los Angeles Times interview saying “I always
had a hunch that someday somebody would say: ‘Hey, let’s try smoking them.’ And lo and
behold, that’s what happened” (Zucchino, 2011). Beginning in 2004, small packages of inert
plant material imbued with unknown cannabimimetic agents labeled “not for human
consumption” began to emerge (UNODC, 2014). Despite this disclaimer, these preparations with
names such as “K2” and “Spice” were imbibed usually via smoking and soon precipitated
unexpected health-related consequences. Ten cases of seizures were reported in Sweden in 2007
(EMCDDA, 2014), and soon after these incidents formal monitoring process of these abused
preparations began. These events also spurred research to identify the chemical components that
might be responsible for producing this alarming phenotype. The plant material itself was
determined to be largely inert, serving primarily as a vehicle (EMCDDA, 2014). CP47,497
(Melvin et al., 1993), cannabicyclohexanol (Melvin et al., 1993), and JWH-018 (Wiley et al,
1998) were the first SCs positively identified in several different “Spice” products (Auwärter et
5

al, 2009). Their detection led to emergency scheduling of CP47,497, cannabicyclohexanol,
JWH-018, JWH-073, and JWH-200 by the Drug Enforcement Administration (DEA) (The Drug
Enforcement Administration, 2011), which in turn led the sellers to circumvent the law by using
a new variety of SCs in their preparations. Subsequent emergency scheduling in 2013 of the SCs
UR-144, XLR-11, APINACA, and AKB48 (The Drug Enforcement Administration, 2013),
further actions in 2014 to schedule PB-22, 5F-PB-22, AB-FUBINACA, and ADB-PINACA (The
Drug Enforcement Administration, 2014), and the more recent scheduling of AB-CHIMINACA,
AB-PINACA, and THJ-2201 (The Drug Enforcement Administration, 2015) highlight the
difficulty in keeping pace with the emergence of new SCs. Especially alarming is the emergence
of compounds such as XLR-11, synthesized de novo with unknown pharmacology and
toxicology (Center for Disease Control, 2013). This evidence suggests that newer SCs are likely
produced by clandestine chemists with knowledge concerning structure activity relationships,
given commonplace modifications, such as the addition of biosteric fluorine moieties that
typically improve binding affinity at the CB1 receptor (Banister et al, 2015). Each new
cannabinoid structure also requires development of new methods of detection (Scheidweiler and
Huestis, 2014), further complicating assessment of the risk to human health.
Numerous case reports point to potential health risks associated with SC use. Heart and
kidney failure, respiratory depression, and seizures are repeatedly mentioned in case reports, as
well as psychiatric indications, such as acute onset psychosis, anxiety, and cognitive impairment
(Table 1). Alarmingly, a subset of synthetic cannabinoids has been linked to several deaths
(Trecki et al, 2015). These reports are in marked contrast to THC, which has not been linked to a
direct cause of death, despite its prolonged and high incidence of use. A large scale survey
determined the risk of an emergency department visit is approximately 30 times higher for SCs
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than for THC (Winstock et al, 2015), corroborating the trends seen in the plentiful case reports.
The continued emergence of new SCs contributes to public health concerns of these drugs, but
the underlying reasons for their higher health risk compared to THC remains poorly understood.
Given the diversity in structures of abused cannabinoids, one explanation for these adverse
events could be a non-CB1 target which produces toxicity either through direct action of the
parent compound or via metabolites. Alternatively, notable distinctions between THC and SCs
are their abilities to bind and activate the CB1 receptor. SCs are often more potent and more
efficacious than THC (for review see Howlett, 2005). Thus, increases in the magnitude of CB1
stimulation combined with high doses of SCs may potentially contribute to their toxic effects. In
contrast, doses of THC obtained from marijuana consumption and its relatively low efficacy at
the CB1 may be insufficient to elicit these actions. Notable toxicological effects of high affinity,
high efficacy SCs are consistent with of CB1 expression in the relevant organs, such as the heart
lungs, kidneys, and vast abundance in the central nervous system (CNS) (Galiègue et al, 1995),
though a causal link between increased efficacy and the resulting deleterious health effects
remains to be established. In order to evaluate the degree to which potency and/or efficacy at the
CB1 receptor contribute to the adverse effects of SCs, an efficient method of assessing these
measures would be a helpful tool for both basic research and public health. The effects of SCs on
CB1 in the CNS represent an important aspect to study given the large number of psychiatric
effects associated with their use.
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JWH-019

Health effects
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driving impairment
driving impairment
driving impairment
memory impairment, inappropriate
giggling
driving impairment, slurred speech,
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driving impairment, slurred speech,
confusion
withdrawal, seizures
seizure
Seizure
seizure
seizure
seizure
delirium
death
respiratory depression
sudden cardiac death
sudden death
acute cerebral ischemia, stroke
acute kidney injury
schizophrenic symptoms
seizure
driving impairment, hypothermia,
rigid muscle tone
xerostomia, chest pain, tachycardia
xerostomia, chest pain, tachycardia
mutilation, amputation
impaired driving, dizziness,
somnolescence
impaired driving, dizziness,
somnolescence
impaired driving, dizziness,
somnolescence
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JWH-122
JWH-210
JWH-307
MAM-2201
UR-144
"Spice/K2"
XLR-11
AM-2201
JWH-018
JWH-081
JWH-122
JWH-250
RSC-4
AM-2201
JWH-122
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"Spice"
JWH-018

JWH-018
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impaired driving, dizziness,
somnolescence
impaired driving, dizziness,
somnolescence
impaired driving, dizziness,
somnolescence
toxic hepatitis
acute cerebral ischemia
driving impairment
driving impairment
driving impairment
driving impairment
driving impairment
driving impairment
diffuse pulmonary infiltrates
diffuse pulmonary infiltrates
diffuse pulmonary infiltrates
oliguric acute kidney injury
acute cerebral ischemia, stroke
mild agitation, laugh attacks, panic
attacks, vomiting, myoclonic
jerking
mydriasis, aniscoria, retrograde
amnesia, somnolescence
mydriasis, mild tachycardia,
hypokalemia, leukocytosis
seizures, difficulty breathing
mild agitation, laugh attacks, panic
attacks, vomiting, myoclonic
jerking
mild agitation, laugh attacks, panic
attacks, vomiting, myoclonic
jerking
mydriasis, aniscoria, retrograde
amnesia, somnolescence
mydriasis, mild tachycardia,
hypokalemia, leukocytosis
seizures, difficulty breathing
seizures, difficulty breathing
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Sheikh et al., 2014
Takematsu et al., 2014
Tuv et al., 2014

Alhadi et al., 2013

Bhanushali et al.,
2013
Freeman et al., 2013
Hermanns-Clausen et
al., 2013

UR-144
AM-2201
AM-694
JWH-0122
JWH-018
JWH-073
AM-2201
"Mr. Nice Guy"
THC
AM2201
JWH-073
XLR-11
AM-2201
JWH-081
JWH-122
JWH-210
JWH-250
"K2"
"Spice"
"K2"
"K2"
"Spice"
"K2"
JWH-018
JWH-018
"K2"
JWH-018
JWH-073
JWH-018
JWH-073

"Spice Gold"

mydriasis, aniscoria, retrograde
amnesia, somnolescence
cannabinoid hyperemesis
cannabinoid hyperemesis
cannabinoid hyperemesis
cannabinoid hyperemesis
cannabinoid hyperemesis
seizures
withdrawal not alleviated by THC,
anxiety, cramps, loss of appetite
withdrawal not alleviated by THC,
anxiety, cramps, loss of appetite
psychiatric complications, death,
mutilation
psychiatric complications, death,
mutilation
acute kidney injury
driving impairment
driving impairment
driving impairment
driving impairment
driving impairment
catatonic, non-responsive to verbal
or painful stimuli
aggression, tachycardia
emesis, tachycardia
respiratory depression
psychosis
suicidal ideation
respiratory depression, tachycardia,
fever
seizure, tachyarrhythmia
myocardial infarction
anxiety
anxiety
tachycardia, unresponsiveness
tachycardia, unresponsiveness
anxiety, nocturnal nightmares,
sweating, nausea, tremors,
headache
10

Hopkins and Gilchrist,
2013

McQuade et al., 2013
Nacca et al., 2013

Patton et al., 2013

Thornton et al., 2013
Yeakel and Logan,
2013

Cohen et al., 2012
Faircloth et al., 2012
Jinwala and Gupta,
2012
Peglow et al., 2012
Thomas et al., 2012
Tofighi and Lee, 2012
Lapoint et al., 2011
Mir et al., 2011
Schneir et al., 2011
Simmons et al., 2011

Zimmermann et al.,
2009

Table 1. A summary of case reports detailing the health effects linked to specific SCs detected in
abused preparations. Many earlier SCs were diverted research chemicals, while later generations
of “Spice” and “K2” preparations possessed SCs with novel structures and unknown
pharmacology.
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1.4

Structure activity relationships of synthetic cannabinoids.
Cannabinoid SAR studies used THC as a molecular scaffold to explore the effects of

structural modifications in producing cannabimimetic activity. As depicted in Figure 1, four
primary pharmacophores on the molecule were targeted for structural alterations: 1) alkyl chain
length at C-3, 2) the hydroxyl at the C-1 position, 3) the methyl at the C-9 position, and 4) the
“B” ring at the C-6 position. The earliest SAR studies explored the alkyl chain length and methyl
substitutions at the first position on the alkyl chain in producing static ataxia in dogs (Adams et
al, 1948a, 1948b), and found that 1ˊ,2ˊ-dimethyl-heptyl chains were the most potent. Martin and
colleagues demonstrated that the alkyl chain length was an important determinant of in vivo
potency (Martin et al, 1999). Structural modifications of the dimethylheptylpyran backbone
elucidated the SAR of these highly potent cannabinoids (Razdan and Dalzel, 1976). Later work
by Mechoulam and would explored the stereospecificity of the dimethyl additions at the first
position of the alkyl chain, leading to the synthesis of HU-210, a highly potent synthetic
cannabinoid approximately 85 times more potent than 1-tetrahydrocannabinol to produce
subjective effects in rats (Mechoulam et al, 1988). Modifications to the hydroxyl at the C-1
position revealed a mechanism to convey CB2 selectivity via methylation of the hydroxyl
(Pertwee et al, 2000; Zitko et al, 1972) as measured in radioligand binding studies. The C-11
methyl group was determined to be nonessential for binding, but modifications, such as ketone
(nabilone) (Archer et al, 1977) or dimethyl hydroxyl (HU-210) (Mechoulam et al, 1988) groups
enhanced CB1 receptor binding affinity. Representative classical, tricyclic cannabinoids (Figure
2) demonstrated modifications at the aforementioned positions alongside THC. The
aforementioned structures utilized the tricyclic structure of cannabinoids, but work by chemists
from Pfizer utilized the bicyclic CP47,497 as the backbone structure to reveal the “B” ring as
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non-essential (Figure 3), while the other three pharmacophores continued to exert their predicted
effects on binding affinity to cannabinoid receptors (Melvin and Johnson, 1987; Melvin et al,
1993a).
The aminoalkylindole WIN55,212-2 was initially developed as a structural derivative of
pravadilone, a non-acidic, potent inhibitor of cyclooxygenase enzymes. Surprisingly,
WIN55,212-2 and pravadilone inhibited electrically-evoked mouse vas deferens contractions,
inhibited adenylyl cyclase, and possessed greater than expected antinociceptive properties (Bell
et al, 1991). WIN55,212-2 was later discovered to bind to cannabinoid receptors with nanomolar
affinity, which accounted for its unexpected in vivo and in vitro cannabimimetic activity, and it
failed to appreciably inhibit prostaglandin synthesis (D’Ambra et al, 1992). Ensuing studies
investigated the SAR of this new class of cannabinoid compounds. Much of the SAR work in
this series of compounds was performed in collaboration with John W. Huffman, who helped
established the amino portion of the aminoalkyl side chain could be eschewed for an alkyl chain,
thus resembling more closely the classical and non-classical cannabinoids (Wiley et al, 1998).
Important contributions were also made by Alex Makriyannis, who demonstrated common
pharmacological moieties between classical cannabinoids and the seemingly structurally
dissimilar aminoalkylindoles (Xie et al, 1995). The benzene ring was also discovered to be
nonessential (Figure 4), and from these modifications the JWH series was born including the
eventually abused JWH-018 and JWH-073 (Huffman, 1999; Huffman et al, 1994).
Other cannabinoid SAR studies searched for CB2-selective indoles and pyrroles for
therapeutic purposes, though many of these compounds retained appreciable affinity for the CB1
receptor (Frost et al, 2010). Once emergency scheduling events began (The Drug Enforcement
Administration, 2011), a rapid increase in clandestine synthesis of structurally unique
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cannabinoids began, resulting in myriad structures designed to maintain cannabimimetic effects
while evading legal restrictions and established assays of detection, accomplished by utilizing
small substitutions such as fluorination (Banister et al, 2015; Gatch and Forster, 2014).
Adamantylindoles, such as APICA and APINACA, became increasingly found in preparations
and were subsequently scheduled (Figure 5) (The Drug Enforcement Administration, 2013,
2014). Unlike the older generation of SCs, new SCs were synthesized to evade illegality and
generally lack the preclinical testing, which resulted in abused compounds that possessed
unknown pharmacodynamics, pharmacokinetics, and toxicology. To date, the relationship
between enhanced efficacy and potency at the CB1 receptor and the health risks remains
unexplored, though SCs generally possess much higher efficacy and affinity at the CB1 receptor
than THC.

14

Figure 1. The pharmacophores of THC were established via SAR studies. The alkyl chain at C-3
was determined to be an important determinant of both binding affinity and efficacy, with an
optimal chain length of 6-7 carbons. An addition of a dimethyl group at the first carbon of the
chain also improved binding affinity. Substitution of the C-1 or C-9 pharmacophores could
drastically change binding affinity at the CB1 receptor, while methylation of the C-1 hydroxyl
could enhance selectivity for the CB2 receptor. The B ring, specifically the oxygen at position 5
and the carbon at position 6, was determined to be nonessential via SAR work utilizing Pfizer’s
nonclassical, bicyclic cannabinoid series.
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Figure 2. Classical cannabinoids, based upon the structure of THC, were instrumental in
discovering the CB1 receptor. Researchers identified discrete cannabinoid binding in rat brains
utilizing the THC analogue 5´-trimethylammonium-8-tetrahydrocannabinol. HU-210,
synthesized by Mechoulam and colleagues, allowed investigation of the stereospecificity of
cannabinoids, strongly suggesting the presence of a discrete cannabinoid receptor. Likewise,
nabilone represents a series of structural modifications to improve binding affinity of THC,
notably the dimethyl substitution at the first carbon of the alkyl chain at C-3 and the ketone at C9.
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Figure 3. Nonclassical cannabinoids developed by Pfizer were instrumental in demonstrating the
B ring of classical cannabinoids as nonessential for cannabinoid receptor binding and
cannabimimetic activity. CP47,497 and its C-8 homologue cannabicyclohexanol were among the
first synthetic cannabinoids detected in abused “Spice” and “K2” formulations. CP55,940
emerged as an important research tool to explore cannabinoid pharmacology in vitro and in vivo,
and contributed to the discovery of cannabinoid receptor distribution in the CNS via
autoradiography studies.
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Figure 4. The serendipitous discovery of the indole backbone based upon the structure of the
non-steriodal anti-inflammatory drug pravadilone led to the synthesis of many cannanabinoids.
WIN55,212-2 was among the first of the cannabimimetic indoles and became popular as a
research tool in part due to its high efficacy at the CB1 receptor. Later SAR experiments by John
W. Huffman determined the benzene ring of the indole to be nonessential for cannabimimetic
activity as demonstrated by JWH-018 and JWH-073. Along with many other cannabinoids from
the JWH series, JWH-018 and JWH-073 were eventually detected in abused preparations.
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Figure 5. Following the scheduling of many of the first wave of abused synthetic cannabinoids,
a huge variety of structures were detected via toxicological screens following emergency
department visits. AM-2201 and XLR-11 represented fluorinated analogues of the scheduled
JWH-018 and UR-144, respectively, and reveal how small structural modifications were made to
sidestep scheduling of their parent compounds. APICA and APINACA, similar to the JWH
series, contained the indole backbone, but the addition of the adamantyl moiety instead of the
napthyl exhibit the large variety of cannabinoid structures present in the modern abused
preparations.
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1.5

Determination of efficacy utilizing receptor theory
Modern pharmacology was born of physiologists attempting to empirically determine the

underpinnings of drug interactions with the tissues they acted upon. The concept of the receptor
was a theoretical “receptive substance” for a given compound as described by Langley (Langley,
1905). Clark later expanded this treatment by Langley to incorporate the law of mass action,
defining explicitly the relationships between the amount of ligand present and the amount of
available receptors. Briefly, the ligand-receptor complexes associate and dissociate at a rate
proportional to the number of complexes (Stephenson, 1956). Thus, at equilibrium (or
occupation of half of the available receptors) one may determine the affinity of the ligand. Clark
applied this concept to relate the number of ligand-receptor complexes to the response of the
tissue, generating the familiar hyperbolic dose-response relationship (Clark, 1926, 1927).
However, Clark also assumed the fractional occupancy was proportional to the tissue response,
which later experiments would demonstrate to be a false assumption. Subsequently, Stephenson
showed that compounds varied in their intrinsic activity, or efficacy, at a given target
(Stephenson, 1956). This conceptual frame work led to the definition of a partial agonist as “low
efficacy compounds possess properties intermediate to agonists and antagonists.” Much of this
work culminated in the two-state model (Black and Leff, 1983), which related the concepts of
fractional occupancy, receptor number, and efficacy into a single equation. From this derivation
also came the postulate that to differentiate between the efficacies of ligands, receptors number
must be reduced to deplete spare receptors, such that rightward and downward shifts in doseresponse relationships might be revealed.
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In vitro methods to ascertain efficacy at the CB1 receptor have largely focused on
agonist-stimulated guanosine [35S]5'-O-[gamma-thio]triphosphate ([35S]GTPS) binding. This
assay enabled measuring efficacy at the first step of the canonical G-protein-adenylyl cyclaseprotein kinase A signal transduction pathway and was effective in stratification of ligands by
efficacy in both cell cultures (Glass and Northup, 1999) and tissue harvested from experimental
animals (Griffin et al, 1998, 2001; Selley et al, 2001). However, there are a number of reagents
and assay parameters which interact to determine the relative differences in efficacy, and
variation across studies afforded relatively poor resolution to estimate relative efficacy when
utilizing the body of literature. In vivo, both experimenter imposed constraints and the
underlying neurobiology of the CB1 receptor present challenges to determine efficacy for various
endpoints.
1.6

CB1 signal transduction
CB1 receptors are seven transmembrane G-protein coupled receptors (GPCR) which

classically signal through heteromeric G proteins consisting of , , and  subunits. Upon ligand
binding, a conformational change in the receptor occurs, spurring the dissociation of the 
subunit from the  subunits as well as an exchange of guanosine diphosphate (GDP) for
guanosine triphosphate (GTP), likely mediated by a guanine exchange factor) at the  subunit.
The dissociated  subunit then translocates to its target protein and exerts its action (ConsoleBram et al, 2012). The signal is then terminated by the hydrolysis of bound GTP to GDP and the
and  subunits are once again complexed together to begin the cycle anew. More recently,
GPCRs were found to simultaneously interact with multiple downstream signaling pathways in a
ligand dependent manner, an emerging concept which has been termed “biased agonism” or
“biased signaling” (Kenakin, 2015), although the concept has other names such as “functional
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selectivity” or “stimulus trafficking”. The downstream targets obviously depend on the
expression and abundance of interacting proteins be they scaffolds or metabolically active thus
these pathways are likely to be tissue or even cell specific (Kenakin, 2015). Signaling bias has
been described for the CB1 receptor for numerous ligands, although not all were described with a
focus on elucidating the phenomenon. Therefore, current knowledge of signal transduction
pathways should be considered with the likelihood that multiple pathways could be activated and
the tissue and ligand inherently dictate the pattern of signaling which occurs.
CB1 receptors are among the most abundant GPCRs in the human, non-human primate,
and rodent CNS (Herkenham et al, 1990). They are typically coupled to Gi/o, thus they
attenuate production of cyclic adenosine monophosphate (cAMP) via interactions with
membrane bound adenylyl cyclase (Howlett, 1984; Melvin et al, 1993b). There are multiple
subtypes of both Gi (1,2, and 3) and Go (1 and 2) and differential signaling via Gi or Go
based upon the ligand occurs depending on the agonist used (Glass and Northup, 1999).
WIN55,212-2 is distinct from other cannabinoids (THC, HU-210, CP55,940, 2-AG,
methanandamide (mAEA), and cannabidiol) in its activation of the Gq-inositol phospate
pathway to release intracellular calcium although WIN55,212-2 does so with relatively lower
potency at Gq compared to Gi/o (Felder et al, 1995; Lauckner et al, 2005). When CB1 is coexpressed with dopamine 2 (D2) receptors, its signaling can switch to Gs, thus increasing
adenylyl cyclase activity to produce cAMP in a pertussis toxin insensitive manner (Glass and
Felder, 1997; Jarrahian, 2003). This stimulatory effect may be due to heterodimerization with the
D2 receptor (Kearn, 2005), as D2 receptor KO mice display diminished catalepsy following
CP55,940 treatment (Andersson, 2005). The CB1 receptor also interacts with G-protein activated
inward rectifying potassium (GIRK) channels (Felder et al, 1995; McAllister et al, 1999) via
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translocation of the  dimer following dissociation with the G subunit (Ho et al, 1999).
WIN55,212 also may have effects on outward currents, though they seem to occur in a non-CB1
manner (Zhang et al, 2013).
Repeated administration of THC results G-protein receptor kinase (GRK) 2 and 4
expression and subsequent GRK-mediated phosphorylation of the intracellular surface of the
CB1 receptor (Rubino et al, 2006). This phosphorylation event then recruits beta arrestin 1
(BARR1) and beta arrestin 2 (BARR2) which can then result in internalization of receptors (Jin
et al, 1999), or alternatively serve as a scaffold for proteins which phosphorylate extracellular
signal-regulated kinase (ERK1/2) which seems to be inversely related to desensitization at the Gprotein level (Daigle et al, 2008a). Genetic deletion of BARR2 increases sensitivity to the effects
of THC relative to wild type mice, although CP55,940, methanandamide, and JWH-073, and O1812 failed to produce the same differences (Breivogel et al, 2008). However, the lack of effects
may be due to the high doses of each compound relative to reported ED50 values. Some
experiments indicate downregulation drives the switch from G signaling to BARR2-ERK1/2
(Flores-Otero et al, 2014), while other studies posit that these signaling events occur
simultaneous in a ligand-dependent manner (Laprairie et al, 2014). Interestingly, these two
hypotheses are not mutually exclusive. Ligands could possess an initial bias for one pathway or
another, and following chronic administration of the same agonist one pathway may become
energetically unfavorable resulting in an alternative coupling to another pathway or pathways. In
the context of cumulative dosing, a shift to the BARR2 signaling is entirely possible during
testing though measuring this potential shift remains to be done.
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1.7

Assay parameters and their effect on measuring efficacy in agonist stimulated

GTPS binding
The vast majority of studies conducted to differentiate cannabinoids by their efficacy
employ the agonist-stimulated [35S]GTPS binding technique. Thus, these experiments served as
a guide to select ligands to test in the whole animal. Though reliable, this in vitro technique may
utilize a variety of reagents which may affect the sensitivity of the assay to detect the efficacy of
ligands. In principle, agonist-stimulated [35S]GTPS binding measures the maximum possible
stimulation of GDP for radiolabeled GTPS in cells or membranes from biological samples,
which triggers the dissociation of the G subunit from the  dimer. The G subunit signal is
normally terminated by hydrolysis of GTP to GDP, yet the GTPS resists this catabolism such
that accumulation of bound GTPS can be measured via a liquid scintillation counter. The
relative concentrations of MgCl2, GTPS, GDP, Na+, and membrane protein will each affect the
resolution in measuring efficacy. Each of these reagents can be used within a wide range of
concentrations and still produce the desired accumulation of GTPS bound to G-proteins. The
available literature reflects this considerable tolerance. Emax values for the widely used, high
efficacy agonist CP55,940 varies from 136±11% above basal (Burkey et al, 1997a) to 200±7%
(Hillard et al, 1999). In contrast, THC produces ~25% above basal (Burkey et al, 1997b) in some
cases and in others produce no discernable stimulation (Griffin et al, 1998). Addition of
adenosine deaminase (Moore et al, 2000) reduces basal activity by destroying ATP present in the
tissue. This in turn increases resolution to distinguish high efficacy ligands by eliminating
purinergic GPCR activity. A summary of cannabinoid agonist-stimulated GTPS studies that
includes reported Emax values of various ligands and assay conditions is included in Table 2.
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SEM

MgCl2
[mM]

Na+
[mM]

GDP
[]

GTPS
[nM]

GDP/
GTPS

Tissue
Conc.
[g/ml]

Species/Strain

Tissue Type

129.2

1.82

3

100

100

0.1

1000

300

C57BL6 mice

whole brain

20

121.1

0.71

3

100

100

0.1

1000

300

DBA mice

whole brain

180

20

130

1.18

3

100

100

0.1

1000

300

C57BL6 mice

whole brain

HU-210

160

10

120.6

2.5

3

100

100

0.1

1000

300

DBA mice

whole brain

WIN55,212-2

330

10

155.4

4.08

3

100

100

0.1

1000

300

C57BL6 mice

whole brain

WIN55,212-2

350

30

142.9

3.2

3

100

100

0.1

1000

300

DBA mice

whole brain

WIN55,212-2

ND

ND

132

7

3

100

30

0.05

600

10 to 15

Sprague-Dawley

cerebellum

WIN55,212-2

ND

ND

115

18

3

100

30

0.05

600

10 to 15

Sprague-Dawley

WIN55,212-2

ND

ND

249

48

3

100

30

0.05

600

10 to 15

Sprague-Dawley

hippocampus
striatum plus
globus pallidus

3 mM levonantrodol

ND

ND

620

36

3

100

30

0.05

600

10 to 15

Sprague-Dawley

cerebellum

3 mM levonantrodol

ND

ND

210

12

3

100

30

0.05

600

10 to 15

Sprague-Dawley

hippocampus

3 mM levonantrodol

ND

ND

140

15

3

100

30

0.05

600

10 to 15

Sprague-Dawley

hypothalamus

AEA

3600

2000

41

3

3

100

30

0.1

300

5

CB1 KO

cerebellum

AEA

1400

300

150

7

3

100

30

0.1

300

5

CB1 WT

cerebellum

WIN55,212-2

1800

700

64

7

3

100

30

0.1

300

5

CB1 KO

cerebellum

WIN55,212-2

170

80

180

11

3

100

30

0.1

300

5

CB1 WT

cerebellum

CP55,940

ND

ND

149

13

3

100

30

0.1

300

10 to 30

Sprague-Dawley

cerebellum

HU-210

ND

ND

141

13

3

100

30

0.1

300

10 to 30

Sprague-Dawley

cerebellum

mAEA

80

23

154

7

3

100

30

0.1

300

10 to 30

Sprague-Dawley

cerebellum

THC

74

3

40

8

3

100

30

0.1

300

10 to 30

Sprague-Dawley

cerebellum

WIN55,212-2

18

5

212

8

3

100

30

0.1

300

Sprague-Dawley

cerebellum

AEA

846

84

96

5

2.5

150

50

0.1

500

Sprague-Dawley

whole brain

CP55,940

61.7

11.6

136

11

2.5

150

50

0.1

500

Sprague-Dawley

whole brain

HU-210

2.26

0.38

123

4

2.5

150

50

0.1

500

Sprague-Dawley

whole brain

THC

59

2.5

150

50

0.1

500

10 to 30
not
reported
not
reported
not
reported
not
reported

Sprague-Dawley

whole brain

Ligand

EC50
[nM]

SEM

Emax
%net

CP55,940

270

30

CP55,940

230

HU-210

25

25

Reference
Basavarajappa
and Hungund,
1999

Breivogel et
al., 1999

Breivogel and
Childers, 2000

Breivogel et
al., 2001

Breivogel et
al., 2003

Burkey et al.,
1997a

THC

70.9

WIN55,212-2

357

31.7

37

2

ND

2.5

150

50

0.1

500

2.5

150

50

0.1

500

not
reported
not
reported

Sprague-Dawley

whole brain

Sprague-Dawley

whole brain

2-AG

7585.78

1570.2
6

cannabidiol

ND

ND

ND

ND

3

100

30

0.1

300

10

shrew

whole brain

CP55,940

5.25

1.33

105

1

3

100

30

0.1

300

10

shrew

whole brain

HU-210

0.19

0.19

120

5

3

100

30

0.1

300

10

shrew

whole brain

HU-211

ND

ND

ND

ND

3

100

30

0.1

300

10

shrew

whole brain

mAEA

1230.27

650.81

120

25

3

100

30

0.1

300

10

shrew

whole brain

68

4

3

100

30

0.1

300

10

shrew

whole brain

SR141716A

ND

ND

ND

ND

3

100

30

0.1

300

10

shrew

whole brain

THC

36.31

6.68

53

14

3

100

30

0.1

300

10

shrew

whole brain

WIN55,212-2

107.15

98.58

104

8

3

100

30

0.1

300

10

shrew

whole brain

5 mM WIN55,212-2

ND

ND

166.2

25.7

3

100

5

0.05

100

1 to 3

Wistar

cerebellum

5 mM WIN55,212-2

ND

ND

163.3

11.6

3

100

5

0.05

100

1 to 3

Wistar

striatum

5 mM WIN55,212-2

ND

ND

167

15.3

3

100

5

0.05

100

1 to 3

Wistar

hippocampus

5 mM WIN55,212-2

ND

ND

147.9

25.9

3

100

5

0.05

100

1 to 3

Wistar

cerebral cortex

5 mM WIN55,212-2

ND

ND

112.4

12.5

3

100

5

0.05

100

1 to 3

Wistar

limbi forebrain

5 mM WIN55,212-2

ND

ND

94.8

14.7

3

100

5

0.05

100

1 to 3

Wistar

brainstem

AEA

538

54

71

6

1

100

4

0.4-0.8

50

20 to 40

NA

Sf9 cells-Gi

AEA

776

78

45

2

1

100

4

0.4-0.8

50

20 to 40

NA

Sf9 cells-Go

HU-210

2.3

0.3

100

ND

1

100

4

0.4-0.8

50

20 to 40

NA

Sf9 cells-Gi

HU-210

3.1

0.3

100

ND

1

100

4

0.4-0.8

50

20 to 40

NA

Sf9 cells-Go

THC

196

13

64

10

1

100

4

0.4-0.8

50

20 to 40

NA

Sf9 cells-Gi

THC

185

28

42

0.4

1

100

4

0.4-0.8

50

20 to 40

NA

Sf9 cells-Go

WIN55,212-2

330

53

72

12

1

100

4

0.4-0.8

50

20 to 40

NA

Sf9 cells-Gi

WIN55,212-2

362

93

65

3

1

100

4

0.4-0.8

50

20 to 40

NA

Sf9 cells-Go

AEA

ND

ND

ND

ND

3

150

100

0.05

2000

2

Sprague-Dawley

cerebellum

cannabinol

ND

ND

ND

ND

3

150

100

0.05

2000

2

Sprague-Dawley

cerebellum

CP55,244

0.47

0.25

165

17

3

150

100

0.05

2000

2

Sprague-Dawley

cerebellum
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CP55,940

ND

ND

61

28

3

150

10

0.05

200

2

Sprague-Dawley

cerebellum

CP55,940

17.57

10.54

114

17

3

150

100

0.05

2000

2

Sprague-Dawley

cerebellum

deoxy-HU-210

9.6

8.5

150

55

3

150

100

0.05

2000

2

Sprague-Dawley

cerebellum

fluoro-mAEA

25.37

20.39

97

42

3

150

100

0.05

2000

2

Sprague-Dawley

cerebellum

HU-210

0.55

0.3

140

23

3

150

100

0.05

2000

2

Sprague-Dawley

cerebellum

JWH-030

82.4

68.4

56

19

3

150

100

0.05

2000

2

Sprague-Dawley

cerebellum

JWH-073

104.8

87.86

29

20

3

150

100

0.05

2000

2

Sprague-Dawley

cerebellum

O-1064

246.2

233.75

60

55

3

150

100

0.05

2000

2

Sprague-Dawley

cerebellum

THC

ND

ND

51

7

3

150

10

0.05

200

2

Sprague-Dawley

cerebellum

THC

ND

ND

ND

ND

3

150

100

0.05

2000

2

Sprague-Dawley

cerebellum

WIN55,212-2

ND

ND

89

14

3

150

10

0.05

200

2

Sprague-Dawley

cerebellum

WIN55,212-2

151.1

50.5

156

12

3

150

100

0.05

2000

2

Sprague-Dawley

cerebellum

8-THC

0

ND

0

ND

9

150

100

0.05

2000

2

Sprague-Dawley

cerebellum

O-1125

165

12.8

17.4

6

9

150

100

0.05

2000

2

Sprague-Dawley

cerebellum

O-1176

0

ND

0

ND

9

150

100

0.05

2000

2

Sprague-Dawley

cerebellum

O-1184

0

ND

0

ND

9

150

100

0.05

2000

2

Sprague-Dawley

cerebellum

O-1236

87.5

9.7

16.6

5

9

150

10

0.05

200

2

Sprague-Dawley

cerebellum

O-1237

51.3

5.5

10.6

8

9

150

10

0.05

200

2

Sprague-Dawley

cerebellum

O-1238

58.3

8.5

29.7

15

9

150

100

0.05

2000

2

Sprague-Dawley

cerebellum

O-584

0

ND

0

ND

9

150

100

0.05

2000

2

Sprague-Dawley

cerebellum

O-806

0

ND

0

ND

9

150

100

0.05

2000

2

Sprague-Dawley

cerebellum

O-823

0

ND

0

ND

9

150

100

0.05

2000

Sprague-Dawley

cerebellum

11-OH-9-THC

94

6

132

4

5

150

10

0.65

15.38

Sprague-Dawley

cerebellum

AEA

276

53

166

6

5

150

10

0.65

15.38

Sprague-Dawley

cerebellum

CP55,940

29.6

11

199

7

5

150

10

0.65

15.38

Sprague-Dawley

cerebellum

HU-210

4.3

1.7

179

13

5

150

10

0.65

15.38

Sprague-Dawley

cerebellum

THC

91

32

126

17

5

150

10

0.65

15.38

Sprague-Dawley

cerebellum

WIN55,212-2

102

28

217

8

5

150

10

0.65

15.38

2
not
reported
not
reported
not
reported
not
reported
not
reported
not
reported

Sprague-Dawley

cerebellum
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AEA

490

ND

134

3

3

0

30

0.5

60

10 to 15

CB1 KO

cerebellum

AEA

3040

ND

343

29

3

0

30

0.5

60

10 to 15

CB1 WT

cerebellum

HU-210

ND

ND

ND

ND

3

0

30

0.5

60

10 to 15

CB1 KO

cerebellum

HU-210

17

ND

492

24

3

0

30

0.5

60

10 to 15

CB1 WT

cerebellum

THC

ND

ND

ND

ND

3

0

30

0.5

60

10 to 15

CB1 KO

cerebellum

THC

1490

ND

171

13

3

0

30

0.5

60

10 to 15

CB1 WT

cerebellum

WIN55,212-2

1780

ND

206

16

3

0

30

0.5

60

10 to 15

CB1 KO

cerebellum

WIN55,212-2

1720

ND

444

21

3

0

30

0.5

60

10 to 15

CB1 WT

cerebellum

11-hydroxy-THC
11-nor-8-THC-9carboxylic acid
11-nor--THC-9carboxylic acid

110

50

162

6

1

0

50

0.2

250

30

rat

cerebellum

>10000

ND

ND

ND

1

0

50

0.2

250

30

rat

cerebellum

>10000

ND

ND

ND

1

0

50

0.2

250

30

rat

cerebellum

AEA

2300

1100

186

12

1

0

50

0.2

250

30

rat

cerebellum

cannabinol

170

30

130

2

1

0

50

0.2

250

30

rat

cerebellum

CP55,940

9

3

200

2

1

0

50

0.2

250

30

rat

cerebellum

mAEA

180

80

204

14

1

0

50

0.2

250

30

rat

cerebellum

THC

530

310

154

8

1

0

50

0.2

250

30

rat

cerebellum

WIN55,212-2

99

45

175

10

1

0

50

0.2

250

30

rat

cerebellum

WIN55,212-3

>10000

ND

ND

ND

1

0

50

0.2

250

30

rat

cerebellum

cannabidiol

0

ND

0

ND

1

0

100

0.2

500

30

Sprague-Dawley

cerebellum

cannabinol

187

ND

24

ND

1

0

100

0.2

500

30

Sprague-Dawley

cerebellum

CP55,940

53

ND

84

ND

1

0

100

0.2

500

30

Sprague-Dawley

cerebellum

THC

216

ND

54

ND

1

0

100

0.2

500

30

Sprague-Dawley

cerebellum

WIN55,212-2

ND

ND

WIN55,212-2

ND

ND

WIN55,212-2

ND

ND

WIN55,212-2

ND

ND

WIN55,212-2

ND

ND

140.2
5
173.7
1
171.0
4
110.0
7
105.5
5

10.15

3

100

50

0.1

500

?

Sprague-Dawley

medial prefrontal
cortex

12.63

3

100

50

0.1

500

?

Sprague-Dawley

caudate-putamen

26.71

3

100

50

0.1

500

?

Sprague-Dawley

hippocampus

2.98

3

100

50

0.1

500

?

Sprague-Dawley

5.26

3

100

50

0.1

500

?

Sprague-Dawley

amygdala
dorsal raphe
nucleus
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mAEA

114

4.2

542

84

3

100

30

0.08

375

5 to 10

CB1 HET

cerebellum

mAEA

63

0.4

277

36

3

100

30

0.08

375

5 to 10

CB1 HET

mAEA

33

4.9

551

103

3

100

30

0.08

375

5 to 10

CB1 HET

hippocampus
striatum plus
globus pallidus

mAEA

ND

ND

ND

ND

3

100

30

0.08

375

5 to 10

CB1 HET

cingulate cortex

mAEA

160

14

375

23

3

100

30

0.08

375

5 to 10

CB1 WT

cerebellum

mAEA

96

6.9

265

33

3

100

30

0.08

375

5 to 10

CB1 WT

mAEA

67

5.6

227

47

3

100

30

0.08

375

5 to 10

CB1 WT

hippocampus
striatum plus
globus pallidus

mAEA

56

3.6

183

42

3

100

30

0.08

375

5 to 10

CB1 WT

cincgulate cortex

THC

34

7.7

215

69

3

100

30

0.08

375

5 to 10

CB1 HET

cerebellum

THC

24

3.2

63

24

3

100

30

0.08

375

5 to 10

CB1 HET

THC

12

2.1

220

94

3

100

30

0.08

375

5 to 10

CB1 HET

hippocampus
striatum plus
globus pallidus

THC

ND

ND

ND

ND

3

100

30

0.08

375

5 to 10

CB1 HET

cingulate cortex

THC

51

5.7

153

41

3

100

30

0.08

375

5 to 10

CB1 WT

cerebellum

THC

44

1.7

55

31

3

100

30

0.08

375

5 to 10

CB1 WT

THC

23

2.7

92

44

3

100

30

0.08

375

5 to 10

CB1 WT

hippocampus
striatum plus
globus pallidus

THC

28

4

93

17

3

100

30

0.08

375

5 to 10

CB1 WT

cingulate cortex

WIN55,212-2

204

18

167

26

3

100

30

0.08

375

5 to 10

CB1 HET

cerebellum

WIN55,212-2

134

5.5

176

12

3

100

30

0.08

375

5 to 10

CB1 HET

WIN55,212-2

60

5.7

204

27

3

100

30

0.08

375

5 to 10

CB1 HET

hippocampus
striatum plus
globus pallidus

WIN55,212-2

106

7.9

287

43

3

100

30

0.08

375

5 to 10

CB1 HET

cingulate cortex

WIN55,212-2

248

29

104

18

3

100

30

0.08

375

5 to 10

CB1 WT

cerebellum

WIN55,212-2

181

14

137

19

3

100

30

0.08

375

5 to 10

CB1 WT

WIN55,212-2

112

13

126

17

3

100

30

0.08

375

5 to 10

CB1 WT

hippocampus
striatum plus
globus pallidus

WIN55,212-2

139

3.3

178

220

3

100

30

0.08

375

5 to 10

WIN55,212-2

0.04

0.01

119

1.5

3

100

30

0.1

300

3.5 to 8

WIN55,212-2

0.06

0.03

102

1.8

3

100

30

0.1

300

3.5 to 8

CB1 WT
Long-Evans
female
adolescent
Long-Evans
female
adolescent
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cingulate cortex

prefrontal cortex

striatum
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WIN55,212-2

0.19

0.02

87

10.6

3

100

30

0.1

300

3.5 to 8

WIN55,212-2

0.08

0.02

205

10

3

100

30

0.1

300

3.5 to 6

WIN55,212-2

0.13

0.02

194

5.1

3

100

30

0.1

300

3.5 to 6

WIN55,212-2

0.08

0.03

137

8.5

3

100

30

0.1

300

3.5 to 6

WIN55,212-2

0.16

0.01

112

5.4

3

100

30

0.1

300

3.5 to 9

WIN55,212-2

0.14

0.02

96

5.1

3

100

30

0.1

300

3.5 to 9

WIN55,212-2

0.14

0.01

105

5.8

3

100

30

0.1

300

3.5 to 9

WIN55,212-2

0.88

0.38

135

2.9

3

100

30

0.1

300

3.5 to 7

WIN55,212-2

1.46

0.45

100

2.6

3

100

30

0.1

300

3.5 to 7

WIN55,212-2

0.41

0.17

91

5.1

3

100

30

0.1

300

3.5 to 7

Long-Evans
female
adolescent
Long-Evans
female adult
Long-Evans
female adult
Long-Evans
female adult
Long-Evans
male adolescent
Long-Evans
male adolescent
Long-Evans
male adolescent
Long-Evans
male adult
Long-Evans
male adult
Long-Evans
male adult

midbrain
prefrontal cortex
striatum
midbrain
prefrontal cortex
striatum
midbrain
prefrontal cortex
striatum
midbrain

Table 1. Assay conditions of agonist stimulated [35S]GTPS binding experiments as determinants of Emax estimations. Concentrations
of MgCl2, Na+, relative concentrations of GDP and GTPS, strain, and selected CNS region all influence the magnitude of measured
efficacy. Relative differences in efficacy, especially at either extreme, are highly dependent on the interplay of each reagent.
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Intracellular Na+ allosterically inhibits G-protein mediated signaling stimulated by
dopaminergic, opioidergic, and serotonergic, and many other GPCRs (Katritch et al, 2014). CB1
receptors are similarly regulated by Na+ via the same evolutionarily conserved aspartate residue
on the second transmembrane helix (Tao and Abood, 1998). While mutation of the sodiumbinding aspartate appears to affect binding affinity of certain ligands, such as
desacetyllevonantrodol (Houston and Howlett, 1998), it nonetheless reduces downstream
inhibition of adenylyl cyclase resulting in greater than expected cAMP formation for
WIN55,212-2, CP55,940, AEA, and THC (Tao and Abood, 1998). These results suggest the
existence of an inverse relationship between the concentration of Na+ and the Emax measured by
agonist-stimulated [35S]GTPS binding. Some experiments report no Na+ in the assay (Petitet et
al, 1998), though most are within the 100-150 mM range (Breivogel and Childers, 2000; Griffin
et al, 1998), a physiologically relevant concentration.
Magnesium ions (Mg2+) are important co-factors for the binding of both GDP and GTP to
the G-protein and typical concentrations in agonist-stimulated [35S]GTPS binding typically
range from 1 mM (Petitet et al, 1997) to 5 mM (Thomas et al, 2005), though one study reports
using 9 mM in the GTPS assay buffer (Griffin et al, 1999). In the absence of Mg2+ the affinities
of GDP and GTP are drastically reduced, and if the concentrations of both are sufficiently low,
G-proteins become unstable and may degrade (Sprang, 1997). Magnesium also extends the
duration of GTPS binding (Higashijima et al, 1987); thus manipulating this ion can enhance the
sensitivity to measure accumulation via scintillation counting.
The quantity of protein for agonist-stimulated [35S]GTPS binding may also affect the
measured Emax value. A high protein concentration should increase the relative concentration of
CB1. Accordingly, the Stephenson equation predicts a positive relationship between protein
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concentration and the maximum effect. Thus, ligands appear indistinguishable regardless of
efficacy in preparations containing a large receptor reserve. As the density of CB1 expression
varies with CNS region, different brain regions are often used to change the relative
concentration of the receptor. All other factors being equivalent, the choice of protein
concentration need only be sufficiently high to detect stimulation and not so high that it
precludes differentiation. Thus, comparisons made between studies utilizing the same drugs, but
different tissues, will likely yield calculated different Emax values. However, a series of ligands
varying in efficacy assessed in different tissues may be comparable in a qualitative manner.
Typical protein concentrations range from as low as 2 g/ml (Griffin et al, 1998) to as high as 30
g/ml (Petitet et al, 1998). The brain region most utilized in in vitro cannabinoid studies is the
cerebellum (Table 2), likely due to the ease of dissection and its relatively high expression of
CB1. It also possess rather low endogenous basal activity, which bolsters the resolution to detect
small, but significant, increases in binding of low efficacy cannabinoids. If the anatomical
distribution of the functional activity of CB1 in the presence of an agonist is desired, agoniststimulated [35S]GTPS autoradiography is of great value (Sim et al, 1996a). However, this
technique does not readily lend itself to testing a large range of drugs under the same conditions,
as is the case with agonist-stimulated [35S]GTPS binding. Autoradiography does provide
exquisite neuroanatomical detail but only one test ligand may be utilized per sample. For
agonist-stimulated [35S]GTPS binding, samples are often distributed over many assay wells or
tubes, thus affording the flexibility to assess the effect of many dose-effect curves in the same
tissue. Importantly, this design allows quantitative inferences to be made regarding the
pharmacological properties of the drugs tested, specifically as they relate to GDP-GTP exchange.
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The relative concentration of GDP to [35S]GTPS can be easily manipulated and
represents a highly useful assay parameter to vary in order to increase the resolution of the
binding assay. Progressively increasing concentrations of GDP drives down basal activity (Sim
et al, 1995), but facilitates detecting differences in efficacy for ligands clustered near the top of
the continuum. Conversely, very low concentrations of GDP favor differentiation between
agonists of very low efficacy, such as THC and analogs (see Table 2, Griffin et al., 2001). As
with the tissue concentration, the range of GDP employed across studies is quite wide, ranging
from 4 M (Glass and Northup, 1999) to 100 M (Griffin et al, 1998). As predicted, low
concentrations do not as readily distinguish between high efficacy ligands, while high
concentrations more easily separate high efficacy ligands (Griffin et al, 1998). The [35S]GTPS
concentration in these assays often falls in the sub-nanomolar range, rendering the ratio of
GDP/[35S]GTPS anywhere from 15 (Kearn et al, 1999) to 2000 (Griffin et al, 2001). Both GDP
and GTP have nanomolar affinities for most G-proteins, with GTP having approximately 1-10
fold higher affinity depending on the G-protein type and/or subtype (Sprang, 1997). [35S]GTPS
has an even greater affinity for the G-protein that may, in part, account for the large discrepancy
in relative concentrations, which are necessary to detect differences among ligands. Additionally,
binding of a ligand to the CB1 receptor reduces the apparent affinity of GDP for G-proteins and
increases that of GTPS (Breivogel et al, 1998).
To effectively assess whether CB1 ligands differ in efficacy, the assay parameters must be
able to capture agonist stimulation of CB1 activity for both high and low efficacy compounds.
The NaCl (100 mM) and MgCl2 (3mM) should be sufficiently high to reduce basal activity and
extend the time course of GTPS binding, respectively. Incubation with adenosine deaminase
will metabolize much of the present ATP, reducing purinergic GPCR activity and reducing the
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non-CB1 activity further. Concentrations of GTPS (0.1 nM) and GDP (30 M) will reflect a
moderate ratio of GDP to GTPS (300) to facilitate sensitivity to both high and low efficacy
compounds. This moderate concentration would likely reduce sensitivity to ligands with
extremely high or low efficacy. However, this experimental window can be altered by varying
the GDP concentration, and concomitantly altering the ratio of GDP to GTPS. In this thesis, I
captured respective high and low receptor conditions by using cerebellum and spinal cord
samples. Additionally, receptor levels were further varied through the employment of CB1 WT,
HET, and KO mice will be used. The overall protein concentrations were held constant
irrespective of genotype and brain region to ensure observed differences are the result of relative
changes in CB1 expression, as well as to enable quantitative comparisons between brain regions
and genotypes.
1.8

Selection of cannabinoid ligands and controls based upon evidence from previous

[35S]GTPS binding experiments
The ligands THC, CP47,497, JWH-073, CP55,940, and WIN55,212-2 were selected for
study in the cumulative dosing triad and agonist-stimulated [35S]GTPS binding due to their
apparent relative differences in efficacy, as reviewed in Table 2. CP47,497 and JWH-073 were
also selected because of their historical detections in abused preparations of Spice and K2
products (Auwärter et al, 2009). To aid in these studies, the heat degradant of the highly
efficacious A-834,375 (A-834,735D) was selected as another high efficacy cannabinoid ligand.
Preliminary data indicate the degradant form has very high efficacy at the CB1 receptor in
recombinant human CB1 (hCB1) expressing human embryonic kidney (HEK) cells, and it will
serve as an archetypal representative of newer SC compounds (Thomas and Wiley, 2014).
Preliminary data from our own lab also indicated CP47,497 was lower in efficacy than
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CP55,940. Although many of these ligands have been tested under the same conditions, the
assays were often not optimized to detect differences between both and low efficacy ligands, and
only WIN55,212-2 and THC were tested in CB1 KO tissue. Unlike most other cannabinoid
agonists, WIN55,212-2 stimulates [35S]GTPS binding in these tissues suggesting that this nonCB1 activity yields an over-estimation of reported Emax values. Indeed, reported studies do not
account for the non-CB1 stimulation (Monory et al, 2002). The potential off-target stimulation is
especially important to consider in the case of the only agonist-stimulated [35S]GTPS binding
study conducted utilizing CB1 HET mice to manipulate receptor density (Selley et al, 2001). The
same study also utilized methanandamide, which may stimulate [35S]GTPS binding in a similar
fashion as the structurally related endocannabinoid anandamide (Breivogel et al, 2001; Monory
et al, 2002). Accordingly, the estimated Emax values reported in WT and HET membranes might
be equally inflated, rendering the relative efficacies closer to one another than when non-CB1
stimulation is subtracted. In the studies reported in this thesis (Chapter 2), the same
concentrations of agonists will be used in both WT and HET samples, while KO tissue will be
used to detect potential non-CB1 stimulation. Each of the ligands selected has similar affinities
for the CB1 receptor and the CB2 receptor. However, it is important to note that CB2 receptor
mRNA is expressed at very low levels within the CNS, and likely contributes little to the overall
signal. In contrast, CB1 mRNA and protein are vastly abundant (Galiègue et al, 1995) and
represents among the highest expressed GPCRs in the brain. Therefore, CB2 contribution to the
signal is negligible and off target-stimulation is likely to reflect a heretofore unknown target or
targets.
For in vivo experiments, the selectivity of the assay for cannabimimetic agents was
assessed using the mu opioid receptor agonist morphine and the atypical antipsychotic
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chlorpromazine. Despite possessing non-CB1 mechanisms of action, these drugs produce a
subset of the triad endpoints. Importantly, both morphine and chlorpromazine were expected to
be equipotent to produce their effects irrespective of genotype, indicating the specificity for CB1
activity.
1.9 Potential methods to determine efficacy at the CB1 receptor in vivo
CB1 receptors are heterogeneously expressed throughout the mammalian brain, with high
receptor concentrations in brain regions believed to mediate the pharmacological effects of
cannabis and THC (Herkenham et al, 1990, 1991). Many cannabimimetic effects occur via this
receptor (Ledent et al, 1999; Rinaldi-Carmona, 1994; Rinaldi-Carmona et al, 1995; Zimmer et
al, 1999a), including catalepsy, hypothermia, antinociception, and hypolocomotion.
Consequentially, the receptor reserve mediating the pharmacological actions of cannabinoids
may be sufficient for even very low efficacy compounds produce effects a similar magnitude to
high efficacy agonists across many endpoints. This inability to distinguish efficacy due to dense
CB1 receptor expression presents unique challenges to ascertain in vivo efficacy at the CB1
receptor, especially with the knowledge that CB1 receptor expression varies considerably across
brain regions (Herkenham et al, 1990). The requisite reduction in CB1 receptors available for
signaling may be achieved through pharmacological and/or genetic approaches. In the following
discussion, three general experimental approaches are discussed in which CB1 expression is
experimentally reduced to investigate efficacy.
First, repeated administration of THC and synthetic cannabinoids leads to tolerance and
cross tolerance to other cannabinoids (Fan et al, 1994; Pertwee et al, 1993). This tolerance
occurs concomitantly with receptor downregulation and desensitization which occurs in a brain
region specific manner, as determined by radioligand and agonist-stimulated [35S]GTPS
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autoradiography (Lazenka et al, 2014; Tai et al, 2015a). Potency shifts may be used to infer
differences in efficacy following chronic treatment in the case of drug discrimination (Hruba et
al, 2012), though the neural substrates, which underlie this behavior, are not well understood.
Other studies which demonstrate varying degrees of tolerance depending on which agonist is
repeatedly administered also may not readily differentiate between efficacy of the test drugs, and
the duration and timing of the dosing of the toleragen are determining factors for the degree of
tolerance (Fan et al, 1994). Another limitation of this approach may lie within the inherent
differences in ligand bias, which almost assuredly exist among cannabinoid agonists (Laprairie et
al, 2014). BARR2 plays a role in both acute CB1-mediated effects of THC (Breivogel et al,
2013) and tolerance following repeated administration (Nguyen et al, 2012). BARR2 also
promotes CB1-mediated signaling via ERK1/ERK2 (Franklin et al, 2013); thus, observed
tolerance may be the result of decreased Gi/o signaling and a shunting towards BARR2. In cell
cultures, ERK1/ERK2 signaling elevates during prolonged CP55,940 exposure suggesting this
may be the case (Daigle et al, 2008a). Unsurprisingly, this apparent shunting of pathways likely
occurs in a CNS region dependent manner (Rubino et al, 2006), further complicating
interpretations of chronic dosing regimens as they relate to efficacy. Chronic THC treatment
induced changes in BARR2 and ERK/Ras signaling in striatum and cerebellum, but not in
hippocampus or prefrontal cortex, and the desensitization observed may occur via alternate
mechanisms (Rubino et al, 2006).
A second pharmacological approach to infer efficacy involves the use of an irreversible
antagonist to progressively and dose-dependently reduce the number of receptors available.
Irreversible antagonists are associated with insurmountable rightward and downward shifts in
dose response curves. The reduction in receptor population in turn facilitates the estimation of ,
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𝑅

or 𝐾𝑇 , via isolation of 𝐾𝐸 , or the concentration of the agonist receptor complex to produce a 50%
𝐸

effect, as seen in the operational model (Black and Leff, 1983; Kenakin, 2014). As 𝑅𝑇
approaches zero, the EC50 will collapse upon the KA. This approach has been demonstrated
utilizing the irreversible mu opioid antagonist clocinnamox to estimate the of various mu
opioid ligands (Pawar et al, 2007). However, this approach is not feasible to investigate efficacy
of compounds at CB1, as no irreversible antagonist is available yet for this receptor. On the other
hand, the anandamide analog AM3577, which binds covalently to the orthosteric site and inhibits
adenylyl cyclase (Janero et al, 2015), may provide a tool for this sort of approach. However,
AM3577 would unlikely be able to distinguish between agonists of lower or similar efficacy.
Genetic approaches represent third way to reduce CB1 expression. Short interfering
ribonucleic acid (siRNA) represents another potential method to reduce the overall expression of
CB1, though the degree of knockdown may be challenging to be implemented in systematic and
controlled manner throughout the entire CNS. Alternatively, the use of CB1 wild type (WT),
heterozygous (HET), and knockout (KO) transgenic mice reflects a simple tool to reduce
receptor levels in a controlled fashion (Ledent et al, 1999; Zimmer et al, 1999b). WT mice
express the normal abundance of CB1, HET mice express approximately half of normal levels
(Selley et al, 2001), and KO do not express functional CB1 (Zimmer et al, 1999b). Thus, these
transgenic mice represent a way to assess the loss of potency and/or efficacy of different
compounds at CB1, while simultaneously maintaining sensitivity to potential off target effects.
This approach has several advantages versus the alternative methods described above. First, the
reductions in receptor population are presumably constitutive and stable. Second, the reduction
in CB1 expression is proportional to the tissue. While CB1 receptor density varies considerably
with brain region (Herkenham et al, 1990), the expression in HET mice is approximately half of
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WT levels in cerebellum, hippocampus, striatum, and cingulate cortex (Selley et al, 2001), and
this pattern of half expression in HET mice presumably continues throughout the brain. A
limitation of this approach is that it does not provide the graded reduction in receptor an
irreversible antagonist would afford. Accordingly, the estimation of KE is not possible with a
great degree of confidence. Instead, a simple formulation of the receptor theory equation may
predict the pharmacological effects of agonists varying in CB1 efficacy.
1.10

Theoretical predictions based upon the Stephenson receptor theory model
𝐸 = [𝑅𝑇 ] ∗ [𝜀] ∗

[𝐴]
[𝐴] + 𝐾𝐷

E = maximum effect
𝑅𝑇 = receptor population
ε = efficacy of the drug
[𝐴]
[𝐴]+ 𝐾𝐷

= fractional occupancy

The Stephenson equation (Stephenson, 1956) is an extension of the Furchgott receptor
occupancy equation, but it includes the term “” which acknowledges the inherent differences in
ligands in terms of the degree of activation they are able to produce. This equation also
determines the maximum amount of activation an individual ligand can stimulate which accounts
[𝐴]

for the existence of partial agonists. The fractional occupancy term [𝐴]+𝐾 produces the
𝐷

characteristic hyperbolic (in a linear-linear scale) and sigmoidal (in a log-linear scale) shapes
seen in dose-effect studies. Importantly, when [A] = 𝐾𝐷 then the fractional occupancy is half
which in turn reflects the equilibrium between bound and unbound ligand. The affinity and
efficacy terms determine potency insofar as drugs which are more efficacious or possess higher
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affinity also tend to be more potent, with the most potent drugs tending to have high efficacy and
high affinity. The other determinant of the effect of a drug is the number of receptor available to
signal through. The number of receptors may vary from tissue from tissue, and in the case of
cannabinoids definitely does. Another implication of this variance in receptor expression is
differential tissue sensitivity given the same ligand. In the case of CB1 transgenic mice, the
consequences of 100%, 50%, and 0% receptor expression may be modeled and explored (Figure
6).
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Figure 6. Utilizing the Stephenson receptor theory equation, predictions regarding changes in
efficacy and potency regarding reductions in receptor populations were depicted. In WT tissue,
which expresses normal levels of CB1, maximal activation was achieved. In HET tissue, exactly
half of WT activation occurred and in KO tissue no activation was observed. This activation
corresponds with 100%, 50%, and 0% expression of CB1. At a given dose of the agonist, the
fractional occupancy in WT and HET tissues were identical.

41

Using a single agonist in each genotype, the maximum effect is assumed to be
proportional to the reduction in total receptor number. Accordingly, a given CB1 agonist is
predicted to possess the following efficacies in the three genotypes, assuming no receptor
reserve: 1) WT mice that possess 100% of the receptors will show a maximum effect; 2) HET
mice, which possess 50% of the receptors, a concordant 50% reduction in efficacy will be
observed; 3) KO mice, which have no receptors available for signaling, will not show any
measurable effect regardless concentration. However, the proportion of the available receptors
occupied does not change for a given concentration, as indicated by the vertical dotted line in
Figure 6. At the EC50 in WT mice half of 100% of the receptors are occupied whereas half of
50% of the receptors are occupied in HET mice. There is no occupancy in the KO mice as there
are no receptors. It should be noted that these conditions do not allow for reliable estimation of
KE as derived from the Operation Model as only two EC50 concentrations are observed, obviating
the necessary nonlinear regression necessary to calculate KE.
The pharmacological effects of cannabinoids are mediated by distinct pools of CB1
receptors. Moreover, the concentration of CB1 receptors are known to vary throughout the CNS.
Intuitively, pharmacological effects mediated by circuits containing very high CB1 expression
were hypothesized to show very small shifts between WT and HET mice (Figure 7). Under
conditions of moderate receptor levels, more resolution is gained to distinguish between low and
high efficacy ligands in which rightward and downward shifts may be readily observed with low
efficacy ligands (Figure 8). Very low receptor expression conditions may further differentiate
between ligands of varying efficacy when compared amongst the genotypes, but the resolution to
do so may be lost as the dose-effect relationships begin to congregate towards the abscissa
(Figure 9). For instance, ligands that both possess low, but different levels of efficacy could be
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tested under both moderate and low receptor conditions. The moderate expression may
differentiate between the efficacies of the two test ligands whereas the low receptor conditions
would display a floor effect, preempting differentiation under those conditions. Consequently, it
remains important to assess efficacy under a variety of conditions to properly ascertain actual
differences in efficacy.
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Figure 7. High receptor expression conditions revealed only small changes in potency between
WT and HET dose-effect curves utilizing ligands with high or medium efficacy. Larger shifts
were observed with low efficacy ligands, but maximal effects were achieved in WT but not HET
mice.
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Figure 8. Moderate levels of CB1 expression show better resolution to distinguish between
ligands that vary in efficacy utilizing differential potency between WT dose effect curves.
Additionally, downward shifts are readily observed across ligands which vary in efficacy due to
a 50% reduction in receptor population.
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Figure 9. Low receptor conditions differentiate high efficacy ligands more readily than low
efficacy ligands. When low efficacy ligands are utilized under low receptor expression
conditions, dose-effect curves collapse on the abscissa. In practice, experimental error may
eclipse a potential differences between genotypes.
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Practical and experimentally imposed limits of detection also influence the ability to
stratify ligands based upon efficacy. The experimental floor may be a function of the sensitivity
of the assay and/or tissue, or an experimenter imposed minimum value. In situations in which the
floor is very high, the EC50 estimate will be shifted to the right relative to the theoretical (Figure
10). The experimental ceiling is usually arbitrarily determined and may not be based upon the
true maximum effect that might be achieved by various agonists. For example, in assays that can
evoke tissue damage (e.g. warm water tail withdrawal and radiant heat tail-flick tests), a cutoff
time is used for animal welfare concerns. Practical considerations such as the length of the test
can also contribute, as in some cases additional observation does not yield a substantial degree of
additional information. In cases where the ceiling is very low relative to the maximum
observable effect, the potency of agonists which do achieve a maximum effect will shift to the
left relative to the true measurable maximum (Figure 11). Although ceiling and floor effects
represent challenges in deriving potency estimations, as long as the same assay conditions are
applied for each agonist then the relative rank order efficacy among the agonists does not
change. Provided the observable effects capture a sufficient portion of each dose-effect
relationship, then whatever potency estimations are calculated will reflect the interrelationships
between the agonists. In the context of using CB1 transgenic mice that express different
concentrations of receptors, ceiling effects likely impose the largest restrictions on measuring
actual differences in maximum effect. Although the maximum effect in HET mice will be half of
what is observed in WT mice, the experimental window may afford maximum effects in both
genotypes with the only apparent difference being potency. Therefore, the potency shift between
the WT and HET mice may reflect efficacy differences, though Emax values may not differ. The
shift in potency, however, would not reflect non-CB1 mediated contributions.
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Figure 10. The experimental floor (as indicated by the solid black line) is often defined by the
sensitivity of the assay. When the floor is high (i.e. sensitivity is low) then the calculated EC50
may be shifted to the right. As the floor becomes lower (i.e. sensitivity is increased) the EC50
shifts left.
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Figure 11. The ceiling (solid black line) of the assay may be the result of experimenter imposed
conditions. If the ceiling is high then it could reflect the actual gain of the system, although
practically it is often reduced due to outside constraints. When the ceiling is low then EC50
estimations are shifted left.
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1.11

The cannabinoid tetrad: a summary of previous findings
As detailed above, numerous synthetic cannabinoids were synthesized utilizing a variety

of backbone moieties. Binding properties of ligands to both cannabinoid receptors have been
investigated using radioligand binding assays, while downstream signaling events such as Gprotein signaling, cAMP accumulation, or ERK1/2 phosphorylation have also been characterized
using variety of in vitro and in vitro techniques. The physiological relevance of these
biochemical measurements requires translational studies. Initial cannabinoid research utilized the
common dog (Canis familiaris) because of their considerable sensitivity to the psychoactive
effects of cannabinoids. THC and other cannabinoid agonists produced ataxia (Dewey et al,
1972), bradycardia (Cavero et al, 1973), and analgesia (Kaymakçalan et al, 1974) in dogs. The
use of canines began to fall out of favor, as reliable bioassays using mice and rats were
increasingly employed. The first iteration of the cannabinoid tetrad was used to investigate
structure activity relationships of THC analogs (Skinner et al, 1979). Later, Billy Martin and
colleagues began heavy use of this method, recognizing that cannabimimetic agents produced a
common spectrum of behavioral and physiological effects. specifically reduction of spontaneous
activity (Martin, 1985), catalepsy, hypothermia (Beardsley et al, 1987), and antinociception
(Martin, 1985) were utilized for these efforts. Catalepsy is defined as a fixed, rigid posture and is
often measured utilizing the bar test or ring test. In the bar test, the forepaws of the subject are
placed on a bar and the latency to remove themselves from the bar as set number of times
(usually four) is measured. In the ring test, the animal is draped across a metal ring and latency to
remove itself is measured. For both the ring test and the bar test, animals which do not have rigid
posture (e.g. immobile but not cataleptic) will not remain on the apparatus. Usually the
experimenter imposes a cut off time to limit the duration of the test. Antinociception can be
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measured a number of ways, though the tail flick assay using radiant heat or immersion in hot
water are the most common methods. In both cases, latency to remove the tail from the
nociceptive stimulus is recorded. Stimulus intensity can be manipulated by adjusting the
temperature, and the maximum may max also be altered though animal welfare concerns usually
determine the ceiling.
This constellation of effects was eventually coined the cannabinoid “tetrad” and
employed to explore in vivo structure activity relationships (Little et al, 1988b). Little and Martin
also employed the stereoselective effects of cannabinoids (Little et al, 1989), corroborating the in
vitro work, which satisfied the requirements for the existence of a distinct cannabinoid receptor
(Devane et al, 1988). Subsequent work featuring the CB1 antagonists rimonabant (Compton and
Martin, 1996; Rinaldi-Carmona, 1994; Rinaldi-Carmona et al, 1995) or AM251 (McMahon and
Koek, 2007), CB1 KO mice (Ledent et al, 1999; Zimmer et al, 1999a) further verified the tetrad
as a reliable screen for in vivo cannabimimetic activity. If a given ligand exhibited these four
effects, it was likely to be a cannabinoid, especially when complemented by biochemical assays
to determine both receptor binding and activation (Compton et al, 1993). A later study adapted
the cannabinoid tetrad assay into a cumulative dosing procedure (Falenski et al, 2010) to afford a
more expeditious manner of generating dose-effect relationships. Because repeated exposure to a
test apparatus leads to acclimation and reduction in exploratory motor behavior, the
hypolocomotion measure was eschewed.

1.12

CB1 transgenic mice as a model: advantages and limitations
Initially cloned in 1990, the CB1 receptor gene Cnr1 encodes a 473 amino acid sequence

contained in a single large exon (Matsuda et al, 1990), and is a seven transmembrane G-protein
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coupled receptor, which signals via Gi/o to inhibit downstream adenylyl cyclase (Devane et al,
1988). The creation of CB1 knockout mice represented a complementary tool to CB1 antagonists
in discerning whether this receptor mediated the pharmacological effects of cannabinoids and to
investigate function of endogenous cannabinoids. Three varieties of mice with constitutive
deletion of CB1 mice exist: outbred CD1 strain (Ledent et al, 1999), the inbred C57BL6/J
(Zimmer et al, 1999a), and another on the C57BL6/J (Robbe et al, 2002). Both the Ledent and
Manzoni approaches replaced a large portion of the gene as well as the upstream promoter region
with a neo cassette. The Zimmer line did not replace the promoter, but rather replaced all but the
first 32 and flanking 24 amino acids. Regardless, none of the lines exhibit CB1 radioligand
binding and the vast majority of putative cannabinoid ligands do not stimulate G-proteins in
these KO mice. The Zimmer line is used by the vast majority of laboratories employing CB1
transgenic mice, although a fourth, doxycycline-inducible CB1 line exists (Marsicano et al,
2002), affording temporal control of CB1 expression.
CB1 KO mice display stark physiological and behavioral phenotypes compared to their
WT and HET siblings. In vivo, they display reduced bodyweight, higher mortality rates, reduced
locomotor activity, and a higher incidence of seizures (Zimmer et al, 1999a). Physiologically,
they display progressive loss of hippocampal neurons with age, though adolescent CB1 KO mice
will sometimes outperform their WT littermates in the rotorod task (Bilkei-Gorzo et al, 2005),
and increased expression of dopamine D2 receptors conveys a resistance to ethanol-induced
conditioned place preference (Houchi et al, 2005) suggesting the deletion of CB1 may not be
entirely deleterious. This finding could be specific to ethanol, although it may reflect a more
general hyposensitivity to reward as CB1 KO imbibe lower totals of a sweetened saccharine
solution (Sanchis-Segura et al, 2004) and do not acquire cocaine self-administration as readily as
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their WT counterparts (Soria et al, 2005). Curiously, basal activity of delta, kappa, and mu
opioid receptors seems to be elevated in CB1 KO mice relative to WT mice (Urigüen et al,
2005), expression and function of GABAA and GABAB receptors is altered (Urigüen et al,
2011), and hypofunction of serotonergic receptors (Mato et al, 2007), though the behavioral
ramifications of these phenotypes are not yet explored.
CB1 KO mice are generally difficult to breed. CB1 KO dams often display poor blastocyst
implantation due to deficiencies in AEA-CB1 signaling (Wang et al, 2003). CB1 also plays a role
in healthy development of sperm, as sperm from CB1 deficient mice show impaired motility
(Maccarrone, 2005). Combined, these consequences of CB1 deletion render KO-KO breeding
pairs generally unsuccessful, but the use of HET mice presents its own set of complications.
During breeding, HET to HET sires and dams often do not yield a Mendelian (1:2:1
WT:HET:KO) distribution of offspring, with the knockouts often underrepresented among their
littermates. Some evidence exists for pre-implantation dynamic regulation of CB1 mRNA and
endocannabinoid signaling (Paria et al, 1995), as well as impaired oviductal transport in CB1 KO
embryos (Wang et al, 2004) which may contribute to the observed, unexpected offspring
distribution. This inevitably necessitates the use of both male and female mice in some cases
when maintenance of large numbers of breeding HET pairs is impractical.
The use of both male and female mice introduces potential variability given known
interactions of the endocannabinoid system and sex-linked characteristics and hormones. Female
rats display dynamic changes in CB1 expression during the estrous cycle, ovarectemized (OVX)
rats express less CB1 in the hypothalamus, and progesterone may rescue this deficit (Rodríguez
de Fonseca et al, 1994). A similar study corroborated the reduced CB1 density in the
hypothalamus of OVX and male Sprague-Dawley rats, and also reported increases in amygdalar
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expression of CB1 in OVX and male rats (Castelli et al, 2014; Riebe et al, 2010). Fluctuations in
a variety of endocannabinoids and related lipids also occur in tandem with estrous (Bradshaw,
2006) potentially affecting the exogenous administration of cannabinoids. Stressors may also
induce changes in CB1 expression in a sex-dependent manner, though a daily non-contingent
shock paradigm may be a severe example (Xing et al, 2011). The potency of some cannabinoids
including THC show sex-dependent differences in producing antinociception, hypolocomotion
(Tseng and Craft, 2001), anti-allodynic effects, and reduction of edema (Craft et al, 2013) in
Sprague-Dawley rats. On the other hand, the synthetic agonist CP55,940 failed to elicit
significant differences in potency to increase the tail withdrawal response in adolescent SpragueDawley male and female rats (Romero et al, 2002), and THC produced few sex-related
differences when injected via the intracerebroventricular route of administration (Wakley and
Craft, 2011). In Long-Evans rats, THC elicited catalepsy, antinociception, hypothermia, and
hypolocomotion irrespective of sex (Wiley et al, 2007). Agonist-stimulated [35S]GTPS of male
and female rats treated chronically with THC revealed greater desensitization in female rats
relative to males following application of CP55,940 (Burston et al, 2010).
In mice, the pattern of results is similarly mixed. Following acute treatment with THC,
female mice from the outbred Swiss-Webster strain displayed both locomotor enhancement at
low doses (3-10 mg/kg), and suppression at the highest dose tested (30 mg/kg) whereas males
displayed exclusively suppression (Wiley, 2003b). No locomotor enhancement was detected in
mice bred for wheel running behavior following WIN55,212-2 (0.5-3.0 mg/kg) administration,
though females seemed resistant to the locomotor suppressing effects of the highest dose tested
relative to males (Keeney et al, 2012)
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The pharmacokinetics may also differ between male and female rodents, depending upon
the drug. Both THC and its bioactive metabolite 11-hydroxy-9-tetrahydrocannabinol (11-OHTHC) are detected in higher concentrations in the female rat brain than in male brains following
an acute administration, although differences in magnitude to produce antinociception and
catalepsy for either sex were not directly compared (Tseng and Craft, 2001; Wiley and Burston,
2014). In addition to pharmacokinetic differences, sex may influence the downstream signaling
events which CB1 receptors modulate. In female, but not male, guinea pig hypothalamic neurons,
WIN55,212-2 increased the necessary voltage to activate A-type potassium channels (Tang et al,
2005), and female Listar Hooded rats display larger depolarization-induced suppression of
inhibition (DSI) compared to their male counterparts (Melis et al, 2013).
The numerous studies highlighting the potential for sex differences when testing
cannabimimetic agents collectively indicate that researchers should remain sensitive to these
outcomes. Transgenic mice are often in short supply necessitating mixed sex groups of mice
during experiments. While utilizing both sexes may not result in measurable differences between
them, this approach also has the advantage of being potentially sensitive to these outcomes
should they arise. Moreover, humans display sex-related cannabinoid effects including frequency
of use, anxiety, mental health status, and pharmacokinetic differences (Fattore and Fratta, 2010),
thus highlighting the importance of sensitivity to these effects via inclusion of both sexes in
preclinical assays of cannabimimetic effects.

1.13

Experimental design to determine efficacy
To determine in vivo efficacy at the CB1 receptor, CB1 WT, HET, and KO mice were

cumulatively dosed (similar to Falenski et al., 2010) with cannabinoid agonists until a pre-
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determined maximum has been reached in for catalepsy (60 seconds of immobility),
antinociception (10 seconds in a 52C water bath), and hypothermia (C from baseline). The
use of cumulative dosing does, however, preclude the use of hypolocomotion as measured by
spontaneous activity. Observed reductions in spontaneous activity due to habituation are difficult
to distinguish from CB1-mediated hypolocomotion during repeated testing (Drew and Miller,
1973). Dose ratios calculated between WT and HET dose-effect curves via linear regression will
serve as a proxy measure for efficacy differences which are not observable under these
conditions due to extenuating factors influencing the ceiling of the assay. KO mice will serve as
controls for potential off target effects of drugs. In cases where the solubility limits of a given
compound preclude observing maximum effects, potency ratios will not be calculated although
this pattern of effects provides strong evidence that the tested ligand possesses low efficacy. An
alternative approach may be to consider the maximum effect stimulated by the ligands in HET
mice, although solubility of the compounds at extremely high doses rendered interpretation of
the data in this manner difficult. Finally, selection of ligands should include ligands of both very
high and very low efficacy as determined by previously published results.
In addition to relinquishing the hypolocomotion measure, cumulative dosing versus
dosing distinct groups presents a number of methodological differences and practical
considerations. Practically, cumulative dosing affords the use of a much smaller number of mice,
can be completed at a much faster pace, and it allows the use of repeated measures statistics.
Separate dosing requires many more mice and as such is much more time consuming. One must
also use between subject experimental designs which may necessitate the use of a higher number
of experimental animals per group to detect statistically significant differences. Additionally,
with repeated testing of the same mice one can look at the relative differences between doses in
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addition to change from baseline for each individual mouse therefore permitting normalization at
each data observation for each mouse rather than a before and after approach often used with
separate dosing procedures. Cumulative dosing was employed here as it allowed a high
throughput, within subject approach to determine dose-effect relationships with reduced number
of mice compared to separate groups of animals used to determine dose-effect relationships.
Cumulative dosing is associated with potential pitfalls, notably pharmacokinetic and
pharmacodynamics considerations, which are more adequately controlled in separate dosing
procedures. Rodents dosed cumulatively are exposed for a much longer duration of time to drug
and are often dosed at a specific interval (every 40 minutes typically) irrespective of the optimal
onset and duration of the test drug. If the pretreatment time is too short or too long then maximal
effects of a given dose may be missed or observed later in the presence of additional drug. This
may result in an erroneous estimation of the ED50. Separate dosing necessarily avoids this
complication, as each animal is given the same pretreatment time for a given dose of drug.
Additionally, time course studies may readily be incorporated into separate dosing experiments
so that the peak effects at each dose are observed, informing the timing of dosing in subsequent
experiments. In the case of cannabinoids, the duration of effects in the tetrad are typically quite
long, even in mice, so in many cases a 30 minute pretreatment is likely sufficient (see Chapter 2,
Figures 17-23). However, the characteristic long duration of action also introduces potential
pharmacodynamic confounds to estimation of the ED50 and therefore potency. Tachyphylaxis, or
rapid changes in the response to a drug, is a form of short term adaptation. The mechanisms
underlying tachyphylaxis are not well understood in relation to cannabinoids, but on longer
timescales receptor level adaptations occur. Repeated administration of numerous cannabinoids
produce tolerance and cross tolerance to the acute effects of these drugs in the tetrad (Fan et al,
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1994), and concurrent internalization, downregulation, and desensitization (Nguyen et al, 2012)
likely occur. If an animal is exposed to progressively higher doses of an agonist capable of
producing these adaptations, the likelihood that these same changes occur within session may
correspond with the current cumulative dose. Thus, as increasing concentrations are administered
the number of receptors available will be reduced and the remaining receptors may be less
sensitive to the application of the same agonist. If tachyphylaxis occurs under cumulative dosing
conditions the ED50 would be underestimated when compared to separate dosing. These
stipulations do not consider differences among test ligands in regards to efficacy which can cause
differential degrees of receptor adaptation.
The Stephenson model of receptor theory predicts that lower efficacy drugs must occupy
a higher fraction of the available receptors to elicit the same response. In mice continuously
infused with ED50 doses of  opioid agonists which differ in efficacy, lower efficacy ligands
produced the greatest degree of tolerance while much smaller magnitudes of tolerance were
observed for those ligands with high efficacy (Madia et al, 2009). As low efficacy ligands must
occupy more receptors than high efficacy ligands to elicit the same response, receptor occupancy
may drive tolerance. When naloxone was administered at the peak effect of morphine
administered intravenously (Hovav and Weinstock, 1987), diminished or no tolerance occurred,
implicating receptor occupancy as a potential determinant of tolerance. Many cannabinoid
agonists induce downregulation and desensitization in vitro, such as THC (Sim et al, 1996a),
CP55,940 (Rinaldi-Carmona et al, 1998), and WIN55,212-2 (Jin et al, 1999). THC has been
reported to cause considerable desensitization measured at the G-protein level while not
appreciably reducing receptor number in some brain regions such as cerebellum, hippocampus,
and striatal regions (Breivogel et al, 1999), perhaps indicating higher efficacy ligands reduce
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receptor sensitivity to subsequent stimulation while occupying few receptors resulting in
minimal downregulation. Another study using WIN55,212-2 and THC in which ED50 doses were
doubled every three days revealed that this may not be correct, as each drug caused similar
reductions in CB1 receptors across brain regions while THC produced much higher levels of
desensitization. Additionally, chronic administration of the low efficacy endocannabinoid AEA
(Breivogel et al, 2001; Griffin et al, 1998) in rats does not result in downregulation while
substantial desensitization occurs (Rubino et al, 2000). This study does not however, consider
the rapid metabolism of AEA by fatty acid amide hydrolase (FAAH) (Giang and Cravatt, 1997),
which would effectively render AEA concentration in the brain negligible. Additionally, AEA is
known to produce agonist-stimulated [35S]GTPS binding in mice devoid of CB1 (Di Marzo et
al, 2000); thus, a non-CB1 mechanism likely accounts for the observed desensitization. Though
evidence for receptor occupancy driving cannabinoid tolerance remains inconclusive, it
nonetheless should be considered in terms of cumulative dosing when utilizing mice which
already possess a reduced number of receptors as is the case with CB1 HET mice. A high
efficacy ligand would require fewer receptors to elicit the same response as a lower efficacy
ligand, therefore a higher fractional occupancy is necessary. The degree of tachyphylaxis may be
higher for drugs which require higher numbers of receptors, therefore the ED50 estimation under
cumulative dosing conditions might shift further to the right for lower efficacy drugs as
compared to the same drug tested with separate dosing. When trying to make comparisons
between drugs to assess efficacy with cumulative dosing, the apparent ED50 for higher efficacy
drugs is likely closer to that of separate dosing groups while lower efficacy drugs may be shifted
considerably to the right. This effect means that resolution to differentiate CB1 ligands which
possess high efficacy would be diminished while lower efficacy drugs may more readily be
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differentiated. Utilizing experimental endpoints which depend upon CNS regions possessing
lower concentrations of CB1 would potentially exacerbate this effect, while very high
concentrations of CB1 could functionally negate this effect.
The CB1 ligands tested were chosen based upon previously published results in both
triad/tetrad experiments as well as agonist-stimulated [35S]GTPS binding. Most cannabimimetic
agents elicit full suppression of spontaneous locomotor activity, up to several minutes of
catalepsy in the ring immobility (Wiley et al, 1998) and bar tests (Falenski et al, 2010),
significant reductions in body temperature, and increases in latency to withdrawal responses
from a noxious stimuli. However, considerable methodological differences exist across the
literature for each endpoint and in most cases the ceiling of the assay is determined arbitrarily.
Agonist-stimulated [35S]GTPS binding provides an enhanced ability to distinguish efficacy
between ligands via measuring the functional activity at the CB1 receptor as one may readily
measure difference in maximal activation, (Emax). The differentiation in efficacy depends on a
number of factors which are discussed more specifically above, but it should be noted that GDPGTP exchange at the G-protein does not fully encompass the spectrum of effects elicited by
cannabinoids via the CB1 receptor. Many other pathways are possible including BARR2mediated ERK1/2 signaling, which may interfere with the a priori selection of cannabinoids
based upon their efficacy to produce effects at one level for one pathway. As such, it will be
necessary to compare findings in the triad to functional CB1 activity via agonist-stimulated
[35S]GTPS binding.
1.14

Cannabinoids in preclinical abuse liability testing assays
Homo sapiens have imbibed marijuana in various forms for millennia, both for

therapeutic and recreational uses. The intoxicating effects are well documented and elicited
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primarily by THC through the activation of CB1 receptors (Huestis et al, 2001), and marijuana
remains the most popular drug of abuse worldwide. CB1 receptors are expressed on GABAergic
and glutamatergic neurons (Tsou et al, 1998) and are abundant in reward-relevant regions of the
mammalian brain such as the ventral tegmental area (VTA) and the nucleus accumbens (NAcc)
(Herkenham et al, 1990). Relatively low doses of THC evoke dopamine release in the NAcc
(Chen et al, 1991; Ng Cheong Ton et al, 1988), which is thought to be a common mechanism for
many drugs of abuse (Di Chiara and Imperato, 1988). Despite its abundant use by man, THC
remains an enigma in preclinical abuse liability testing, as it fails to elicit reliable abuse-related
effects in the many assays of abuse liability, including conditioned place preference (CPP), selfadministration (SA), and intracranial self-stimulation (ICSS).
CPP is a Pavlovian conditioning procedure in which animals (typically mice or rats) are
exposed to two chambers with a variety of differing cues including the pattern on the walls, the
floor texture, and potentially other cues. A neutral connecting chamber is sometimes present as
well. A drug is then randomly paired for each subject to one of the chambers while an
appropriate vehicle is paired to the other. The subject is later returned to the apparatus with
access to all chambers and the time it spends in each is counted. Common drugs of abuse such as
psychomotor stimulants (Spyraki et al, 1982), opiates (Mucha et al, 1982), ethanol (Shimizu et
al, 2015), and nicotine (Kota et al, 2008) produce condition place preference wherein the subject
spends more time in the drug paired side than it did prior to conditioning (or more time in the
drug-paired versus vehicle-paired chamber), whereas aversive drugs, such as kappa opioid
receptor agonists (Suzuki et al, 1992) or lithium chloride (Mucha et al, 1982), elicit conditioned
place aversion such that the subject spends less time in the drug paired side. THC has been
reported to elicit conditioned place preference (Braida et al, 2004; Lepore et al, 1995; Manwell
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et al; Valjent et al, 2002) as well as place aversion (Cheer et al, 2000; Manwell et al; Parker and
Gillies, 1995; Sañudo-Peña et al, 1997). Similarly, SCs, such as CP55,940 (McGregor et al,
1996), WIN55,212-2 (Chaperon et al, 1998), and HU-210 (Cheer et al, 2000), tend to elicit
conditioned place aversion though a conditioned place preference has been reported for very low
doses of CP55,940 (Braida et al, 2001a). Pre-exposure to the test ligand in the absence of the
chamber may unmask a conditioned place preference for THC (Valjent and Maldonado, 2000)
and the synthetic cannabinoid AM281 (Botanas et al, 2015), although the underlying
neurobiological mechanisms are not well understood.
SA has long stood as the standard for testing the abuse liability of drugs. Laboratory
animal models of SA are generally highly predictive of abuse potential in humans. While abused
drug classes, such as opiates and psychomotor stimulants, are readily self-administered (van Ree
et al, 1978), cannabinoid SA has been difficult to demonstrate in laboratory animals. Rhesus
monkeys failed to acquire THC self-administration under fixed-interval schedule (Mansbach et
al, 1994), while squirrel monkeys self-administered very low doses of THC (Justinova et al,
2003; Tanda et al, 2000). Intracerebroventricular self-administration of THC was also achieved
in Wistar rats (Braida et al, 2004). SA of SCs is also difficult to demonstrate in laboratory
animals, though WIN55,212-2 SA seems comparatively robust relative to that of other
cannabinoids. WIN55,212-2 is self-administered by DBA mice at very low doses (Martellotta et
al, 1998) and by Long-Evans rats at low doses as well under an FR1 schedule (Fattore et al,
2001). CD1 mice also self-administer WIN55,212-2 if given a priming dose (Mendizábal et al,
2005). Sprague-Dawley rats trained to self-administer WIN55,212-2show an elevation of
extracellular dopamine in the NAcc shell, but not in the core (Lecca et al, 2006). This effect was
also found in Listar Hooded and Long-Evans rats (Fadda et al, 2006). In a subsequent study by
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the same research group, Lister Hooded and Long-Evans rats, but not Sprague-Dawley rats, selfadministered WIN55,212-2 (Deiana et al, 2007). In another study, Long-Evans rats learned to
self-administer WIN55,212-2, but failed to acquire THC self-administration, calling into
question the validity of WIN55,212-2 as a screen for cannabinoid abuse liability (Lefever et al,
2014). Other cannabinoid agonists are also self-administered to some degree, though reports are
scarce. Wistar rats self-administered CP55,940 via the intracerebroventricular route of
administration (Braida et al, 2001b) and the endogenous cannabinoid 2-AG was selfadministered by squirrel monkeys (Justinová et al, 2011). Finally, JWH-018 was selfadministered by both Sprague-Dawley and C57BL/6J mice and increases extracellular dopamine
in rats (De Luca et al, 2015). To date, it is unknown why some SCs, and WIN55,212-2 in
particular, are readily self-administered by some strains while THC is generally not regardless of
strain. This effect may be related to the partial agonist properties of THC, or the apparently very
narrow dose range at which THC might be self-administered. Higher doses of THC produce
aversive-like states in other assays such as CPP thus SA of THC may also elicit a similarly
aversive state.
ICSS is another preclinical assay of abuse liability which has good predictive validity for
drugs of abuse (Negus and Miller, 2014). ICSS functions via implantation of an electrode into
the medial forebrain bundle (MFB) (Olds & Milner, 1954), a tract of ascending and descending
neuronal projections, some of which synapse onto dopaminergic neurons in the VTA, which then
project into the NAcc resulting in release of dopamine in the NAcc (Phillips et al, 1989; Stellar
and Stellar, 1985). The results of tandem ICSS and fast scan cyclic voltammetry (Kruk et al,
1998) and microdialysis studies (Miliaressis et al, 1991) suggest that dopamine release alone
may not be sufficient to drive the behavior, though strong neurochemical evidence implicates
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dopamine release as a major component of ICSS (Fiorino et al, 1993). Electrical stimulation of
the MFB elicits vigorous operant responses for brain stimulation. The electrical stimulation
offers tight temporal control and the frequency and amplitude of the electrical stimulation can be
easily manipulated within session to generate a wide range of response rates in a relatively short
period of time. Facilitation of ICSS is considered predictive of abuse liability, while suppression
may indicate abuse-limiting effects (Negus and Miller, 2014). Monoamine releasers (Bauer et al,
2013), mu opioid agonists (Altarifi et al, 2013), GABAA agonists (Tracy et al, 2014), and
nicotinic agonists (Freitas et al, 2015) facilitate ICSS. In contrast, kappa opioid agonists (Negus
et al, 2010) and serotonin releasers (Bauer et al, 2015) tend to suppress ICSS. THC has been
reported to modestly facilitate ICSS in Lewis rats at a dose of 1.5 mg/kg (Gardner et al, 1988)
and Sprague-Dawley rats at doses of 1.0 mg/kg and 0.1 mg/kg (Katsidoni et al, 2013; Lepore et
al, 1996), though other experiments indicate it produces little effect at low doses and suppression
of ICSS at high doses in Sprague-Dawley rats (Kwilasz and Negus, 2012; Vlachou et al, 2007)
and C57BL/6J mice (Wiebelhaus et al, 2015). In contrast to its effects in self-administration
studies, WIN55,212-2 produces marked suppression of ICSS in Sprague-Dawley rats (Mavrikaki
et al, 2010; Vlachou et al, 2004). CP55,940 suppresses ICSS in Sprague-Dawley rats (Arnold et
al, 2001; Kwilasz and Negus, 2012; Vlachou et al, 2004) and in C57BL/6J mice (Grim et al,
2015). HU-210 (Vlachou et al, 2004) suppresses ICSS in Sprague-Dawley rats. Inhibition of
FAAH, the primary catabolic enzyme of anandamide, does not affect ICSS at low doses but
produces a small suppression of ICSS via a non-CB1, non-CB2 mechanism (Kwilasz and Negus,
2012; Wiebelhaus et al, 2015). Similarly, inhibition of monoacylglycerol lipase (MAGL), which
elevates endogenous 2-AG, suppresses ICSS in a CB1-dependent manner (Wiebelhaus et al,
2015).
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Although cannabinoids do not display the usual pattern of results that most other drugs of
abuse display, the fact remains that humans abuse them. This discrepancy may reflect a failure to
identify assay conditions in which abuse-related properties are unveiled. For instance, blood
concentrations of THC in humans smoking marijuana are quite low (~10 ng/ml peak) (Cone et
al, 2015) compared to blood concentrations achieved via interperitoneal injection necessary to
produce robust catalepsy, hypothermia, and antinociception in mice (~500-1000 ng/ml) (Falenski
et al, 2010), reflecting a large gap between the doses that are self-administered in humans versus
the experimentally-induced doses in preclinical assays. Route and method of administration may
also play a role. Animal models generally rely upon non-contingent, intravenous or
interperitoneal injection as opposed the human method of ingestion which is generally smoked
and done so purposefully. Ongoing efforts to identify the abuse liability of cannabinoids
nonetheless remain important, and alternative approaches are clearly needed. Testing for
tolerance and dependence represents a possible mechanism by which other aspects of drug abuse
beyond the acute abuse-related effects could be assessed.

1.15

Dependence and synthetic cannabinoids in humans and laboratory animals
Abrupt cessation of marijuana consumption following prolonged use can lead to

withdrawal in humans. Cannabinoid withdrawal features at least three of the following seven
clinical signs: 1) irritability, anger, or aggression; 2) nervousness or anxiety; 3) sleep difficulty
(e.g. insomnia, disturbing dreams); 4) decreased appetite or weight loss; 5) restlessness; 6)
depressed mood; and 7) physical symptoms such as abdominal pain, shakiness, tremors,
sweating, fever, chills, or headache (American Psychiatric Association, 2013). Heavy cannabis
users report experiencing robust withdrawal symptoms following discontinuation of cannabis use
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(Allsop et al, 2012). Laboratory animal models of cannabinoid dependence have been developed
in which a cannabinoid is administered over a period of days, and then subjects are challenged
with a CB1 receptor antagonist to precipitate withdrawal. The most common precipitated somatic
withdrawal signs include paw tremors and head shakes, and are readily observed following
rimonabant challenge in THC-dependent rats (Aceto et al, 1995, 1996) and mice (Cook et al,
1998). Rimonabant is known to act as an inverse agonist (Smith et al, 2015), suggesting that the
ensuing withdrawal signs in cannabinoid-treated animals is the result of this property, instead of
simple displacement of the agonist. However, recent work by Jarbe’s group demonstrated that
the neutral CB1 receptor antagonist AM4113, precipitated withdrawal responses in THCdependent animals, demonstrating that CB1 receptor blockade is sufficient to precipitate
withdrawal (Tai et al, 2015b). In contrast to precipitated withdrawal models, spontaneous
withdrawal from cannabinoids is more difficult to detect, though spontaneous somatic signs of
withdrawal were detected following continuous infusion of WIN55,212-2 (Aceto et al, 2001).
Non-somatic signs of withdrawal have been more difficult to demonstrate, even when
withdrawal is precipitated. Mice treated with THC sub-chronically and administered rimonabant
displayed deficits in spatial memory as measured by the Morris water maze (Wise et al, 2011).
Rimonabant precipitated withdrawal also unveils an anxiety-like phenotype in mice (Huang et al,
2010). Abrupt cessation of CP55,940 (0.5 mg/kg, b.i.d., 7 days) produced an anxiety-like
phenotype and locomotor depression in rats (Aracil-Fernández et al, 2013), while cessation of
HU-210 elicited only hypolocomotion (Moreno et al, 2005). To date, only two studies
investigated the consequences of repeated cannabinoid administration on reward processes
utilizing the ICSS procedure (Chapter 3) (Grim et al, 2015; Mavrikaki et al, 2010). In the case of
WIN55,212-2, rats did not become tolerant to the rate decreasing effects of WIN55,212-2,
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despite 22 days of administration, and no mention of withdrawal from these effects was reported.
Similarly, mice treated repeatedly with CP55,940 did not display signs of spontaneous or
precipitated withdrawal following seven days of dosing, though tolerance was reported (Chapter
3) (Grim et al., 2015).
1.16

Objectives and hypotheses
Given the dissimilar patterns of abuse-related and toxicological effects between THC and

SCs, there is a need to assess potential mechanisms that might mediate the obvious discrepancy.
SCs also generally possess unknown pharmacology and toxicology, and they are generally used
first in man, highlighting the need for in vivo methods of assessing their pharmacological
properties. One aspect of abused SCs which distinguishes them from THC is their enhanced
potency and efficacy at the CB1 receptor. A first step to determine whether or not this enhanced
CB1 activity plays a role in the health complications engendered by SCs is determination of their
relative efficacies in vivo, and what effect that may have upon abuse-related behaviors. The
research presented in this thesis investigated the consequences of acute and repeated
administration of synthetic cannabinoids in established mouse models of abuse and
cannabimimetic activity.
As SCs possess a spectrum of effects ranging from toxicity to abuse-related effects, they
should be assessed in assays that capture effects on various physiological effects and effects on
reward processes. Here, I utilized a “bottom-up” approach, first characterizing the efficacy of six
cannabinoids for their CB1 functional activity in an in vitro assay and centrally-mediated
physiological consequences of CB1 activation in the whole animal. Next, one ligand (CP55,940)
was selected as a representative SC and assessed for abuse-related effects on reward processes.
More specifically, I applied basic pharmacological principles to determine in vitro and in vivo
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efficacy and receptor mediation of synthetic cannabinoids (see Chapter 2) and then assessed the
abuse- and dependence-related properties of the synthetic cannabinoid CP55,940 in the ICSS
(see Chapter 3). Together, these aims will explore the contribution of efficacy to elucidate
possible differences between THC and abused SCs.

Hypothesis: SCs will have enhanced efficacy at the CB1 receptor as compared to THC to elicit
in vivo cannabimimetic effects, and this will translate into enhanced abuse-related effects.

1.17

Chapter 2: hypothesis
Determination of in vivo efficacy and receptor mediation of cannabimimetic effects were

conducted using CB1 WT, HET, and KO mice in a cumulative dosing procedure in which mice
were assessed for catalepsy, hypothermia, and antinociception (the cannabinoid triad) after each
dose The cannabinoid triad was utilized to establish a rapid screening method to ascertain in vivo
efficacy as well as test whether a 50% reduction in CB1 receptors will produce a concordant loss
of potency in the CB1 HET mice. Additionally, CB1 KO mice enabled the detection of whether
any of the test compounds elicited non-CB1 triad effects. ED50 values were calculated by linear
regression after conversion to % effect, when appropriate, to examine shifts in potency between
CB1 WT and HET mice. The ceiling of each measure is as follows: 60 seconds for catalepsy, 8C from baseline for hypothermia, and 10 seconds for tail withdrawal. Data transformations are
detailed below. Dose ratios will be calculated by dividing the WT ED50 by the HET ED50.

Catalepsy

=

Hypothermia

=
68

𝑡𝑒𝑠𝑡
60

x 100

𝑡𝑒𝑠𝑡−𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
−8

x 100

=

Antinociception

𝑡𝑒𝑠𝑡−𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
10−𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒

x 100

Hypothesis: For the in vivo determination of efficacy, the efficacy of the test ligand is expected
to vary inversely with the potency shift observed between WT and HET mice, while KO display
no pharmacological effects of each agonist. Furthermore, this potency shift will correlate with ex
vivo agonist stimulated [35S]GTPgS binding utilizing the same test drugs in WT, HET, and KO
CNS tissue. The non-CB1 drugs morphine and chlorpromazine are expected to be equipotent
across WT, HET, and KO mice.
1.18. Chapter 3: hypothesis
For abuse liability and dependence testing in ICSS, CP55,940 was selected as an
archetypal representative of highly potent and efficacious synthetic cannabinoids commonly
found in abused preparations. To assess whether synthetic cannabinoids facilitate ICSS an acute
dose response of CP55,940 will be determined. To determine whether rate decreasing or rate
increasing effects are CB1-mediated, a high dose of CP55,940 will be preceded by a dose of
rimonabant sufficient to return responding to baseline levels. Tolerance to these effects will be
assessed over seven days of dosing with a high dose of CP55,940 after which changes in baseline
responding will be analyzed for changes related to spontaneous withdrawal. The same seven day
dosing procedure will be used again, this time with a high dose of rimonabant on the final day to
assess precipitated withdrawal. Together, these studies will examine the effect of both acute and
repeated administration of a highly potent and efficacy cannabinoid on brain reward processes.

Hypothesis: For abuse-liability and dependence testing utilizing the representative SC CP55,940
in ICSS, mice will display changes in rates of responding for ICSS following spontaneous and
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precipitated withdrawal. Acutely, CP55,940 will suppress rates of responding in a CB1
dependent manner, and rimonabant will elicit no rate-suppressing effects.
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Chapter 2

Stratification of cannabinoid 1 receptor (CB1) agonist efficacy: Manipulation of CB1 density
through use of transgenic mice reveals congruence between in vivo and in vitro assays

Grim TW1, Morales AJ1, Gonek MM1, Wiley JL2, Thomas BF2, Sim-Selley LJ1, Selley DE1,
Negus SS1, Lichtman AH1.
Virginia Commonwealth University – Pharmacology and Toxicology, Richmond, VA, USA1
Research Triangle Institute, Winston-Salem, NC, USA2
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ABSTRACT
Diversion of synthetic cannabinoids (SCs) from research purposes to abused preparations
threatens public health. Ensuing emergency scheduling resulted in clandestine synthesis of novel
SCs with heretofore unseen structures detected in abused preparations. Here, we incorporated
commonly employed in vivo and in vitro assays, CB1 transgenic (CB1 wild type (WT),
heterozygous (HET), and knockout (KO)) mice to vary receptor density, and basic
pharmacological principles to provide insight into the potency, selectivity and efficacy of CB1
receptor-mediated effects produced by these rapidly emerging drugs of abuse. Accordingly, we
examined the dose-response relationships of THC and five SCs in producing well-established in
vivo (catalepsy, hypothermia, and antinociception) and in vitro (agonist-stimulated GTPS
binding) pharmacological effects of cannabinoids. Whereas cannabinoid-induced catalepsy was
resistant to a 50% reduction in CB1 density, hypothermia and antinociception showed liganddependent increases in agonist ED50 values and decreases in Emax values. In contrast, noncannabinoid compounds (morphine and chlorpromazine) produced pharmacological effects in
subsets of these assays, regardless of genotype. In vitro CB1 activity assessed by agoniststimulated GTPS binding significantly correlated with altered drug potency (WT ED50 ÷ HET
ED50) to produce hypothermia (r=0.84) and antinociception (r=0.95), but not catalepsy. These
findings suggest that neural substrates subserving cannabinoid-induced antinociception and
hypothermia contain a smaller CB1 reserve than for cannabinoid-induced catalepsy. More
generally, this study offers a conceptual framework and high-throughput screening method to
evaluate potency, selectivity and efficacy of not only emerging abused cannabimimetic ligands,
but also naturally-occurring cannabinoids and other cannabinoids being developed as research
tools or potential therapeutics.
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1. Introduction
Synthetic cannabinoids (SCs), comprised of myriad structures and largely unknown
pharmacology (Kronstrand et al, 2013; Louis et al, 2014; Sobolevsky et al, 2015), have emerged
as drugs of abuse representing significant public health threats (Law et al, 2015; Trecki et al,
2015). In stark contrast to THC, the primary psychoactive constituent of cannabis, SCs have
been linked to life-threatening medical complications (Clark et al, 2015; Freeman et al, 2013;
Mir et al, 2011; Takematsu et al, 2014; Thornton et al, 2013), psychological complications
(Celofiga et al, 2014; Meijer et al, 2014; Peglow et al, 2012; Schwartz et al, 2015; Thomas et al,
2012), and death (Behonick et al, 2014; Gerostamoulos et al, 2015; Shanks et al, 2015; Westin et
al, 2015). These clinical observations suggest that SCs pose a more general threat than
cannabis/THC to public safety. Withdrawal-like symptoms from SCs have also been reported
(Nacca et al, 2013; Sampson et al, 2015), indicating a possibility for dependence.
The mechanisms that underlie heightened risk for medical complications by SCs in
comparison to cannabis/THC are not known and may vary according to the particular SC under
consideration. Similar to THC, SCs bind and activate CB1, a GPCR, which plays an important
role in mediating behavioral effects produced by marijuana and CB1 agonists (Huestis et al,
2001; Rinaldi-Carmona, 1994). Effects of SCs at non-CB1 could be one factor that contributes
to toxicity associated with these drugs (Sherpa et al, 2015). Moreover, based largely on results
from in vitro assays of agonist-stimulated [35S]GTPS binding (Burkey et al, 1997a, 1997b;
Selley et al, 1996), THC is defined as a low-efficacy CB1 agonist, whereas many SCs are defined
as high efficacy CB1 agonists. Accordingly, high efficacy of SCs at CB1 may also contribute to
heightened risk for clinical complications. However, existing in vivo assays used to assess
cannabinoid effects have poor resolution for distinguishing CB1 agonist efficacy. For example,
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although in vitro assays of agonist-stimulated [35S]GTPS binding indicate that THC and the SC
WIN55,212-2 possess low and high efficacy at CB1 receptors, respectively (Griffin et al, 1998),
these drugs produce similar maximal effects in assays of catalepsy, hypothermia and
antinociception that are commonly used to assess behavioral pharmacology of cannabinoids in
mice (Fan et al, 1994). Drug discrimination procedures, in which efficacy requirements are
manipulated by using different training doses of a high-efficacy cannabinoid training drug (Järbe
et al, 2014) or by induction of tolerance to THC (Hruba et al, 2012), represent effective
strategies to improve sensitivity of behavioral assays to detect agonist efficacy. However,
throughput with these procedures is relatively slow, and they have not been widely used.
Consequently, new strategies for rapid in vivo evaluation of CB1 selectivity and efficacy could
facilitate efforts to evaluate pharmacology of novel SCs and predict potential for abuse or
clinical harm.
Here, we hypothesize that comparison of in vivo drug effects in CB1 wild type (WT) and
knockout (KO) mice will provide information on CB1 selectivity of SCs, and comparison of drug
effects in WT and CB1 heterozygous (HET) mice will provide information on CB1 efficacy. To
test this hypothesis, we utilized CB1 KO, HET, and WT mice to determine in vivo and in vitro
effects of THC, CP55,940, WIN55,212-2, and SCs associated with abuse (CP47,497, JWH-073
(Atwood et al, 2011), and A-834,735D). We incorporated a similar in vivo approach to that used
previously for investigation of mu opioid receptor (MOR) agonist efficacy, in which MOR HET
mice showed diminished morphine antinociception compared with WT mice (Sora et al, 2001).
The present study employed a cumulative dosing procedure to increase throughput in
determining the dose-response relationships of each ligand to elicit well described
cannabimimetic effects (i.e., catalepsy, hypothermia, and antinociception). In addition, the non-
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cannabinoids morphine and chlorpromazine, which are active in some of these assays (Wiley,
2003a), were included as negative controls predicted to produce effects independent of CB1
genotype. Finally, [3H]SR141716A binding was conducted to confirm that CB1 density was
reduced by half in HET mice, and drug effects on agonist-stimulated [S]GTPS binding were
evaluated to provide an in vitro correlate for in vivo measures of CB1 selectivity and efficacy.
Membranes from both cerebellum and spinal cord from WT, HET and KO mice were used in
assays of [S]GTPS binding to provide tissue sources with varying CB1 densities.
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2. Methods
2.1 Subjects
Male and female CB1 WT, HET, and KO mice (Zimmer et al, 1999a) derived from CB1
HET breeding pairs backcrossed at least 15 generations with C57BL/6J mice served as subjects.
Mice had ad libitum access to food and water and were maintained on a 12 h light/dark cycle.
Approximately 80 mice between 8 and 36 weeks of age were used for all experiments, which
were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals
and were approved by the Virginia Commonwealth University Institutional Animal Care and Use
Committee (IACUC).
2.2 Drugs
Studies were conducted with THC and with five SCs purported to have higher efficacy
than THC at CB1 receptors. The five SCs were (in order from purported highest to lowest
efficacy) A-834-735D, WIN55,212-2, and CP55,940, JWH-073, CP47,497 (Atwood et al, 2011;
Auwärter et al, 2009; Griffin et al, 1998). The mu opioid receptor agonist morphine and
dopamine receptor antagonist chlorpromazine were also studied as negative controls expected to
produce behavioral effects insensitive to the CB1 receptor density. A-834,735D, WIN55,212-2,
CP47,497, JWH-073 and chlorpromazine were obtained from Cayman Chemical (Road, Ann
Arbor, MI), and morphine, THC and CP55,940 were generously supplied by the National
Institutes on Drug Abuse Drug Supply Program (Research Triangle Institute, Raleigh, NC) for
behavioral experiments. Each drug was dissolved in 100% ethanol, an equal volume of
Emulphor EL-620 was added, and then 18 parts of 0.9% saline was added for a final ratio of
1:1:18. For binding assays, THC-CRM was acquired from Cayman, and [3H]SR141716A was
purchased from Perkin-Elmer (Waltham, MA).
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2.3 Behavioral Assays
To assess in vivo cannabimimetic activity, catalepsy, hypothermia and antinociception
(see Supplementary Methods for details) were measured at baseline, and cumulative dose
response curves were established for each test compound as previously described (Falenski et al,
2010). The three tests required approximately 10 min to complete for six mice; thus groups of six
mice were injected every 40 min with increasing doses of the test agonist and tested 30 min after
each injection. Dose-effect curves for each agonist on each behavioral endpoint were analyzed
by two-way ANOVA, with dose and genotype as the two factors. A significant ANOVA was
followed by Holm-Sidak post hoc analysis, assessing dose-dependent changes within genotype
as well as differences in drug effect between genotypes at each dose. In addition, ED50 values
and 95% confidence limits for drug effects on behavioral measures were determined via linear
regression (Colquhoun, 1971), and ED50 values were considered to differ if 95% confidence
limits did not overlap. The ED50 was defined as the dose to produce immobility for 30 sec in the
catalepsy test, a 4°C loss in body temperature in the hypothermia test, or 50% of the maximum
possible effect in the antinociception test. To assess changes in agonist effects produced by the
lower CB1 receptor density in HET vs. WT mice, dose ratios (DR) were calculated using the
equation (WT ED50/HET ED50) for each agonist on each behavioral measure. We hypothesized
that this dose ratio would serve as an in vivo measure of agonist efficacy.

2.4 Cellular Assays
2.4.1 Membrane Preparation
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Male and female CB1 WT, HET, and KO mice were euthanized via rapid decapitation.
Cerebellum were harvested and bisected and spinal cords were taken from lumbar to cervical
regions. Details for membrane can be found under Supplementary Methods.
2.4.2 [3H]SR141716A radioligand binding
Using established methods (Selley et al, 2001), cerebellum and spinal cord samples were
diluted with assay buffer to 10 g/ml and 15 g/ml, respectively. Membrane homogenates were
then incubated with [3H]SR141716A (0.03-10 nM) in the absence and presence of a saturating
concentration of unlabeled SR141716A (5 M) to assess specific and non-specific binding. The
assay was incubated until equilibrium was attained (90 min) at 30 °C, and then the reaction was
terminated by rapid filtration under vacuum through Whatman GF/B glass fiber filters presoaked in Tris buffer containing 0.5% bovine serum albumin (BSA) followed by three washes.
Bound radioactivity was measured via liquid scintillation spectrophotometry at 45% efficiency
after a 9 h delay to allow the liquid scintillation fluid to dissolve the filter paper. For
[3H]SR141716A radioligand binding assays, saturation binding (Bmax) and affinity were
determined by non-linear regression saturation analysis in GraphPad Prism 6.0. Data are
expressed as mean values ± standard error of the mean.
2.4.3 Agonist-stimulated [35S]GTPS binding
Following membrane preparation, varying doses of cannabinoid agonist were added to 12
mm x 75 mm silicate tubes along with 30 M guanosine diphosphate (GDP), 0.1 nM
[35S]GTPS, and 0.1% bovine serum albumin in duplicate and incubated at 30° C for 2 h
(Lazenka et al, 2015). Non-specific binding was determined in the presence of 20 M unlabeled
GTPS. The reaction was terminated by vacuum filtration through grade GF/B glass fiber filters
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followed by two washes with cold Tris buffer (50 mM, pH 7.4). After overnight extraction in
scintillation fluid (Research Products International, Mount Prospect, IL), bound radioactivity was
assessed via liquid scintillation spectrophotometry at 95% efficiency. In agonist-stimulated
[35S]GTPS binding experiments, non-specific binding was subtracted from each drug curve, and
data were expressed as % net stimulation (net stimulation / basal x 100). As a small magnitude of
stimulation was detected in CB1 KO tissue in certain instances (e.g., WIN55,212-2) (Breivogel et
al, 2001; Monory et al, 2002), the stimulation from KO tissue was subtracted from CB1 WT and
HET curves to provide a clearer representation of CB1-mediated agonist-stimulated binding.
Maximal stimulation (Emax) and EC50 values were determined via nonlinear regression using
GraphPad Prism 6.0 software. Significant differences between WT and HET Emax values were
determined by Student’s T-test for each drug. Differences in Emax across WT samples were
analyzed using one-way ANOVA followed by a Tukey post hoc test.
2.5 Data Analyses
To assess whether decreases in drug potency to produce behavioral effects in CB1 HET
mice correlated with reductions in Emax values generated in agonist-stimulated [35S]GTPS
binding assays, Pearson correlations were calculated between dose ratios (WT ED50 / HET ED50)
from behavioral experiments and WT Emax from in vitro studies. These correlations were
performed using in vivo data from each behavioral assay (catalepsy, hypothermia, and
antinociception) vs. in vitro data from each tissue source (cerebellum and spinal cord).
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Results
3.1 in vivo effects of cannabinoids in CB1 WT, HET, and KO mice
Figure 12 depicts tail withdrawal responses of A-834,735D (Figure 12A), WIN55,212-2
(Figure 12B), CP55,940 (Figure 12C), JWH-073 (Figure 12D), CP47,497 (Figure 12E), and
THC (Figure 12F) in WT, HET, and KO mice. As shown in Table 3, the antinociceptive potency
of WIN 55,212-2 was similar between HET and WT mice, while the dose ratio of each of the
other cannabinoids revealed decreased potency in HET mice compared with WT mice. Within
the dose range tested, the maximum %MPE values for JWH-073, CP47,497, and THC were
lower in HET mice than in WT mice. As the magnitude of respective effects of CP47,497 and
THC did not surpass 50% and 25% MPE, neither the antinociceptive ED50 values in HET mice
nor the dose-ratios (WT/HET mice) could be calculated.
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Figure 12. Dramatic differences in potencies and efficacies of THC and SCs between CB1 WT
and HET mice in producing antinociception. The high efficacy agonists A-834,735D (A, PR
(95% CL) = 1.83 (1.11-3.11)) and WIN55,212-2 (B, PR (95% CL) = 2.54 (1.38-4.97)) produced
comparable shifts in potency. CP55,940 (C, PR (95% CL) = 7.32 (3.47-18.48)) differed
significantly from A-834,735D, but not from WIN55,212-2. JWH-073 (D), CP47,497 (E), and
THC (F) failed to produce maximal effects in CB1 HET mice, which precluded the accurate
calculation of potency ratios. The mean ± SEM baseline tail withdrawal latency for all groups
was 2.05 ± 0.05 s. VEH indicates an injection of 1:1:18 vehicle prior to cumulative dosing with
the indicated drug. Filled shapes indicate p<0.05 CB1 WT and HET versus CB1 KO controls,
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 WT versus CB1 HET mice, n=7-10 mice per
genotype per drug.
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Figure 13 shows hypothermic effects of A-834,735D (Figure 13A), WIN55,212-2 (Figure
13B), CP55,940 (Figure 13C), JWH-073 (Figure 13D), CP47,497 (Figure 13E), and THC
(Figure 13F). Each cannabinoid, with the exception of THC, produced dose-dependent
hypothermia in WT and HET mice, but not in KO mice. THC produced significant hypothermia
in all three genotypes, but effects in HET and KO mice were similar to each other and less in
magnitude than those in WT mice. Table 3 shows ED50 values and dose ratios for all
compounds. All drugs were more potent in WT mice than in HET mice. Neither the ED50 value
nor the dose ratios (WT/HET mice) could be could be calculated for THC in HET mice because
the magnitude of hypothermia did not achieve the level required (-4°C) required for calculation.
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Figure 13. Differential potencies of THC and SCs between CB1 WT and HET mice in producing
hypothermia. A-834,735D (A, PR (95% CL) = 1.82 (1.44-2.34)), WIN55,212-2 (B, PR (95%
CL) = 1.80 (1.34-2.45)), CP55,940 (C, PR (95% CL) = 2.05 (1.54-2.76)), and JWH-073 (D, PR
(95% CL) = 2.74 (2.00-3.81)) produced similar, significant shifts in potency, while CP47,497 (E,
PR (95% CL) = 3.55 (2.69-4.67)) produced an increased rightward shift relative to A-834,735D
and WIN55,212-2. THC-induced hypothermia (F) showed an apparent loss of efficacy in CB1
HET mice, with CB1 HET and KO mice showing identical drops in body temperature (2.9 ± 0.5
C and 2.8 ± 0.4 C, respectively) at THC (560 mg/kg). The pre-injection mean ± SEM rectal
temperatures for all groups was 36.72 ± 0.05 C. Data are expressed as a change from baseline.
VEH indicates an injection of 1:1:18 vehicle prior to cumulative dosing with the indicated drug.
Filled shapes indicate p<0.05 CB1 WT and HET versus CB1 KO controls, *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001 WT versus CB1 HET mice, n=7-10 mice per genotype per drug.
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Figure 15 shows cataleptic effects of each drug in WT, HET and KO mice. Each drug
produced dose-dependent catalepsy in WT and HET mice, but did not produce significant effects
in KO mice. Table 3 shows that ED50 values did not differ between WT and HET mice for any
drug, and dose ratios (WT ED50/HET ED50) ranged from 0.56 to 1.15.
Figure 16 depicts the in vivo pharmacological effects of morphine and chlorpromazine in
each genotype. Morphine produced dose-dependent hypothermia and antinociception that was
equivalent in WT, HET, and KO mice. Chlorpromazine produced dose-related catalepsy and
hypothermia irrespective of genotype. Figure 16 also shows that repeated vehicle injections
generally was without effect in each genotype, with the exception of KO mice, which displayed a
small increase in catalepsy after the fifth vehicle injection. Figures 17-23 show the time courses
of single doses of each agonist and vehicle on each endpoint in WT and HET mice. All drugs
had onsets of action by 30 min and durations of action ranging from 3-6 h. Table 5 contains
results from ANOVAs for each drug and cannabinoid triad endpoint.
3.2 Radioligand binding and agonist-stimulated [35S]GTPS binding in CB1 WT, HET, and KO
mice
[3H]SR141716A binding experiments (Table 6) confirmed high and low CB1 expression
in cerebellum and spinal cord, respectively, with CB1 HET possessing approximately half of the
number of receptors compared with WT mice in each case. Cerebellum and spinal cord
membranes from CB1 WT, HET, and KO mice were assessed for differences in maximal
stimulation of GTPS binding. Consistent with previous results (Breivogel et al, 2001; Monory
et al, 2002), WIN55,212-2 elicited significant stimulation in CB1 KO samples in cerebellum
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(Figure 24, Table 7); therefore, CB1 KO stimulation was subtracted to eliminate non-CB1
mediated stimulation from WT and HET binding dose-effect curves (Figure 25). Nonlinear
regression analyses of the curves prior to subtraction are shown in Table 7. None of the other
ligands stimulated G protein activity in cerebellar homogenates from CB1 KO mice. In
cerebellum membranes (Table 4), A-834,735D (T (6) = 2.544, p<0.05), WIN55,212-2 (T (6) =
5.482, p<0.01), CP55,940 (T (6) = 3.474, p<0.05), JWH-073 (T (6) = 20.97, p<0.0001),
CP47,497 (T (6) = 6.837, p<0.001) and THC (T (6) = 4.442, p<0.01) had significantly lower
Emax values in CB1 HET membranes than in WT membranes. THC yielded a significantly
reduced Emax relative to the other ligands (F (5,18) = 23.14, p<0.0001). In spinal cord (A834,735D (T (6) = 5.826, p<0.01), WIN55,212-2 (T (6) = 4.283, p<0.01), CP55,940 (T (6) =
2.601, p<0.05), and CP47,497 (T (6) = 5.332, p<0.01) Emax values were significantly lower in
membranes from CB1 HET than in WT membranes (see Table 2). Statistical differences were not
detected between CB1 HET and WT spinal membranes for JWH-073 (p=0.052) or THC (p =
0.11), the latter of which failed to produce stimulation above basal levels in CB1 HET mice.
Across agonists in WT samples, THC (F (5, 18) = 15.26, p<0.0001) produced significantly less
stimulation than each other ligand, while none of the other drugs differed from one another.
3.3 Correlation of in vivo and in vitro measures of agonist efficacy
Figure 14 shows correlations between in vivo dose ratios (WT ED50/HET ED50) from
each behavioral assay and in vitro WT Emax from [35S]GTPS binding assays in cerebellum and
spinal cord membranes. Pearson correlation coefficients are shown in Table 4. HET and WT
binding showed strong correlations between cerebellum and spinal cord. Catalepsy, hypothermia,
and antinociception did not correlate with cerebellum binding. However, both hypothermia and
antinociception highly correlated with [35S]GTPS binding in spinal cord.
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Figure 14. Correlations between in vivo potency differences between WT and HET mice and in
vitro Emax values from agonist-stimulated [35S]GTPS binding experiments were assessed to
elucidate whether triad measures reflected differences in functional CB1 activity. In both
cerebellum (A) and spinal cord (B), WT Emax correlated with HET Emax demonstrating the
reduction in receptor population results in a concordant reduction in the Emax magnitude.
Cerebellum WT Emax values were not correlated with catalepsy, hypothermia, or
antinociception (C) while spinal cord WT Emax values were highly correlated with in vivo
losses of potency between WT and HET mice for both hypothermia (r=0.91; p<0.05) and
antinociception (r=0.97; p<0.01) (D).
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4 Discussion
The cumulative dose-response cannabimimetic screen utilizing CB1 transgenic mice that
express varying levels of CB1 receptors provides a high throughput in vivo method to discern
relative differences in agonist selectivity and efficacy. The results presented here extend
knowledge regarding the application of receptor theory to modern pharmacological challenges
regarding cannabinoids, as it applies to the CB1 receptor. Specifically, we elucidated the impact
of reducing total CB1 population on the relationship between in vivo potency/efficacy and in
vitro functional activity.
Of the three in vivo pharmacological effects measured, antinociception was the most
sensitive to reduction in receptor density. Specifically, CB1 HET mice showed the greatest
reductions in antinociceptive potency and efficacy to the cannabinoids tested compared with WT
mice. A-834,735D, WIN55,212-2, and CP55,940 produced full antinociceptive effects in WT
and HET mice, but CB1 HET mice displayed 2 fold decreases in potency to A-834,735D,
WIN55,212-2, and ~7 fold decrease in potency to CP55,940. THC was the least potent
cannabinoid in producing antinociception in WT mice, and failed to achieve greater than 25%
MPE in CB1 HET mice, rendering the ED50 value incalculable. Similarly, the dose-response
analyses of JWH-073 and CP47,497 within the dose ranges tested revealed reduced magnitudes
of antinociceptive effects in HET mice compared with WT mice. KO mice did not display
relevant antinociception following administration of any of the cannabinoids. In contrast, the
non-cannabinoid morphine produced full antinociceptive effects irrespective of genotype, while
chlorpromazine did not produce antinociception. CB1 density is relatively low in CNS areas
purported to mediate antinociception (e.g., periaqueductal gray, dorsal horn of the spinal cord)
compared to other brain regions, such as the cerebellum (Herkenham et al, 1990, 1991; Matsuda
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et al, 1990). Thus, these findings indicate relatively low CB1 receptor reserve for
antinociception. Accordingly, THC, CP47,497, and JWH-073 behaved as low efficacy CB1
agonists, while CP55,940 had higher efficacy, and A-834,735D and WIN55,212-2 were the
highest efficacy compounds in producing antinociception.
Similar to antinociception, the dose response curve for each agonist in producing
hypothermia was rightward shifted in CB1 HET mice compared with WT mice. Interestingly,
THC-induced hypothermia showed a profound reduction of Emax in CB1 HET mice, with body
temperature only partially reduced at 300 and 560 mg/kg THC. The observation that body
temperature drops did not differ between HET and KO mice suggests off-target effects at these
excessively high concentrations of THC. However, none of the other cannabinoids, at the doses
assessed, produced hypothermia in CB1 KO mice. Morphine and chlorpromazine elicited dosedependent hypothermia irrespective of genotype (Figure 16). These findings taken together with
the reduced level of CB1 expression in the POA (Herkenham et al, 1990) suggest relatively low
CB1 receptor reserve for cannabinoid-induced hypothermia.
In contrast to the antinociceptive and hypothermic measures, WT and HET mice
displayed similar dose-response relationships to the cataleptic effects of the six cannabinoid
tested (Figure 15), suggesting a relatively high CB1 receptor reserve. Chlorpromazine produced
catalepsy in all three genotypes, while morphine did not elicit catalepsy (Figure 16). The
minimal rightward shift in the dose-response relationship of cannabinoids in CB1 HET mice is
consistent with idea that the high levels of CB1 expression in brain areas mediating this behavior
yield sufficient receptor reserve. Indeed, dorsal striatum (~3-4 pmol/mg) and cerebellum (4-6
pmol/mg) CB1 expression represent among the highest levels in brain (Selley et al, 2001). Work
from Dhawan et al. 2006 suggests cannabinoid-induced catalepsy requires low CB1 occupancy.
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Accordingly, a 50% reduction in receptor expression (Table 6) is likely insufficient to decrease
ligand potency and efficacy in producing catalepsy. Similarly, THC, a low efficacy CB1 agonist
as determined in agonist-stimulated [35S]GTPS binding experiments, elicited catalepsy that
differed little between CB1 HET and WT mice. Interestingly, small, but significant differences
between WT and HET mice were found for A-834,735D, WIN55,212-2, CP55,940, and THC,
but not for JWH-073 and CP47,497. This pattern of effects does not follow the expected efficacy
continuum, but rather may be mediated by other aspects of the ligand, such as alternative and/or
additional signaling mechanisms, in addition to the canonical Gi/o and downstream cAMP
inhibition pathway.
In the present study, we determined dose-response relationships of each drug using a
cumulative dosing within subject procedure, which allowed a fairly high throughout with a
reduced total number of mice required (i.e., the entire dose-range was tested in each mouse
during a single session). Consequently, the possibility of tachyphylaxis occurring during the
cumulative dosing procedure may have contributed to potency reductions in HET mice,
especially for measures that may be mediated by low CB1 receptor reserve. However, the timecourse studies (Figures 17-23) suggest a relatively long duration of action for each cannabinoid
tested in both WT and HET. Thus, even if the dosing regimen leads to adaptive changes at CB1
within the timeframe of the assay, the conditions were relatively similar across drugs and
genotypes. Although the assessment of pharmacokinetic factors was beyond the scope of the
present study, we previously reported similar blood and brain THC levels resulting from single
bolus injection and cumulative dosing regimen at 10, 30, and 56 mg/kg (Falenski et al, 2010).
Nonetheless, as CB1 agonists vary profoundly in structure, with endogenous cannabinoids
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undergoing rapid hydrolysis within seconds or minutes (Blankman and Cravatt, 2013), future
studies may need to take pharmacokinetic factors into consideration.
Agonist-stimulated [35S]GTPS binding experiments generally corroborated the a priori
selection of CB1 agonists, which vary from high to low efficacy (A-834,735D ≥ WIN55,212-2 >
CP55,940 > JWH-073 ≥ CP47,497 > THC), when relative Emax differences of WT and HET mice
were taken into account. This continuum was consistent under high (i.e., cerebellum
homogenates) and low CB1 (i.e., spinal cord homogenates) expression conditions. The absence
of a correlation between catalepsy and GDP-GTP exchange is consistent with the idea of high
CB1 receptor reserve. Significant correlations were detected between in vitro WT Emax values
from [35S]GTPS binding experiments in spinal cord and the in vivo hypothermia and
antinociception measures, suggest that low receptor conditions reveal stratification of ligands by
efficacy.
One issue these assays do not address is potential signaling events outside of the
canonical G-protein-cAMP pathway. Of the ligands tested here, potential bias has been described
for CP55,940, WIN55,212-2, and THC in striatal cell cultures (Khajehali et al, 2015; Laprairie et
al, 2014), though more work remains to be done in this emerging area. CB1 ligands with extreme
bias for one pathway or another would be highly useful to test whether alternative signaling
pathways play determining roles in the in vivo potency and efficacy of cannabinoids. For
instance, the endogenous cannabinoid/endogenous TRPV1 agonist N-arachidonoyl dopamine
(Redmond et al, 2015) preferentially modulates Ca2+ via Gq, though this compound may not be
a good candidate for in vivo testing due to its likely rapid hydrolysis. Future studies may focus on
investigating where novel, abused SCs fall along the efficacy continuum. Utilizing ligands with
extreme bias may be particularly revealing in this assay. Although not commercially available,
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irreversible CB1 antagonists would also provide great utility to investigate CB1 receptor density
across relevant endpoints. This approach has already been implemented successfully for the mu
opioid receptor (Madia et al, 2009; Pawar et al, 2007; Walker et al, 1998).
In conclusion, the present study establishes a high throughput, within subjects approach
to assess in vivo efficacy of SCs as well as naturally occurring cannabinoids by assessing their
pharmacological effects in established assays using CB1 WT, HET, and KO mice. In particular,
the strong relationship between loss of efficacy of cannabinoids in GTPS binding in spinal cord
tissue and potency reductions of the six cannabimimetic ligands in producing antinociception and
hypothermia in CB1 HET mice suggests that these endpoints reflect good predictors of in vivo
efficacy. The lack of correlation between GTPS binding and catalepsy is likely due to the high
number of spare CB1 receptors in brain regions mediating this pharmacological effect, which is
consistent with the small reduction in potency observed in HET mice. The present study
describes a solid preclinical approach, based on pharmacological principles, to provide valuable
insight into the pharmacology of emerging abused SCs. More generally, the use of CB1
transgenic mice through examination of dose-response relationships of cannabinoids on
antinociception and hypothermia as well as on agonist-stimulated GTPS binding in spinal cord
tissue possesses utility in determining in vivo and in vitro efficacy of emerging abused SCs,
cannabinoids being investigated for basic research or being developed as potential medications,
and naturally occurring cannabinoids.
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Antinociception

WT ED50 (95% CL)

HET ED50 (95% CL)

Dose Ratio
(WT/HET)

A-834,735D

0.85 (0.61-1.19)

1.84 (1.66-2.04)*

0.46

WIN55,212-2

9.64 (6.44-14.41)

17.77 (10.61-29.77)

0.54

CP55,940

1.00 (0.66-1.51)

4.04 (2.69-6.09)*

0.24

JWH-073

7.74 (6.08-9.84)

96.58 (47.41-196.76)*

0.08

CP47,497

6.20 (4.22-9.10)

100 mg/kg: 44.3±11.2 %MPE*

<0.06

THC

81.69 (51.32-130.03)

560 mg/kg: 19.2±2.7 %MPE*

<0.15

Hypothermia

WT ED50 (95% CL)

HET ED50 (95% CL)

Dose Ratio (WT/HET)

A-834,735D

0.85 (0.67-1.00)

1.64 (1.59-1.69)*

0.52

WIN55,212-2

6.97 (5.24-9.29)

15.68 (9.95-24.71)*

0.45

CP55,940

1.06 (0.74-1.51)

2.27 (1.85-2.79)*

0.47

JWH-073

8.75 (6.99-10.94)

31.16 (21.08-46.06)*

0.28

CP47,497

9.84 (7.81-12.39)

47.53 (32.29-69.97)*

0.21

THC

155.67 (120.63-200.88)

560 mg/kg: -2.75±0.57ºC*

<0.28

Catalepsy

WT ED50 (95% CL)

HET ED50 (95% CL)

Dose Ratio (WT/HET)

A-834,735D

0.82 (0.62-1.08)

0.94 (0.73-1.21)

0.87

WIN55,212-2

4.06 (3.09-5.34)

5.75 (4.43-7.47)

0.71

CP55,940

0.93 (0.18-1.83)

0.81 (0.50-1.29)

1.15

JWH-073

7.72 (5.97-9.99)

8.03 (6.01-10.73)

0.96

CP47,497

3.68 (1.81-7.51)

6.57 (4.15-10.38)

0.56

THC

28.36 (17.99-44.72)

49.27 (36.35-66.78)

0.58

Table 3. The antinociceptive and hypothermic effects of each ligand were more potent in WT
mice than in HET mice, with the exception of WIN55,212-2-induced antinociception, which did
not significantly differ between genotypes. For catalepsy, none of the ligands differed in potency
between WT and HET mice. ED50 values (expressed in mg/kg) for each dependent measure were
calculated in WT and HET mice. Dose ratios were calculated by dividing the WT ED50 by the
HET ED50. In the cases in which ED50 estimations were not possible to calculate (i.e., CP47,497
for antinociception, and THC for antinociception and hypothermia in HET mice), the maximum
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effect at the highest dose tested is presented. * indicates non-overlapping confidence intervals
between WT and HET ED50 values.
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Cerebellum
WT

HET

Agonist

Emax

EC50

Emax

EC50

HET Emax/
WT Emax

A-834,735D

211.1 ± 11.4

22.3 ± 5.6

164.9 ± 14.1*

29.4 ± 11.9

0.78

152.6 ± 4.9**

50.4 ± 8.0

0.75

4.1 ± 0.6

166.3 ± 7.6*

6.1 ± 1.4

0.84

WIN55,212-2

202.5 ± 7.6

CP55,940

198.7 ± 5.2

39.4 ± 7.6

JWH-073

185.5 ± 1.7

25.6 ± 1.2

95.5 ± 3.9****

38.3 ± 7.1

0.51

CP47,497

212 ± 8.6

102.1 ± 18.2

133.3 ± 7.6***

94.5 ± 22.8

0.63

THC

119.9 ± 4.6^

24.3 ± 4.7

73.8 ± 8.7**

52.4 ± 29.0

0.62

EC50

HET Emax/
WT Emax

Spinal Cord
WT
Agonist

Emax

HET
EC50

Emax

A-834,735D

57.8 ± 2.4

15.0 ± 3.0

35.0 ± 3.0**

24.1 ± 9.6

0.61

WIN55,212-2

56.3 ± 3.8

65.4 ± 22.0

36.9 ± 2.4**

84.8 ± 21.6

0.66

CP55,940

49.6 ± 5.9

8.61 ± 5.1

30.4 ± 4.3*

9.5 ± 6.9

0.61

JWH-073

41.3 ± 3.5

77.8 ± 29.9

20.6 ± 7.7

46.6 ± 91.0

0.49

CP47,497

41.2 ± 3.9

93.2 ± 38.1

17.1 ± 2.2**

45.9 ± 24.2

0.42

THC

11.4 ± 2.3^

6.1 ± 11.2

ND

ND

ND

Correlations
Cerebellum

r

p

Catalepsy

0.10

0.53

Hypothermia

0.02

0.80

Antinociception

0.08

0.65

Spinal Cord

r

p

Catalepsy

0.22

0.34

Hypothermia

0.84

<0.05

Antinociception

0.95

<0.01

Table 4. Each agonist was assessed for its ability to stimulate [35S]GTPS binding in cerebellum
and spinal cord membranes of CB1 WT, HET, and KO mice. In cerebellum, all agonist elicited
comparatively lower stimulation in HET membranes than in WT membranes. Comparison of
WT Emax values across drugs revealed that THC elicited the least stimulation of all ligands
tested. Spinal cord membranes revealed a similar pattern of results, with only JWH-073 failing to
elicit significant differences in Emax between WT and HET samples. No stimulation above basal
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was detected for THC in HET spinal cord; therefore, Emax and EC50 values could not be
determined (ND). Similar to cerebellum, only THC displayed significantly lower Emax values
across WT samples in spinal cord. This loss of efficacy is expressed additionally as the HET
Emax/WT Emax to show relative differences between the higher receptor conditions of cerebellum
and low receptor conditions of spinal cord. ^indicates significant differences versus all other
ligands within WT Emax values, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 for WT versus
HET samples within tissue. No significant differences in EC50 were detected across brain region
or genotype for each drug.
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Figure 15. All drugs tested maintained comparable potency in the catalepsy measure of the triad
in HET mice compared to their WT counterparts. There were significant dose by genotype
interactions for A-834,735D (0.03-10 mg/kg, Figure 1A, F (14, 147) = 41.99, p<0.0001),
WIN55,212-2 (0.3-50 mg/kg, Figure 1B, F (14, 133) = 31.69, p<0.0001), CP55,940 (0.03-56
mg/kg, Figure 1C, F (16,168) = 29.84, p<0.0001), JWH-073 (0.3-100 mg/kg, Figure 1D, F (16,
160) = 22.91, p<0.0001), CP47,497 (0.1-100 mg/kg, Figure 1E, F (18, 189) = 10.75, p<0.0001),
and THC (1-560 mg/kg, Figure 1F, F (16, 176) = 13.70, p<0.0001). Table 1 shows no significant
differences between WT and HET mice across drugs. BL indicates baseline and VEH indicates
an injection of 1:1:18 vehicle prior to cumulative dosing with the indicated drug. Filled shapes
indicate p<0.05 versus respective vehicle for each genotype, *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001 WT versus KO, ^p<0.05, ^^p<0.01, ^^^p<0.001, ^^^^p<0.0001 HET versus KO,
n=7-10 mice per genotype per drug.

96

Figure 16. The mu opioid receptor agonists morphine elicits catalepsy in CB1 KO, but not WT
or HET mice, at a cumulative dose of 56 mg/kg (A, F (10, 95) = 4.545, p<0.0001). Morphine
also, produced dose-dependent hypothermia (B, main effect of morphine p<0.0001, no
significant interaction p=0.7285) and antinociception (C, main effect of morphine p<0.0001, no
significant interaction p=0.2545) irrespective of genotype. Cumulative dosing with the
antipsychotic chlorpromazine resulted in dose-dependent increases in catalepsy (D, main effect
of chlorpromazine, p<0.0001, no significant interaction p=0.9239) measured as well as dosedependent decreases in body temperature (E, main effect of chlorpromazine p<0.0001, no
significant interaction p=0.5727) with no significant increases in antinociception (F, main effect
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of chlorpromazine, p<0.0001, no significant interaction p=0.4886). To control for repeated
injections, six single volume injections of vehicle followed by two double volume injections
were administered. Significant increases in catalepsy were measured in CB1 KO mice (G, F (16,
168) = 6.396, p<0.0001) though it is unclear whether this is due to repeated injections or
habituation to the bar test itself. No significant changes were detected in hypothermia (H,
p=0.4708) nor antinociception (I, p=0.4935). ****p<0.0001 versus WT and HET, n = 7-9. Filled
shapes indicate p<0.05 versus respective vehicle for each genotype, *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001 WT versus KO, ^p<0.05, ^^p<0.01, ^^^p<0.001, ^^^^p<0.0001
HET versus KO, n=7-10 mice per genotype per drug.
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Antinociception

F ratio

p value

A-834,735D

F (12, 126) = 15.33

<0.0001

WIN55,212-2

F (12, 114) = 15.79

<0.0001

CP55,940

F (14, 147) = 21.52

<0.0001

JWH-073

F (14, 140) = 20.98

<0.0001

CP47,497

F (16, 168) = 10.98

<0.0001

THC

F (14, 154) = 18.74

<0.0001

Hypothermia

F value

p value

A-834,735D

F (12,126) = 67.78

<0.0001

WIN55,212-2

F (12,114) = 37.42

<0.0001

CP55,940

F (14, 147) = 77.85

<0.0001

JWH-073

F (14,140) = 41.82

<0.0001

CP47,497

F (16, 168) = 72.02

<0.0001

THC

F (14,154) = 13.84

<0.0001

Catalepsy

F value

p value

A-834,735D

F (14, 147) = 41.99

<0.0001

WIN55,212-2

F (14, 133) = 31.69

<0.0001

CP55,940

F (16,168) = 29.84

<0.0001

JWH-073

F (16, 160) = 22.91

<0.0001

CP47,497

F (18, 189) = 10.75

<0.0001

THC

F (16, 176) = 13.70

<0.0001

Table 5. The results from the ANOVAs of each cannabinoid for each dependent measure of the
cumulative dosing triad are depicted here. The results of post hoc Holms-Sidak analysis are
depicted in the Figure 12, Figure 13, and Figure 15.
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Figure 17. A-834,375D (3.0 mg/kg) produced cataleptic (A, F (5, 110) = 0.8960, p = 0.4866, no
significant interaction; main effect of time, p<0.0001), hypothermic (B, F (4, 88) = 4.765, p <
0.01), and antinociceptive (C, F (4, 88) = 1.521, p = 0.2028, no significant interaction; main
effect of time, p < 0.0001) effects in a time dependent manner, revealing a long duration of
action peaking at one hour post-injection in all three measures. CB1 WT mice only differed from
HET mice at six hours post-injection in hypothermia. **p<0.01, n = 12.
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Figure 18. A dose (30.0 mg/kg) of CB1 agonist WIN 55,212-2 produced cannabimimetic effects
in a time-dependent manner. Separation between genotypes (indicated by asterisks) is readily
apparent after three hours in catalepsy (A, F (5, 100) = 13.74, p < 0.0001) and after one hour in
hypothermia (B, F (4, 80) = 12.46, p < 0.0001) and antinociception (C, F (4, 80) = 9.929, p <
0.0001). HET mice approached baseline measurements in catalepsy and antinociception six
hours post-injection while WT mice remained near or above peak measurements three hours
post-injection in all three measures before declining at six hours post-injection. Between
genotypes, significant differences were found at half an hour post-injection in antinociception,
one hour in hypothermia and antinociception), three hours in all three measures, and six hours in
all three measures. **p<0.01, ***p<0.001, ****p < 0.0001, n = 8-10.

101

A

B

C

C a t a le p s y ( 3 .0 m g /k g C P 5 5 ,9 4 0 )

H y p o t h e r m ia ( 3 .0 m g /k g C P 5 5 ,9 4 0 )

A n t in o c ic e p t io n ( 3 .0 m g /k g C P 5 5 ,9 4 0 )

HET

****
30
15
0

BL

.5

1

3

T im e (h )

6

10

24

125

0

HET
-4

**

100

****

WT

WT

-2

% MPE

o

Im m o b ility (s )

WT
45

T e m p e ra tu re [ C ]

2
60

***

-6

75

HET

50
25

-8

0

-1 0

-2 5

.5

1

3

T im e (h )

6

10

24

.5

1

3

6

10

24

T im e (h )

Figure 19. Cannabinoid triad time course of CP 55,940 (3.0 mg/kg) showed peak
cannabimimetic activity in both CB1 WT and HET mice at one hour post-injection in catalepsy
(A, F (5, 110) = 5.875, p < 0.0001) and hypothermia (B, F (4, 88) = 8.668, p < 0.0001) and three
hours post-injection in antinociception (C, F (4, 88) = 2.945, p < 0.05), indicating time
dependent effects. Hypothermia and antinociception displayed significant differences between
genotypes at three hours post injection. Catalepsy and hypothermia showed significant
differences between genotypes at six hours post-injection. **p < 0.01, ***p < 0.001, ****p <
0.0001, n = 12.
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Figure 20. JWH-073 (30.0 mg/kg) elicited cataleptic (A, F (5, 90) = 3.025, p < 0.05),
hypothermic (B, F (4, 72) = 5.830, p<0.001), and antinociceptive (C, F (4, 72) = 5.239, p <
0.001) effects in a time dependent manner. Significant differences between CB1 WT and HET
mice are discernible at half an hour post-injection in hypothermia, one hour post-injection in
antinociception, and three hours post-injection in catalepsy. Differences are continuous to six
hours post-injection in catalepsy and hypothermia, and three hours in antinociception. HET mice
extinguished cannabimimetic behavior in all three measures earlier than WT mice. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001, n = 10.
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Figure 21. CP 47,497 displayed a long, consistent duration of action in CB1 WT and HET mice
in cannabinoid triad as evidenced by an absence of significant differences in measurements from
the half hour time point (indicated by filled symbols) until six hours post-injection in catalepsy
(A, F (5, 110) = 2.354, p = 0.0452), and three hours post-injection in hypothermia (B, F (4, 88) =
9.108, p < 0.0001) and antinociception (C, F (4, 88) = 7.576, p < 0.0001). Separation between
genotypes was observed in hypothermia and antinociception beginning half an hour postinjection until six hours post-injection. **p < 0.01, ***p < 0.001, ****p < 0.0001, n = 12.
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Figure 22. THC (100.0 mg/kg) achieved peak cannabimimetic activity time dependently in CB1
WT mice in cannabinoid triad time course at six hours post-injection in catalepsy (A, F (5, 110)
= 2.354, p < 0.05) and hypothermia (B, F (4, 88) = 9.108, p < 0.0001) and three hours postinjection in antinociception (C, F (4, 88) = 7.576, p < 0.0001) and in CB1 HET mice at one hour
post-injection in catalepsy and antinociception and three hours post-injection in hypothermia.
WT mice differed from HET mice at three and six hours for hypothermia, at six hours in
catalepsy, and at six hours for antinociception. *p < 0.05, ***p < 0.001, ****p < 0.0001, n = 1113.
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Figure 23. Vehicle (0.01 mL/g) produced no cannabimimetic effects in catalepsy (A),
hypothermia (B, F (4, 88) = 0.437, p = 0.7812; no significant effect), or antinociception (C, F (4,
88) = 0.5342, p = 0.7109; no significant effect). n = 12.
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Cerebellum
Bmax (pmol/mg)
KD [nM]

Spinal Cord
Bmax (pmol/mg)
KD [nM]

CB1
WT

4.32 ± 0.30

1.15 ± 0.14

0.97 ± 0.09

0.58 ± 0.12

CB1
HET

1.89 ± 0.36***

0.95 ± 0.21

0.58 ± 0.10#

0.90 ± 0.34

Table 6. [3H]SR141716A binding confirmed approximately 50% CB1 expression in the brain
areas tested in the agonist stimulated [35S]GTPS binding assay. The KD of the radioligand did
not change between genotypes or across CNS regions (p=0.3957). Binding curves were fitted
with nonlinear regression in GraphPad Prism 6.0. ***p<0.001 WT versus HET Bmax in
cerebellum, #p<0.05 WT versus HET Bmax in spinal cord, n = 8 for each genotype per tissue.
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Figure 24. All agonists tested stimulated [35S]GTPS binding to a similar degree in wild type
cerebellum, except for THC which displayed significantly lower Emax values in wild-type tissue
(Table 4) and WIN55,212-2 which displayed much higher stimulation. A-834,735D (A),
WIN55,212-2 (B), and CP55,940 (C) displayed similar differences in Emax among heterozygous
tissue (~80% of wild type), while JWH-073(D), CP47,497 (E), and THC (F) each displayed
close to a 50% in efficacy. Dose-related changes in agonist-stimulated binding were detected in
knockout samples for both WIN55,212-2 (F (7, 24) = 6.378, p<0.001) and THC (F (6, 21) =
6.492), thus knockout stimulation was subtracted for the purposes of analysis from both wild
type and heterozygous samples for each drug. EC50 and Emax values for the data here are shown
in Table 7. ND indicates not determined, n = 4 per genotype.
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WT

HET

KO

Agonist

Emax

EC50

Emax

EC50

Emax

EC50

A-834,735D

203.0 ± 15.9

18.6 ± 6.7

152.7 ± 16.3

20.2 ± 9.9

ND

ND

WIN55,212-2

262.6 ± 18.6

86.4 ± 31.6

209.3 ± 13.5

114.5 ± 36.1

ND

ND

CP55,940

179.6 ± 8.1

5.0 ± 1.2

146 ± 6.8

7.8 ± 1.8

ND

ND

JWH-073

199.1 ± 5.9

22.5 ± 3.3

109.9 ± 6.2

29.7 ± 7.9

ND

ND

CP47,497

222.2 ± 11.3

78.0 ± 18.6

142.1 ± 4.3

63.3 ± 8.8

ND

ND

THC

106.6 ± 6.2

14.4 ± 4.6

61.21 ± 4.9

26.8 ± 10.1

ND

ND

Table 7. Emax and EC50 values calculated from agonist-stimulated GTPS binding experiments in
cerebellum which are uncorrected for KO stimulation. WIN55,212-2 achieved a maximum of
40% above basal in KO tissue whereas the other five ligands tested elicited no discernable
stimulation above basal in KO tissue.
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Figure 25. Subtraction of knockout stimulation revealed equal efficacy in WT tissue of all
agonists except for THC. EC50 values in wild type and heterozygous tissue for WIN55,212-2
were much lower following subtraction, implying it may be more potent to activate CB1
receptors than previous reported in cases where off target stimulation was not taken into account.
EC50 and Emax values for the data here are shown in the table below. ND indicates not
determined.
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Figure 26. Unlike cerebellum, no significant stimulation was detected in knockout in spinal cord
thus no subtraction was necessary. EC50 and Emax values for the data here are shown in the table
below. ND indicates not determined, n = 4 per genotype.
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ABSTRACT
Background: Synthetic cannabinoids have emerged as a significant public health concern. To
increase the knowledge of how these molecules interact on brain reward processes, we investigated
the effects of CP55,940, a high efficacy synthetic CB1 receptor agonist, in a frequency-rate
intracranial self-stimulation (ICSS) procedure.
Methods: The impact of acute and repeated administration (seven days) of CP55,940 on operant
responding for electrical brain stimulation of the medial forebrain bundle was investigated in
C57BL/6J mice.
Results: CP55,940 attenuated ICSS in a dose-related fashion (ED50 (95% C.L.) = 0.15 (0.12-0.18)
mg/kg). This effect was blocked by the CB1 receptor antagonist rimonabant. Tolerance developed
quickly, though not completely, to the rate-decreasing effects of CP55,940 (0.3 mg/kg). Abrupt
discontinuation of drug did not alter baseline responding for up to seven days. Moreover,
rimonabant (10 mg/kg) challenge did not alter ICSS responding in mice treated repeatedly with
CP55,940.
Conclusions: The finding that CP55,940 reduced ICSS in mice with no evidence of facilitation at
any dose is consistent with synthetic cannabinoid effects on ICSS in rats. CP55,940-induced ICSS
depression was mediated through a CB1 receptor mechanism. Additionally, tolerance and
dependence following repeated CP55,940 administration were dissociable. Thus, CP55,940 does
not produce reward-like effects in ICSS under these conditions.

Keywords: synthetic cannabinoid, intracranial self-stimulation, mice, withdrawal, tolerance,
dependence, CP55,940.
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1. Introduction
Cannabis sativa has been used both medicinally and recreationally for thousands of years
(Mechoulam et al. 1991). The psychotropic effects of this plant are due mainly to its primary
psychoactive constituent 9-tetrahydrocannabinol (THC) (Mechoulam and Gaoni 1965; MartinSantos et al. 2012). THC falls within the class of drugs known as cannabinoids, which draw their
moniker from the cannabis plant. Cannabinoids are primarily defined by their ability to bind and
activate cannabinoid receptor 1 (CB1) (Herkenham et al. 1990; Matsuda et al. 1990) and
cannabinoid receptor 2 (CB2) (Munro et al. 1993). Although CB1 is well known to play a
predominant role in mediating the behavioral effects of THC and other cannabinoids and to
modulate the rewarding effects of other classes of drugs (Rinaldi-Carmona et al. 1994; Ledent et
al. 1999; Zimmer et al. 1999; Forget et al. 2005), emerging evidence indicates that CB2 plays
opposing roles in the reinforcing effects of cocaine and nicotine (Xi et al. 2011; IgnatowskaJankowska et al. 2013; Navarrete et al. 2013).
In addition to THC, hundreds of synthetic cannabinoids vary in structure and bind and
activate cannabinoid receptors (for review, see (Pertwee 2006)). These synthetic compounds were
crucial for establishing the binding and distribution of cannabinoid receptors in brain (Devane et
al. 1988; Herkenham et al. 1990). However, in recent years, synthetic cannabinoids such as CP47,497 (Hudson et al. 2010), AM-2201 (Denooz et al. 2013), JWH-018, and JWH-073 (Brents and
Prather 2014), emerged as new drugs of abuse. Synthetic cannabinoids are generally abused by
smoking plant material imbued with these compounds in much the same manner as marijuana, and
are readily available as preparations commonly referred to as “Spice” or “K2” among other brand
names (Fantegrossi et al. 2014). Synthetic cannabinoids are often markedly more potent and/or
efficacious than THC (Griffin et al. 1998). Moreover, toxicological information is limited, and
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little is known about how these compounds affect brain reward circuitry in vivo. As synthetic
cannabinoids have emerged as drugs of abuse (Maxwell 2014), further research is needed to
characterize their pharmacology and toxicology. The impact of chronic exposure to nonclassical
cannabinoids also remains to be determined.
Similar to other drugs of abuse, cannabinoids can evoke dopamine release in the nucleus
accumbens (NAcc), a characteristic often indicative of drugs of abuse (Chen et al. 1993; Cheer et
al. 2004). The NAcc is one node in a neural circuit known as the mesolimbic dopamine pathway,
which consists of dopaminergic neurons that originate in the ventral tegmental area (VTA) and
project to NAcc and more rostral targets such as prefrontal cortex (PFC). Intracranial selfstimulation (ICSS) of the medial forebrain bundle is one procedure that has been used to measure
reinforced behavior mediated by the mesolimbic dopamine pathway (Carlezon and Chartoff 2007)
and to assess abuse potential of drugs (Negus and Miller 2014). Although acute administration of
synthetic cannabinoids generally suppresses ICSS (Arnold et al. 2001; Vlachou et al. 2003;
Vlachou et al. 2005), the impact of repeated cannabinoid administration on ICSS has not been
extensively studied but may be important. For example, repeated administration of mu opioid
agonists evokes tolerance to their rate-decreasing effects and unmasks abuse-related ICSS
facilitation (Altarifi and Negus 2011; Altarifi et al. 2012). Additionally, ICSS has been used to
detect withdrawal-related anhedonia for some drugs of abuse such as cocaine, nicotine and
morphine (Altarifi and Negus 2011; Stoker et al. 2012; Stoker et al. 2014).
In the present study we tested the hypotheses that (a) repeated administration of a synthetic
cannabinoid will facilitate ICSS in a similar fashion as other abused drugs, and (b) spontaneous or
antagonist-precipitated withdrawal in mice repeatedly administered cannabinoids will produce an
anhedonia-like depression of ICSS similar to that produced by withdrawal from other abused
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drugs. Because of the wide variety of synthetic cannabinoids and the ever changing composition
of abused preparations, we chose to use a single, representative compound, CP55,940, to model
acute and repeated effects of synthetic cannabinoids. Although CP55,940 has not emerged as a
drug of abuse and has not been scheduled by the Drug Enforcement Agency, it has been
extensively characterized in preclinical studies, and it is structurally similar to the abused and
scheduled nonclassical cannabinoids CP47,497 and cannabicyclohexanol (Logan et al. 2012).
Moreover, these compounds bind with similar affinity to CB1 and CB2 (Huffman et al. 2010;
Atwood et al. 2011). Acute administration of CP55,940 depressed ICSS in rats (Arnold et al. 2001;
Kwilasz and Negus 2012), but its consequences on ICSS following repeated administration are
unknown.
In initial experiments, we examined the dose-response relationship and time course of the
effects of acute CP55,940 administration on ICSS. Rimonabant was used to infer CB1
involvement. We then tested whether the acute effects of CP55,940 on ICSS would undergo
tolerance following repeated administration. Because cannabinoids are well established to alter
motor function, such as catalepsy, we also assessed the relationship between catalepsy and ICSS
measures during repeated administration of CP55,940 (Little et al. 1988). Catalepsy was selected
as a concurrent endpoint because the behavior may confound the ability of the mice to engage in
operant responding, and CB1-mediated depression of ICSS may reflect non-specific disruption of
behavior rather than an ICSS specific effect. Finally, we examined whether mice treated repeatedly
with CP55,940 displayed signs of either spontaneous or precipitated withdrawal in the ICSS
procedure.
1. Materials and Methods
2.1 Subjects
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A total of 43 male C57Bl/6J mice were used (Jackson Laboratories, Bar Harbor, Maine).
Mice were between 10 and 14 weeks of age at the start of each experiment and were individually
housed and maintained on a 12 h light cycle, with lights on from 0600 to 1800 h, with free access
to food and water. All experiments were conducted in accordance with the NIH Guide for the Care
and Use of Laboratory Animals, and were approved by the Virginia Commonwealth University
Institutional Animal Care and Use Committee (IACUC).
2.2 Drugs
CP55,940, rimonabant and cocaine HCl were obtained from the National Institute of Drug
Abuse Drug Supply Program (Rockville, MD). CP55,940 and rimonabant were dissolved in a
vehicle (VEH) consisting of 5% ethanol, 5% Emulphor-620 (Rhone-Poulenc, Princeton, NJ), and
90% 0.9% saline. Cocaine was dissolved in 0.9% saline.
2.3 Intracranial Self-Stimulation (ICSS)
2.3.1 Apparatus.
ICSS testing was conducted in eight mouse operant conditioning chambers (18 X 18 X 18
cm; Med Associates Inc., St. Albans, VT). Each chamber was equipped with a retractable lever
located on one wall, LED stimulus lights over the lever, a chamber house-light, a tone-generator
and an ICSS stimulator. The stimulator was connected to the electrode via bipolar cables routed
through a swivel commuator and into the experimental chamber. Chambers were enclosed within
sound- and light-attenuating chambers equipped with exhaust fans. Custom software was used to
control manipulations in the operant chambers and to record data during training and testing
sessions.
2.3.2 Stereotaxic Surgery
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Surgical procedures for implanting electrodes in mice for ICSS studies were similar to
those previously reported (Carlezon and Chartoff 2007; Wiebelhaus et al. 2014). Mice were
anesthetized with isoflurane for implantation of bipolar twisted stainless steel electrodes (0.280
mm diameter and insulated except at the flat tips; Plastics One, Roanoke, VA) into the right medial
forebrain bundle (2.0 mm posterior to bregma, 0.8 mm lateral from midline, and 4.8 mm below
dura). The electrode was fixed to the skull with anchoring screws and dental cement. Mice were
given acetaminophen (1-2 mg/ml) in their drinking water for one day before and five days after
surgery. Training began one week after surgery.
2.3.4 Training
During initial training, lever-press responding under a fixed-ratio 1 (FR1) schedule
produced both (a) delivery of a 0.5 s train of square-wave cathodal pulses (0.1 ms pulse duration)

light, and tone cues. Responding during stimulation had no scheduled consequences. Amplitudes
of stimulation were individually adjusted for each mouse to maximize response rates, and final
amplitudes ranged from 45–300 μA. Training continued during daily 30–120 min sessions until
response rates exceeded 30 responses per min for at least three days.
Once operant responding was established, mice were promoted to frequency-rate training
as previously reported for mice (Wiebelhaus et al. 2014) and rats (Negus et al. 2010). Frequencyrate sessions were divided into multiple components, and each component consisted of 10
sequential frequency trials for presentation of a descending series of 10 stimulation frequencies
(2.2-1.75 log Hz in 0.05 log increments). Each frequency trial began with a 10 sec time out period,
during which behavior had no scheduled consequences. During the last 5 s of the time out period,
the lever was extended, and non-contingent stimulations were delivered once per second at a given
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frequency together with associated cues The time out period was followed by a 60 s response
period when responding under the FR1 schedule produced brain stimulation at the specified
frequency together with associated cues. After the 60 s response period, the lever was retracted,
the stimulation frequency was decreased by 0.05 log units, and the next frequency trial began.
Sessions consisted of three to five consecutive components per day, and current amplitudes were
adjusted if necessary for each subject to maintain responding for at least three, and fewer than
eight, stimulation frequencies at levels ≥ 50% maximal control rates (see Data Analysis).
Once these criteria were met, preliminary testing was initiated. Test sessions consisted of
three baseline components followed first by a 30 min treatment interval and then by two test
components. Data from the first baseline component for each test session were excluded from
analysis. Data from the next two baseline components were averaged to generate baseline data for
that test session, and data from the test components were averaged to generate test data. Mice were
eligible for drug testing when the total number of stimulations per component during baseline
varied by less than 20% on three consecutive days, and baseline and test numbers of stimulations
per component differed by ≤ 20% in the absence of an injection or after treatment with vehicle
injections. Brains were harvested from select mice, which met criteria throughout testing, and
histological analysis was performed to verify of electrode placement into the lateral hypothalamus
(Figure 31). Microscopy was performed at the VCU Department of Anatomy and Neurobiology
Microscopy Facility, supported, in part, with funding from the NIH-NINDS Center core grant
(5P30NS047463).
1.3.5 Dose-Effect Relationship of CP55,940
Once the training criteria were met, drug testing was initiated using dose-effect, timecourse and repeated-dosing procedures. For antagonism studies, a single dose of CP55,940 (0.03120

1.0 mg/kg, s.c. 30 minutes prior to test components) was administered alone or 15 min after
rimonabant (3-30 mg/kg). The effects of cocaine (10.0 mg/kg, i.p. 10 min prior to testing) were
also tested as a positive control (Figure 32). Test sessions were separated by at least 72 hr.
2.3.6 Time Course of CP55,940.
The procedures described above were modified to assess the onset and duration of effects
produced by CP55,940. Test sessions consisted of three baseline components followed first by a 5
min treatment interval and then by pairs of test components beginning 5 min, 30 min, 2 hr, 4 hr
and 8 hr after injection. Mice were removed from the test chamber between the last four pairs of
test components. If necessary, drug effects were also evaluated after 24 and 48 hr. The time course
of vehicle injection was tested first. If the number of stimulations per component varied ≤ 20% for
all test components from 5 min to 8 hr, then an identical procedure was used to evaluate effects of
0.3 and 1.0 mg/kg CP55,940. Two different groups of mice were used for each dose in the time
course studies. Thus, each group had a corresponding vehicle time course for comparison.
2.3.7 Repeated Administration of CP55,940
To test the effects of a fixed dose of CP55,940 administered repeatedly, two groups of mice
were assessed in three phases, each of which lasted for seven days. On each day of Phases 1 and
2, test sessions consisted of three baseline components followed first by treatment interval and
then by two test components. Injections were administered during the treatment interval, 30 min
before initiation of the test components. In addition, mice were tested for catalepsy (see below)
immediately before the injection and again approximately 20 min after completion of the test
components (75 min after the injection).
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The first phase of testing consisted of seven consecutive days of vehicle testing using the
procedure described above. This phase established a baseline for comparison to phases 2 and 3
and permitted assessment of stability of responding during daily vehicle injections. If the number
of stimulations per component during baseline components varied ≤ 20%, across days, and if the
number of baseline and test stimulations per component varied ≤ 20% on each day, then mice were
advanced to subsequent phases. In phase two, the mice were divided into separate groups. One
group continued receiving daily injections of vehicle, whereas the second group received daily
injections of 0.3 mg/kg CP55,940. In phase 3, treatment with CPP55,940 terminated, and only
baseline components were conducted to probe for evidence of spontaneous withdrawal and to
investigate whether or not mice would return to pre-drug baselines.
Precipitated withdrawal experiments were conducted in a third group of mice in three
phases as described above with the following procedural differences. Four h after the final injection
of phase 1, mice were injected with 10 mg/kg rimonabant to examine its effects on ICSS before
CP55,940 exposure. After two or three days of subsequent vehicle tests to allow for washout of
rimonabant, mice were given daily injections of 0.3 mg/kg CP55,940 (Phase 2). On day 7 of phase
2 mice were given a second test with rimonabant (10 mg/kg, 10 min i.p., 4h after CP55,940) to
precipitate withdrawal.
2.3.8 Data Analysis.
All data were analyzed using GraphPad Prism 6.0 software. The primary dependent
variables were the number of stimulations per min for each frequency and the number of
stimulations per component across all frequencies as described previously (Negus and Miller 2014;
Wiebelhaus et al. 2014). These data were then evaluated using two separate approaches. First, data
for each frequency trial during baseline and test components were expressed as percent Maximum
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Control Rate (%MCR), with maximum control rate defined as the maximum average rate observed
at any frequency during baseline components for that mouse on that day. %MCR data were
averaged across mice to generate the frequency-rate curves that were assessed using repeatedmeasures two-way ANOVAs (treatment x frequency) between baseline and treatment curves for
each drug/dose tested. A significant ANOVA was followed by the Holm-Sidak test, and the
criterion for significance was p<0.05.
In the second approach, the average total number of stimulations per test component was
divided by the average number of stimulations per baseline component for each mouse on each
day, and multiplied by 100, to produce percent baseline stimulations (% baseline stimulations).
These data were averaged across mice for each treatment and compared with one-way ANOVAs
(Wiebelhaus et al. 2014). A significant ANOVA was followed by Dunnett’s post hoc test to
compare treatment groups with VEH controls.
Data from repeated-treatment studies were analyzed using both % MCR and % baseline
stimulations measures. For tolerance studies each day in phase 2 was compared within each group
to each other day as well as to average data from phase 1. Additionally, % baseline stimulations
were also analyzed between groups by day. Selected frequency-rate curves from phase 1 day 7
(i.e. pre-drug), and days 1, 2 and 7 from phase 2 were used to assess both tolerance across days
and the acute effect of CP55,940 each day. Precipitated withdrawal studies compared the
frequency-rate curves between baselines, CP55,940 tests, and rimonabant tests in phase 1 day 7
and phase 2 day 7.
2.4 Catalepsy
2.4.1 Procedure.
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Catalepsy was measured during 60 s test periods. At the start of each test period, the
forepaws of the mouse were placed on a metal bar raised 4.5 cm from a metal platform. If a mouse
removed its forepaws from the bar, the forepaws were replaced up to four times or until the testing
period ended, whichever occurred first. The total time the mouse retained its forepaws on the bar
was recorded. During the spontaneous and precipitated withdrawal experiments, catalepsy was
measured immediately after ICSS baseline and test components. Approximately 75 min lapsed
between these measurements during ICSS studies, so the same interval was used in control
experiments without ICSS.
2.4.2 Data Analysis.
Catalepsy data are expressed as the change from baseline measurements after a 75 min
pretreatment and analyzed utilizing two-way ANOVA. To determine whether the expression of
catalepsy correlated with rate-decreasing effects of repeated dosing with CP55,940, a Pearson
correlation was conducted between the change from baseline in catalepsy versus the % baseline
stimulations.
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3. Results
3.1 Potency, Time Course and Rimonabant Antagonism of CP55,940 Effects on ICSS
Whereas cocaine (10 mg/kg) facilitated ICSS (Figure 31), CP55,940 (30 min pretreatment)
produced dose-related reductions in ICSS. The % baseline stimulations measure shows that
CP55,940 (0.3-1.0 mg/kg) depressed ICSS with no evidence for facilitation at any dose (Figure
27A, (F (2.640, 18.89) = 40.1) p < 0.001). The ED50 (95% confidence limits) of CP55,940 to
produce rate-decreasing effects was 0.15 (0.12-0.18) mg/kg. Similarly, CP55,940 produced dosedependent rightward and downward shifts in the ICSS frequency-rate curve (Figure 27B, (F (9,
63) = 85.9, p < 0.001). Finally, time-course studies revealed that 0.3 and 1.0 mg/kg CP55,940
decreased ICSS within 5 min, and these rate-decreasing effects persisted for up to 8 h (F (18, 132)
= 20.27, p < 0.001).
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Figure 27. Acute administration of CP55,940 suppressed ICSS through a CB1 receptor
mechanism of action. A. (%Baseline stimulations) and B. (%MCR). CP55,940 dose-dependently
decreased ICSS. n=8; filled squares indicate p<0.05 vs. VEH 1, C. CP55,940-induced ICSS
depression persisted for up to 8 h (n=6-7, filled squares indicate p<0.05 vs. respective vehicle
control, *p<0.0001 0.3 mg/kg vs. 1.0 mg/kg CP55,940).
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Whereas rimonabant (3.0-30.0 mg/kg) administered alone had no effect on % baseline
stimulations (Figure 28 and Figure 32), it dose-dependently prevented the depressive effects of
CP55,940 (1.0 mg/kg) on ICSS (Figure 28A: F (2,12) = 104.7, p < 0.001). Analysis of the
frequency-rate data indicated no effect of rimonabant alone (Figure 28B: F (18, 108) = 1.131, p =
0.333), and a dose-dependent reversal of CP55,940-induced suppression of ICSS (Fig 28C: F (27,
162) = 18.4, p < 0.001).
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Figure 28. A. The CB1 antagonist rimonabant (3.0 or 10.0 mg/kg) did not affect ICSS when
administered alone, but blocked the rate-decreasing effects of CP55,940 (n=7, filled squares
indicate p<0.05 VEH vs. 1.0 mg/kg CP55,940, *p<0.0001 vs. 10.0 mg/kg rimonabant) B.
Frequency-rate analysis of rimonabant alone and vehicle test revealed no significant difference
(n=7). C. CP55,940 (1.0 mg/kg) suppressed ICSS, which was prevented by rimonabant (n=7,
filled squares indicate p<0.05 vs vehicle 2).
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3.2 Effects of Repeated CP55,940
The average % baseline stimulations for each mouse during seven days of vehicle
injections was used for comparison to assess effects of phase 2 treatments with vehicle or different
CP55,940 doses (seven day averages (±2.14 SEM) for the number of baseline stimulations per
component: Group 1: 97.73 (±2.14), Group 2: 102.49 (±1.57), Group 3: 99.11 (±2.52)). Figure
29A shows effects of repeated vehicle or 0.3 mg/kg CP55,940 on % baseline stimulations during
phase 2 (F (14, 91) = 3.3, p < 0.001)). Repeated treatment with vehicle during phase 2 did not alter
ICSS. However, the first injection of CP55,940 (0.3 mg/kg) significantly reduced ICSS to a similar
degree as in the dose-effect study (see Figure 27A). Tolerance to rate-decreasing effects developed
by day 3 in both CP55,940-treated groups, and on day 5, both groups of CP55,940-treated mice
no longer displayed differences from the vehicle-injected mice. Repeated treatment with vehicle
during phase 2 also produced no change in frequency-rate measures of ICSS (Figure 29B; F (27,
108) = 0.74, p = 0.81). The CP55,940-treated groups showed an initial suppression of ICSS on day
1 and partial recovery of ICSS occurred on later days (Figure 29C; F (27, 135) = 3.4, p < 0.0001;
Figure 29D; F (27, 135) = 1.784, p < 0.05).
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Figure 29. Partial tolerance developed to a fixed dose of CP55,940 (0.3 mg/kg). A. Tolerance
developed to the rate-decreasing effects of CP55,940 by day 2 in CP55,940 Group 1 (n=6,
$$p<0.01, $$$p<0.001, $$$$p<0.0001 vs. day 1) and by day 3 in CP55,940 Group 3 (n=6,
*p<0.05, **p<0.01, ***p<0.001 vs. day 1, although rates of responding never returned to vehicle
levels within either group. B. The response rates for the repeated vehicle group remained ±20%
of their phase 1 average, indicating no effect of repeated injections on ICSS (n=5).C, D.
Frequency-rate analysis revealed similar pattern of tolerance in mice receiving repeated
administration of CP55,940 (CP55,940 Group 2 and 3 (filled squares p<0.05 vs. pre-drug,
****p<0.0001 day 1 vs. day 7).
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Repeated treatment with 0.3 mg/kg CP55,940 also increased catalepsy in ICSS mice as
well as in a separate group of mice that did not undergo ICSS training and testing. (Supp. Figure
34A, F (14, 105) = 2.693, p < 0.01). Catalepsy was assessed after baseline ICSS and after
CP55,940 administration to assess the role of this motor behavior. The cataleptic effects of
CP55,940 were greatest on day 1 of treatment and reduced by day 2, but significant catalepsy
persisted throughout the seven days of repeated administration. There was no correlation between
the degree of catalepsy and the degree of ICSS suppression (Supp. Figure 34B; r = 0.07, p=0.69).
Termination of vehicle or CP55,940 treatment did not alter ICSS during the subsequent
seven days (Figure 30A; interaction day vs group F (40, 280) = 0.8, p = 0.74). In addition,
administration of 10 mg/kg rimonabant did not depress ICSS when it was administered before or
after repeated treatment with CP55,940. Figure 30B shows that rimonabant did not alter ICSS as
measured by % baseline stimulations in this group of mice (F (18, 90) = 0.80, p = 0.69). Figure
30C shows the effects of 10 mg/kg rimonabant on full frequency-rate curves before CP55,940
treatment (F (18,90) = 0.80, p = 0.69). The final dose of 0.3 mg/kg CP55,940 produced acute
suppression of ICSS relative to the pre-drug baseline, and rimonabant blocked this suppression
(Figure 30D, F (18, 90) = 2.0, p< 0.05).
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Figure 30. There was no evidence of spontaneous or precipitated withdrawal following 7 days of
once daily injections of 0.3 mg/kg CP55,940. A. Basal ICSS responses for each phase of testing
(tests were performed prior to injections of vehicle or drug).Throughout the 21 days of testing,
each group did not deviate ±20% on during basal testing. B. Rimonabant (10.0 mg/kg, i.p.) did
not affect ICSS in mice treated repeated with either vehicle or CP55,940 (n=6) C. Frequency-rate
curves on the same days revealed no effect of rimonabant after 7 days of vehicle on phase 1 day
7 (n=6). D. CP55,940 (0.3 mg/kg) administered on seven consecutive days suppressed ICSS.
Rimonabant (10.0 mg/kg) 4 hours after the final CP55,940 injection returned responding to
baseline levels, consistent with pharmacological blockade of CB1 (n=6, filled square indicate
p<0.05 vs baseline).
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4. Discussion
Acute administration of CP55,940 dose-dependently and time-dependently depressed
ICSS in mice. The observation that rimonabant prevented the rate-decreasing effects of CP55,940
indicates that these effects were CB1 receptor mediated. The fact that rimonabant given alone did
not alter ICSS indicates that CB1 receptors play a negligible role in basal responding in this ICSS
procedure. Partial tolerance developed after repeated exposure to a fixed dose of CP55,940, but
there was no evidence to suggest that this tolerance to rate-decreasing effects of CP55,940
unmasked expression of abuse-related rate-increasing effects. Moreover, neither spontaneous nor
rimonabant-precipitated withdrawal altered ICSS in mice treated repeatedly with 0.3 mg/kg
CP55,940, suggesting that this regimen of CP55,940 treatment was not sufficient to produce
dependence. Finally, catalepsy did not correlate with reduced ICSS after exposure to CP55,940.
Taken together, these results indicate that CP55,940 did not produce reward-like effects in ICSS
after either acute or repeated administration.
4.1 Acute effects of CP55,940 in ICSS
Acute administration of CP55,940 suppressed ICSS in mice with a potency approximately
57 (35-95)-fold greater than that of THC (Wiebelhaus et al. 2014). The observed difference in
potency is consistent with the affinities of THC and CP55,940 for CB1. Reported in vitro Ki values
for THC are approximately 40 nM, whereas CP55,940 Ki is approximately 0.9 nM, reflecting a
difference in affinity of 45 fold for the CB1 receptor (Compton et al. 1993). Potencies between
THC and CP55,940 in vivo range from 4- to 15-fold in catalepsy, tail withdrawal, and rectal
temperature assays (i.v. route of administration) in male ICR mice (Compton et al. 1992) and up
to 82-fold in a drug discrimination procedure (i.p. route of administration) in male C57BL6/J mice
(McMahon et al. 2008). Previous studies examining the acute effects of CP55,940 found that a
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dose range of 0.01-0.05 mg/kg did not affect ICSS, but doses of 0.1 mg/kg and higher depressed
ICSS in rats (Arnold et al. 2001; Mavrikaki et al. 2010; Kwilasz and Negus 2012). The present
study represents the first publication reporting the effects of CP55,940 on ICSS in mice, and we
found that a similar dose range reduced ICSS in this species. Importantly, there was no evidence
for ICSS facilitation at low CP55,940 doses that did not suppress ICSS in mice, consistent with
previous studies investigating synthetic cannabinoids in rat ICSS (Arnold et al. 2001; Mavrikaki
et al. 2010; Kwilasz and Negus 2012). Although facilitation of ICSS by THC has been reported
previously in rats (Gardner et al. 1988; Katsidoni et al. 2013), it should be noted that facilitation
generally occurs at low doses in select strains of rats (Lewis and Sprague-Dawley) in a subset of
published studies, and the magnitude of facilitation is relatively small compared to that produced
by psychomotor stimulants such as cocaine (for review, see Negus and Miller 2014). Furthermore,
THC attenuates ICSS in mice. Given the failure of CP55,940 to produce evidence of ICSS
facilitation even at doses as low 0.03 mg/kg, the results of the present extend the range of
conditions under which cannabinoids fail to facilitate ICSS in rodents.
Whereas rimonabant completely prevented CP55,940-induced depression of ICSS, this
drug given alone did not alter ICSS. Previous studies in rats and mice also found that ICSS was
not altered by CB1 receptor antagonist doses sufficient to block effects of exogenous cannabinoids
(Vlachou et al. 2005; Vlachou et al. 2006; Kwilasz and Negus 2012; Katsidoni et al. 2013). These
findings suggest that endocannabinoids acting at CB1 receptors do not tonically modulate neural
substrates that mediate ICSS.
4.2 Tolerance to the rate-decreasing effects of CP55,940
In the present study, the depressive effects of 0.3 mg/kg CP55,940 on ICSS underwent
tolerance by the second day of treatment. While this tolerance persisted for the remaining seven
134

days of drug administration, tolerance was not complete, as CP55,940 continued to attenuate ICSS.
For comparison, complete tolerance developed to THC-induced depression of ICSS in rats treated
for 22 days with an escalating regimen of THC doses (Kwilasz and Negus 2012), but no tolerance
developed to depression of ICSS by repeated treatment with the synthetic cannabinoid
WIN55,212-2 (Mavrikaki et al., 2010). Although assessment of rightward shifts in the dose
response relationship to quantify the magnitude of tolerance were not conducted, these apparent
discrepancies in tolerance development to a single dose of drug may be related to the rank order
of efficacies of these cannabinoids at CB1 receptors (WIN55,212-2>CP55,940>THC) (Breivogel
et al. 1998). Similarly, the extent of antinociceptive tolerance to mu opioid agonists was found to
be inversely related to efficacy of the agonists at mu receptors (Yaksh 1992; Duttaroy and Yoburn
1995). More generally, it appears that low- vs. high-efficacy ligands occupy higher proportions of
receptors to produce equivalent acute effects, down-regulate a higher proportion of receptors
during chronic treatment, and are more sensitive to reductions in the density of functional receptors
produced by that downregulation.
5. Conclusions
The findings in the present study indicate little evidence for abuse potential and
dependence for CP55,940. Tolerance developed quickly but incompletely to the rate-decreasing
effects of CP55,940 on ICSS. The bulk of studies investigating the effects of synthetic
cannabinoids on ICSS examined acute drug administration, and only one study of which we are
aware examined repeated administration of a synthetic cannabinoid in rats (Mavrikaki et al.
2010). Thus, the present body of work represents the first study to examine tolerance and
dependence of a synthetic cannabinoid in a mouse ICSS procedure. Although there was no
evidence for spontaneous or rimonabant-precipitated withdrawal, the depressive effects of
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CP55,940 on ICSS showed partial tolerance following repeated administration. It is reasonable to
suspect these findings could be extended to other bicyclic cannabinoids which have a history of
abuse such as CP47,497 (Papanti et al. 2013; Koller et al. 2014). Overall, these experiments
reveal the greatly increased potency of synthetic cannabinoids and their potentially detrimental
effects on brain reward following acute or repeated administration.
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Figure 31. Select mice that completed at least one experiment were anesthetized with 2-3%
isoflurane and humanely sacrificed via cervical dislocation. Whole brains were harvested and
immersed in 8-10 ml of 10% formalin for 7-10 days to allow for tissue fixation. The brains were
sliced in 50 m sections using a Leica VT1000S Vibratome, mounted on Superfrost+ slides
(ThermoFisher Scientific, Waltham, MA), and allowed to dry overnight. The sections were
stained for Nissl with cresyl violet and imaged using a Zeiss Discovery V20 Stereo Zoom
microscope. A. Electrode tips are localized to the lateral hypothalamus in mice which qualified
for testing in ICSS utilizing the requirements detailed in the Methods section. B. A
representative section from a mouse showing a partial electrode tract as well as localization of
the tip (8x, 16x, and 24x magnification).

137

Figure 32. Cocaine HCl (10 mg/kg) served as a positive control to demonstrate ICSS-facilitating
effects in mice. Cocaine increased responding in both A. %baseline stimulations and B.
frequency-rate curves (F (1.051, 5.257) = 19.20, p < 0.01, n=6, *p < 0.05 vs. saline 1, filled
squares p<0.05 vs. baseline).
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Figure 33. A single, high dose of rimonabant (30 mg/kg, 45m s.c.) did not suppress ICSS in A.
%baseline stimulations (F (1.481, 5.925) = 0.23, p=0.74) or B. frequency-rate (F (18, 72) =
1.125, p=0.3500).
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Figure 34. A. Tolerance developed to the cataleptic effects of CP55,940 in mice implanted with
electrodes in the medial forebrain bundle (F (14, 105) = 2.69, p < 0.05, n=6-8, #p<0.05 vs. day 1
for 0.3 CP55,940 – ICSS, ****p<0.0001 vs. day 1 for 0.3 CP55,940 – no ICSS). In vehicle and
0.3 mg/kg CP55,940 – ICSS groups, each mouse was assessed for catalepsy following ICSS
baseline and test passes, with 75 min elapsing between measurements. The 0.3 mg/kg CP55,940
– no ICSS group served as a control to determine if ICSS testing prior to catalepsy testing had
any effect on the development of tolerance to the cataleptic effects of CP55,940. B. No
significant correlation (r = -0.22, p = 0.15) was found between ICSS depression (30-60 min after
injection) and catalepsy (75 min following injection).
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Chapter 4: Discussion

4.1

Synthetic cannabinoids remain a prominent public health concern
As more case reports emerge detailing the deleterious effects of SC use, there is a great

need to discover the mechanism by which they engender their dangerous and potentially deadly
effects. Their structures vary considerably; thus the potential for toxic metabolites distinct from
those found in marijuana is high. Few studies have examined the various metabolites in blood or
urine following SC ingestion, and potential toxicological effects of these metabolites have not
yet been elucidated. Another potential mechanism for the elevated risk of use lies within the
pharmacological properties of the abused SC. As has been detailed in previous sections, SCs are
generally more potent and efficacious at the CB1 receptor, and health complications resulting
from SC ingestion are generally congruous with peripheral and central CB1 expression. Thus, if
enhanced, in vivo activation of CB1 is one of the determining factors to cause serious health
complications, there is a need for a way to quickly ascertain efficacy to produce CB1 activation.
Additionally, the abuse-related effects of enhanced CB1 efficacy are not well understood,
especially under repeated dosing conditions. Here, we developed a model utilizing receptor
theory as a framework to use mice which possess 100%, 50%, and 0% CB1 expression in a
model of cannabimimetic activity. The compounds A-834,735D, WIN55,212-2, CP55,940,
JWH-073, CP47,497, and THC were selected, based upon previously published results and
personal communications, to span the efficacy continuum and assess stratification by efficacy in
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vivo. Abuse-related effects of a representative high-efficacy cannabinoid (CP55,940) were tested
employing the ICSS procedure after both acute and repeated administration. Finally, studies of
agonist-stimulated [35S]GTPS experiments corroborated our in vivo results, although the
observed rank order of efficacy did not entirely agree with previous reports.
4.2. Theoretical predictions versus agonist-stimulated [35S]GTPS binding in high and low
receptor conditions
To elucidate whether CB1-mediated G-protein activation correlated with agonist dose
ratios in WT and HET mice, agonist-stimulated [35S]GTPS binding studies were conducted in
WT, HET, and KO tissue. Agonist-stimulated [35S]GTPS binding assesses ligand potency and
efficacy to affect the exchange of GTP for GDP at the G-protein, the first step in the canonical
GPCR signal transduction pathway. Although the ligands for this body of work were selected
utilizing the available body of literature, not all of these drugs had been tested under the same
experimental conditions. WIN55,212-2, CP55,940, JWH-073, and THC were all tested in one
study (Griffin et al, 1998), and the rank order generated for the experiments conducted here is in
accordance with those results. Unpublished results comparing A834,735D versus CP55,940
(Thomas and Wiley, 2014) and CP47,497 and CP55,940 (unpublished results, Lichtman lab) also
agree with our a priori rank order efficacy prediction. Additionally, the literature lacks a rigorous
assessment of potential off-target G-protein stimulation utilizing CB1 KO tissue despite known
examples of non-CB1, non-CB2 mediated WIN55,212-2 stimulated [35S]GTPS binding.
Therefore, a series of binding experiments were performed in high (cerebellum) and low (spinal
cord) CB1 receptor density tissues to assess the loss of efficacy as it relates to total receptor
expression in WT and HET samples.
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Radioligand binding with [3H]SR141716A confirmed high CB1 expression in cerebellum
and low expression in spinal cord in WT mice, and that HET mice displayed roughly 50%
expression in each case. No specific binding was detected in KO samples, confirming the
selectivity of rimonabant. As discussed in the introduction, the Emax in each tissue should vary
with receptor expression such that high expression will yield high Emax values and low
expression will yield low Emax values. All ligands stimulated [35S]GTPS binding to a greater
degree in cerebellum relative to spinal cord. In cerebellum, WIN55,212-2 elicited the highest
Emax values, but unlike the other agonists tested, it also stimulated G-protein activation in KO
tissue consistent with previous findings (Monory et al, 2002). To quantify and express only CB1mediated G-protein activity, the KO stimulation was subtracted from WT and HET stimulation
for all drugs in cerebellar tissue. With this manipulation, A-834,735D, WIN55,212-2, CP55,940,
JWH-073, and CP47,497 produced similar maximum stimulation in WT samples whereas THC
achieved a relatively lower maximum. In HET samples, the predicted 50% decrease in Emax was
not observed for the three highest efficacy ligands (A-834,735D, WIN55,212-2, and CP55,940),
but rather a 20% decrease was observed. This smaller than expected decrease is likely indicative
of a receptor reserve to produce G-protein activation, which is somewhat surprising. The
stoichiometry of the receptors and G-proteins is important to consider when interpreting these
results. Cannabinoids possess a low degree of efficiency to activate G-protein, with the full
agonist WIN55,212-2 stimulating GDP-GTP exchange at three G-proteins per receptor activated
indicating an amplification factor of 3 (Sim et al, 1996b). It is unknown if this amplification
factor is a general property of cannabinoid receptors or if it is ligand-specific. In spinal cord, the
expected 50% reductions were observed for all ligands except for THC, which did not have
detectable efficacy to stimulate any GDP-GTP exchange in HET tissue. This result indicates low
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receptor reserve conditions similar to apparent low receptor reserve for some the in vivo effects,
though it should be noted the basal activity of spinal cord was nearly twice that of cerebellum
(~4000 counts versus ~2000). This basal activity is likely not due exclusively to CB1 receptors
alone but rather reflects the sum of the constitutive activity of all GPCRs present in the sample
aside from purinergic activity. Whether G proteins are pre-coupled to their receptors remains
contentious, though if this is this case, then the high basal activity in the spinal cord might also
reflect sequestration of a portion of the G-proteins by non-CB1 receptors, functionally reducing
the overall ability of the system to respond to cannabinoid ligands. G-proteins may also affect the
conformation of the receptor they interact with, thereby also potentially affecting the affinity of
the ligand for the receptor. Kenakin illustrates this by demonstrating the discrepancy between the
use of agonist versus antagonist radioligands to measure affinity under conditions where [G] <
[RT], [G] = [RT], and [G] >>> [RT] (Kenakin, 1997). Presuming an agonist favors the G-protein
bound state, low [G] would reduce the potency of agonists while high [G] would increase
potency. While the EC50 values reported here do vary somewhat between brain regions for some
agonists, no discernable pattern emerged to suggest this to be the case. Overall, the results were
expected in both cerebellum and spinal cord.
4.3

Differential sensitivity of catalepsy, hypothermia, and antinociception in the

cumulative dosing CB1 efficacy determination model
The cumulative dosing cannabinoid triad procedure revealed differential sensitivity of
each endpoint to a 50% reduction in CB1 receptor expression. The hypothesis that efficacy would
vary inversely with the potency shifts measured between WT and HET mice was tested, with KO
mice serving to detect any non-CB1 effects for each measure. As an ancillary goal, this procedure
was designed as a high throughput method to test in vivo efficacy of novel, putative
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cannabimimetic ligands. Catalepsy, hypothermia, and antinociception are likely mediated by
distinct CNS regions, which may account for observed differences among the measures.
Antinociception was the most sensitive of the three triad measures to a 50% reduction in
CB1 expression, and it was the only measure to display graded downward shifts in the dose
response curve. The choice of a 10 second cutoff for tail withdrawal latency avoids tissue
damage that could confound results, especially in repeated testing situations such as time course
or cumulative dosing studies. Animal welfare concerns also limit the duration of testing, as tissue
damage may occur at temperatures above 52C or if the cutoff extends beyond ten seconds.
Though raising the time limit may better differentiate between high efficacy ligands it would
preclude the use of repeated testing to avoid tissue damage. The intensity of the stimulus (i.e.
temperature of the water bath) is another variable which can be manipulated. As in the case of
the 10 second time limit, the upper limit of the temperature was chosen to allow repeated testing
and avoid confounding tissue damage. However, an alternative approach to differentiate between
high-efficacy cannabinoids ligands such as A-834,735D and WIN55,212-2 would be to raise the
stimulus intensity to elicit antinociception (e.g., increase the temperature of the hot water
noxious stimulus). Although drugs of moderate efficacy may begin to resemble THC (i.e. no
effect in HET mice), resolution would be gained at the top of the efficacy continuum. Reducing
the stimulus intensity by reducing the temperature should have the opposite effect, in essence
causing greater differentiation between low-efficacy compounds but less differentiation between
moderate and high-efficacy compounds.
The tail-flick response (D’Amour and Smith, 1941) is a spinal reflex conducted primarily
by fast conducting A fibers from the source of the noxious insult to the dorsal horn. From there,
the signal is transmitted along the spinothalamic tract to the thalamus, and parallel fibers project
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along the spinomesecephalic tract to the PAG. Descending projects from the PAG through the
rostroventromedial medulla to spinal neurons provide top-down control of the reflex (Morgan et
al, 2008). Importantly, CB1 is expressed in the dorsal root ganglion (Bridges et al, 2003), the
dorsal horn (Farquhar-Smith et al, 2000), and the PAG (Herkenham et al, 1990) with appreciable
abundance, although its expression in the PAG is somewhat higher than in spinal cord. When
utilizing CB1 HET mice, expression was 50% of that observed in WT mice. Given that CB1
expression is already relatively low, receptor reserve may have been depleted sufficiently to
detect downward shifts in the dose-effect relationship in HET mice. Indeed, the low–efficacy
agonist THC did not produce dose-dependent increases in tail withdrawal latency in HET mice
while doing so with relatively low potency in WT mice compared to the other agonists tested.
CP47,497 and JWH-073 did elicit dose-dependent increases in tail withdrawal latency in HET
mice but did not achieve above a 50% effect to allow ED50 potency comparisons. CP55,940,
WIN55,212-2, and A-834,735D all achieved maximal effects in HET mice though they did so
with varying potency. The final efficacy rank order was similar to the hypothesized order (A834,735D ≥ WIN55,212-2 > CP55,940 > JWH-073 ≥ CP,47497 > THC), though the decline in
potency was much steeper when compared to hypothermia. This finding suggests the tail
withdrawal assay under these conditions has the highest efficacy requirement of the three
endpoints, though this sensitivity may be adjusted as discussed above.
Hypothermia displayed modest shifts in dose-effect curves between WT and HET mice
for the synthetic cannabinoids tested, whereas THC did not elicit CB1-mediated reductions in
body temperature in HET mice. The observed distribution of efficacy was consistent predicted in
vitro results (A-834,735D = WIN55,212-2 ≥ CP55,940 ≥ JWH-073 ≥ CP,47,497 > THC), though
only CP47,497 differed significantly from the other synthetic cannabinoids. The hypothermia
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measure provides a somewhat gradual separation of potency ratios with declining efficacy, and
therefore, it may be useful for differentiation of agonists with moderate to low efficacy. This
moderate gradation of efficacy may be due in part to the relatively moderate expression of CB1
in brain areas reported to modulate body temperature, notably the preoptic area (POA) of the
anterior hypothalamus (AH) (Rawls et al, 2002) and possibly the periaqueductal grey (PAG)
(Lichtman et al, 1996). The density of CB1 expression in these brain areas is approximately 2
pmol/mg in rats (Herkenham et al, 1990). Based on the observation that a 50% reduction in CB1
expression resulted in significant rightward shifts in the dose-response curves of cannabinoids
tested suggest that hypothermia is a sensitive measure to differentiate between ligands of varying
efficacy. These brain regions may also dynamically interact with one another as there are
descending neuronal projections from the AH to the PAG and ascending projections in the other
direction, though the interplay between these structures in regards to thermoregulation in the
context of cannabinoids remains to be elucidated.
Ceiling effects for hypothermia measure were arbitrarily imposed based upon
observations during pilot studies, in which an 8C drop in body temperature was observed to
coincide with maximum effects in the catalepsy and antinociception. Maximum hypothermia
values actually observed sometimes reached -12C for individual animals, though mean values at
maximum doses tended to not exceed -10C from baseline across drugs. It is possible an
adjustment of the ceiling to -10C or -12C may reveal apparent differences in Emax between
ligands that vary in efficacy, though this may preclude calculation of potency ratios in cases of
moderate- to low- efficacy ligands, for which the calculated maximum percent effect does not
sufficiently sample the linear portion of the dose-effect relationship.
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The catalepsy measure was the most resistant to a 50% reduction in CB1 expression and
did not display potency ratios that diverged appreciably from a ratio of 1 for all drugs tested.
Even THC, which is generally regarded as a very low-efficacy cannabinoid, displayed a very
small shift in the dose-effect curve between WT and HET mice. The experimenter-imposed
ceiling, underlying receptor expression, and multiple neural circuits mediating motor control
may contribute to this apparent lack of sensitivity to reductions in CB1 receptor population.
Catalepsy is described as a fixed, rigid posture that is measured in seconds of immobility in
either the ring or bar test. Here, we measured the latency of a given mouse to remove its
forepaws from the elevated bar four times. For these experiments, a 60 second window was used
to quantify this response to cannabinoids, so an ED50 represents the effective dose to produce 30
seconds of immobility. The actual duration of catalepsy many last for many minutes beyond the
initial observation period, and as a result the maximum effect engendered by administration of
each agonist to produce immobility was not measured. Practical considerations prevent the
prolonged study of catalepsy in the context of the triad but it should be noted that the
“maximum” effect reported here does not reflect a natural resolution of the cataleptic response
but rather an experimenter imposed limit. Regardless, the potency ratios between WT and HET
mice are the primary endpoint of interest and the small shifts elicited likely speak to the
underlying receptor expression and/or neurobiology of the behavior.
The CB1 receptor is expressed at very high densities in striatal regions of the midbrain in
the rat (Herkenham et al, 1990), and expression in WT (3.33 ± 0.13 pmol/mg) and HET (1.89 ±
0.14 pmol/mg) mice are comparably high (Selley et al, 2001). Additionally, the receptor reserve
to produce catalepsy is quite high as only a small fraction of receptor must be occupied to
produce immobility (Dhawan et al, 2006). Thus, even under condition where 50% of the
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available receptor pool is eliminated, the number of receptors needed to achieve a maximum
effect remains well above what would be necessary to effect a large shift in potency. However,
this apparent large receptor reserve does not entirely account for the differences among the
ligands in HET mice. These mice showed no decreases in potency as measured by overlapping
confidence limits for ED50 estimations. The rank order of the shifts in potency measured (JWH073 ≥ A-834,735D ≥ CP47,497 ≥ CP55,940 > WIN55,212-2 ≥ THC) are also intriguing as they
do not align with the predicted order (A-834,735D ≥ WIN55,212-2 > CP55,940 > JWH-073 >
CP47,497 > THC). Although variability must remain a consideration, this may reflect differences
in signaling events that are sufficient to produce catalepsy and are differentially activated by
these compounds.
Cannabinoid signaling in the striatum and output neurons is a complicated web of
signaling events that involves subregions such as the caudate-putamen (CP), the internal and
external globus pallidus (GPi and GPe), entopeduncular nucleus (EP), and the substantia nigra
(SN). The CP receives excitatory input from the neocortex and sends GABAergic projections to
the GPi, GPe, EP, and SN. From there, dopaminergic neurons from the SN project back to the
CP, while GABAergic neurons from the SN as well as the GPi project to the thalamus, which
then projects back to the neocortex. In addition, the GPe and the SN send GABAergic
projections to the subthalamic nucleus, which contains excitatory inputs back to the GPe, GPi,
SN, and and EP. CB1 expression is most abundant on excitatory glutamatergic neurons and
inhibitory GABAergic neurons, and as a result there are many levels of regulation of synaptic
transmission exerted by cannabinoids in this neuronal network. Microinjections of a CB1 agonist
into the GP suppressed locomotor activity, whereas microinjections into the SN stimulated
locomotor activity (Sañudo-Peña et al, 1999), and systemic injections seem to produce biphasic
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stimulation at low doses and stark locomotor suppression and catalepsy at doses exceeding 2.5
mg/kg (Sañudo-Peña et al, 2000). The exact relationship between the neurocircuitry in the
striatal regions and the resulting behavior remains complex and poorly understood. However,
systemic injections that produce global activation of CB1 receptors seem to produce primarily
inhibition of locomotor activity.
. Although the neurocircuitry is quite complex, CB1 receptor expression in these regions
remains quite high even in HET mice relative to other brain regions. Thus doses required to
produce catalepsy would be expected to be similar in WT and HET mice, even in the case of a
low efficacy agonist such as THC. Although the other agonists did not display the expected
pattern of efficacy distribution, THC did elicit the largest (~2 fold) shift, consistent with the
hypothesis.
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Figure 35. Adapted from Breivogel and Childers, 1998. This schematic displays the
neuroanatomical projections among striatal structures. CB1 receptors are highly expressed
throughout striatal structures on GABAergic and glutamatergic neuron terminals, represented by
+ and - symbols.
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4.4

Potential limitations of the of the in vivo CB1 efficacy determination model
The cumulative dosing employed possesses limitations relative to dosing with separate

groups of subjects (as discussed in the Introduction). Tachyphylaxis could certainly exacerbate
potency differences, especially for low efficacy drugs, and variance in the pharmacokinetics of
the test drugs could result in different optimal pretreatment times. Regardless, the half-lives of
cannabinoids are in general quite long, and time-course studies revealed a long duration of action
of all drugs tested using relatively high doses. Additionally, in the case of THC, cumulative
dosing yields relatively similar brain levels as compared to a bolus dose 20 minutes prior to
harvest (Falenski et al, 2010). That said, the pharmacokinetic and pharmacodynamic information
regarding many compounds utilized in these studies is not well explored, and will not be
examined for clandestinely synthesized SCs in the future. Generally, the half-lives of
cannabinoids tend to be quite long, often on the order of hours, thus cumulative dosing is often
applicable. However, there may be SCs which possess considerably shorter duration of action;
therefore, rigorous assessment of peak effects along with adsorption, distribution, metabolism,
and excretion will likely be necessary to further validate the model. This is especially true for
CB1 HET mice, given the paucity of information regarding specific cannabinoid actions in that
context.
The in vivo determination of efficacy at the CB1 receptor under these conditions is not
able to differentiate between downstream signaling events, but rather, each dependent measure
reflects the a function of all of the relevant signal transduction and associated biochemical events
that occur to elicit a response. For instance, if interplay among multiple CB1-mediated pathways
(e.g. G-adenylyl cyclase-PKA, G-GIRK channels, BARR2-ERK1/2) ultimately determines
antinociception in the tail flick procedure, agonist-stimulated [35S]GTPS binding alone will only
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account for part of the biochemical signaling. The drugs chosen for these experiments span the
efficacy continuum, although only one biochemical correlate of functional CB1 (agoniststimulated [35S]GTPS binding) activity was selected as a correlate. This decision was largely
due to the relative abundance of knowledge regarding this signal transduction pathway in ex vivo
preparations including acute activation and diminished activation after rats or mice were made
tolerant. These data correlate well with in vivo effects, though given recent findings, it is unlikely
these cannabinoids act solely via the canonical G-protein pathway. Whether the GDP-GTPS
exchange accurately accounts for the in vivo effects could be investigated more thoroughly in
theory, although the relative paucity of highly biased, bioavailable CB1 ligands precludes this
sort of investigation at this time.
Although both sexes were used in all cumulative dosing triad experiments, sex-related
differences among the ligands were sparse and did not conform to a discernable pattern (Table
8). Although the total number of mice used for each experiment (n=7-10 per genotype) was
sufficient to detect meaningful differences among genotypes, an even split between sexes
resulted in half that number when separated for analysis of sex effects (n=3-5). As a result, these
comparisons were likely underpowered. Thus any significant differences detected between sexes,
among genotypes, may not be meaningful. Future studies could focus on ascertaining the
veracity of these sex differences, both by increasing the sample size as well as monitoring
estrous cycles in females. Gonadectomies could also provide a useful method to interrogate sex
hormone effects of various SCs tested should sex differences be detected.
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THC
Catalepsy
Hypothermia
Antinociception

WT
ns
ns
ns

HET
ns
ns
ns

KO
ns
ns
ns

CP47,497
Catalepsy
Hypothermia
Antinociception

WT
ns
ns
ns

HET
30
ns
100

KO
ns
ns
ns

JWH-073
Catalepsy
Hypothermia
Antinociception

WT
ns
ns
ns

HET
ns
ns
ns

KO
ns
ns
ns

CP55,940
Catalepsy
Hypothermia
Antinociception

WT
0.3
ns
ns

HET
ns
ns
ns

KO
1, 3
VEH
ns

WIN55,212-2
Catalepsy
Hypothermia
Antinociception

WT
ns
ns
ns

HET
ns
ns
ns

KO
ns
ns
ns

A-834,735D
Catalepsy
Hypothermia
Antinociception

WT
1
ns
ns

HET
ns
ns
ns

KO
ns
ns
ns

Table 8. Two-way ANOVAs followed by Holm-Sidak post hoc analysis were conducted
between males and females in WT, HET, and KO mice for the catalepsy, hypothermia, and
antinociception measures. Significant differences were found for CP47,497, CP55,940, and A834,735D, but not for THC, JWH-073, and WIN 55,212-2. Group sizes were small (n=3-5), thus
Type I and Type II errors could not be ruled out in each case. NS indicates no significant
ANOVA, all other symbols indicate specific doses for which significant sex differences were
detected.
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4.5

Correlations of agonist-stimulated [35S]GTPS binding with in vivo data: the

potential for alternative pathways
The underlying purpose of GTPS binding experiments was to discover the degree to
which G-protein activity correlated with each of the triad measures. Especially when considered
in the context of the agonist-antagonist interaction studies, these correlations would help reveal
whether the potency shift observed between WT and HET mice in vivo correlated with actual
differences in Emax measured in vitro. For in vivo data, dose ratios were calculated by dividing
the WT ED50 by the HET ED50 for each triad measure and then plotted against the WT Emax from
in vitro experiments. Correlations emerged for the hypothermia and antinociception measures
under low receptor density conditions, suggesting G-protein activation as the primary signal
transduction pathway for CB1-mediated hypothermia and antinociception. Additionally, losses in
potency in HET mice are related to reductions in functional activity at CB1 in vitro.
There are numerous alternate pathways documented in addition to Gi/o inhibition of
adenylyl cyclase activity. After dissociation of the  subunit from the G-protein heterotrimer, the
 dimer can interact with GIRK channels (Ho et al, 1999), and BARR1/2 recruitment is also
possible, which can interfere with G-protein coupling (Breivogel et al, 2013), spur
internalization (Daigle et al, 2008b), or recruit other pathways such as ERK1/2 (Flores-Otero et
al, 2014). The results of Flores-Otero and colleagues are particularly intriguing as they suggest
lengthy exposure to cannabinoid agonists shift signal transduction away from G-proteins and
towards BARR2-mediated ERK1/2 phosphorylation. Utilizing radioligand binding techniques
with high concentrations of MgCl2 greatly extends the length of time that GTPS remains bound
to the G-proteins, which likely does not reflect the physiological equilibrium between GDP and
GTP which occurs in vivo, and more importantly, would not capture this shift. This has the
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additional consequence in the case of cumulative dosing, where prolonged exposure to the drug
could result in measurement of multiple pathways at once, each dose possessing its own
independent time courses to shift the equilibrium.
4.6

Lack of acute abuse-related facilitation or withdrawal effects in ICSS by CP55,940
Testing with the synthetic cannabinoid CP55,940 in the ICSS assay revealed no evidence

for facilitation at any dose tested. Two high doses were tested in time course studies and revealed
exclusively rate-suppressing effects for the duration of the testing period. Pretreatment with
rimonabant reversed the rate-suppressing effects, indicating a CB1-mediated mechanism of
action. All of these results point to a lack of abuse liability for CP55,940 that is consistent with
other reports for the same drug and other synthetic cannabinoids (Arnold et al, 2001; Vlachou et
al, 2004). To date, only THC over a low and narrow dose range has displayed facilitating effects
in ICSS. Species and/or strain differences may play a role as facilitation has only been shown in
Lewis and Sprague-Dawley rats (Gardner et al, 1988; Katsidoni et al, 2013).
Given the abundance of cannabinoid abuse in humans, these results remain perplexing. It
may be that ICSS is not well-suited to measure the abuse-related effects of THC and other
cannabinoids. Another option is related to the relatively small facilitation of ICSS observed after
dosing with cannabinoids. The ratio of signal to noise may preempt the ability to measure the
abuse related effects. As discussed in the introduction, other assays of abuse liability also display
mixed results when testing for abuse liability, so perhaps this is not surprising. Although
humans, rodents, and non-human primates possess similar reward circuitry, there may be an
aspect of the human experience of marijuana use that is not readily measured in preclinical
assays. Thus, the majority of experiments using conventional preclinical assays of abuse
potential fail to capture the apparent abuse-related effects that relate to human use.
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4.7

Tolerance, but not dependence, following repeated administration of CP55,940 in

ICSS
ICSS has been previously employed to measure tolerance and dependence for opioids
(Altarifi and Negus, 2011), cocaine (Stoker and Markou, 2011), and nicotine (Stoker et al, 2012).
This type of assay has also been performed following 22 days of administration of WIN55,212-2,
although no evidence for tolerance or withdrawal related changes in rates of responding were
detected (Mavrikaki et al, 2010). Conversely, rats repeatedly dosed with THC displayed
tolerance to the rate-decreasing effects, though they did not exhibit rate-increasing effects at any
dose nor evidence or withdrawal and/or dependence (Kwilasz and Negus, 2012). These results
are interesting in the context of the results reported here with CP55,940 in which partial
tolerance to the rate-decreasing effects occurred. In our studies, WIN55,212-2 maintained most
of its efficacy to elicit triad effects, while CP55,940 produced slightly larger losses in potency in
CB1 HET mice implying that WIN55,212-2 is more efficacious in the whole animal. Given that
both Mavrikaki et al. and our ICSS experiments utilized fixed doses, it is possible compensatory
mechanisms would reduce the receptor population and the higher efficacy ligand could still elicit
rate-decreasing effects of the same magnitude, whereas the somewhat lower efficacy
cannabinoid would display some tolerance. Varying the dose of THC during repeated
administration does result in differing degrees of tolerance to rate-decreasing effects, though no
signs of dependence were unmasked similar to our results (Kwilasz and Negus, 2012).Repeated
administration of a single dose of an agonist to produce tolerance does not, however, provide any
information as to the loss of potency. In each case described above, cumulative dose-effect
experiments before and after the repeated treatment with the selected agonist would have been a
more effective approach. Still more effective would have been to vary the efficacy of the drug
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used for the preceding and flanking potency assessments as has been done with drug
discrimination (Hruba et al, 2012), or to vary the efficacy of the tolerance-inducing agents. An
expanded approach might include varying the dose of the toleragen at ED16, ED50, and ED84
values to assess the dose-response relationship to induce tolerance. Regardless, efficacy might be
an important determinant in the tolerance to the rate-decreasing effects of cannabinoids, but the
abuse-related rate-increasing effects seem to only be detectable utilizing the low-efficacy ligand
THC, and even then rather unreliably.
To test for dependence, both spontaneous and precipitated withdrawal experiments were
performed following the same dosing regimen (0.3 mg/kg CP55,940, i.p., for seven days). In
both cases, no disruptions in baseline responding following cessation of testing were observed,
and rimonabant (10 mg/kg, i.p.) produced no rate-decreasing effects alone or after repeated
dosing with CP55,940. This result is supported in the literature given the relative paucity of
studies reporting significant spontaneous signs of withdrawal. The lack of precipitated
withdrawal may also be related to CP55,940’s ability or lack thereof to produce compensatory
changes in the relevant underlying neural substrates mediating changes in ICSS during
withdrawal. It may simply be that receptor occupancy was not high enough for the potent and
efficacious ligand to engender sensitivity to rimonabant. To test this hypothesis, a higher dose
should be used, though practical considerations must be made in the case of cannabinoids. High
doses of cannabinoids for prolonged periods of time may elicit handling-induced seizures, which
is consistent with CB1 hypoactivity (von Rüden et al, 2015). Although not investigated, electrical
brain stimulation poses a potential risk to animals with already increased susceptibility to
seizures, which may impede the feasibility of these studies. Day to day rate-decreasing effects
are also possible given the long half-life and duration of action of many cannabinoids which may
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also confound sensitivity to tolerance. If none of these limitations are manifested, however, the
relationship of efficacy, tolerance, and dependence for the CB1 receptor may be elucidated.
4.8

Overall Conclusions
In this thesis, I have characterized the relationship of CB1 ligands to cannabimimetic

effects as measured by the cannabinoid triad (catalepsy, hypothermia, and antinociception),
agonist-stimulated [35S]GTPS experiments, and abuse-related effects as measured by ICSS. The
cannabinoid triad represents a novel approach of assessing in vivo efficacy of putative
cannabinoids, endocannabinoids, and potential therapeutics such as anabolic or catabolic enzyme
inhibitors. The cumulative dosing triad in CB1 transgenic mice offers many advantages over
other means of assessing in vivo efficacy. This assay is quick, robust, and experimental
parameters may be easily modified and optimized to ascertain differences along the efficacy
continuum. Additionally, emerging pharmacological tools may aid in the investigation of
downstream mechanisms as they relate to CB1 receptor density. The effect of a noncompetitive
CB1 antagonist could be assessed in WT mice to interrogate receptor reserve for agonists on
different CB1-dependent endpoints, or ligands which possess extreme bias could assess the
relative contribution of various pathways to an in vivo endpoint. Importantly, each endpoint is
differentially sensitive to reductions in receptor population providing insights into the underlying
neurobiology of the endocannabinoid system. Both hypothermia and antinociception appear to be
reliable measure of CB1-mediated G-protein activation in vivo, while catalepsy appears to be a
reliable control for cannabimimetic activity in cases where it has been lost in the other two
measures. Although antinociception and hypothermia are highly correlated with G-protein
activation, multiple CB1-mediated pathways may contribute to in vivo endpoints, which may
have implications for therapeutic application of biased ligands.
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In vitro studies utilizing spinal cord and cerebellum tissue from CB1 WT, HET, and KO
mice demonstrate theoretically anticipated reductions in magnitude of functional activity
concordant with reductions in receptor density. We have also demonstrated for the first time a
dose-effect relationship in CB1 KO tissue with the high efficacy ligand WIN55,212-2. Although
non-CB1 stimulation has been previous reported, this stimulation has not thus far been assessed
in a thorough manner during efficacy determination experiments. These results support the
notion that selectivity of ligands remains important when assessing in vitro versus in vivo effects.
Additionally, five of the six ligands tested here displayed similar efficacy in both high and low
receptor conditions, suggesting that assay conditions could be further optimized to differentiate
ligands of very high efficacy. One way to accomplish this would be to adjust the GDP/GTPS
ratio by addition of either reagent. The presented conditions did not readily differentiate between
A-834,735D and CP55,940 though the expectation based upon preliminary results suggested A834,735D might have been up to twice as efficacious to stimulate binding. Increasing the GDP
concentration should elevate Emax values for most ligands tested, with the highest efficacy
compounds displaying the largest increases (Savinainen et al, 2001).
Though evidence for withdrawal was not detected in ICSS following repeated treatment
with CP55,940, this is the first study of its kind to assess withdrawal-related effects on reward
processes in ICSS for cannabinoids and it serves to expand knowledge related to the topic. It
may be that ICSS is not sensitive to detect cannabinoid withdrawal. Overall, synthetic
cannabinoids are generally more potent and efficacious than THC both in vivo and in vitro. Thus
they carry an increased element of risk when used by humans, especially those users that may
already be tolerant.
4.9

Future directions
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Though the cumulative dosing procedure was used mainly to look at the relationship
between efficacy and potency shifts in CB1 WT and HET mice, this model is quite amenable to
examining efficacy under a variety of conditions. Exogenous cannabinoids can vary greatly in
efficacy and so too can endogenous cannabinoids. Two primary endocannabinoid have been
identified: anandamide (AEA) and 2-arachinodonoylglycerol (2-AG). In agonist-stimulated
[35S]GTPS experiments, AEA has higher efficacy than THC but does not achieve the same level
of activation as synthetic cannabinoids such as HU-210 and CP55,940 (Burkey et al, 1997a). 2AG is much higher in efficacy than even some synthetic cannabinoids, especially under
conditions of very high GDP concentrations (Savinainen et al, 2001). Exogenous administration
of AEA and 2-AG does not typically produce cannabimimetic effects as they are rapidly
catabolized by fatty acid amide hydrolase (FAAH) (Giang and Cravatt, 1997) and
monoacylglycerol lipase (MAGL) (Dinh et al, 2002), respectively. The advent of selective
pharmacological inhibitors of both FAAH (Ahn et al, 2009) and MAGL (Niphakis et al, 2013)
will afford the ability to assess the in vivo efficacy of AEA and 2-AG in WT and HET mice.
Pretreatment with an enzyme inhibitor will allow the accumulation of exogenously administered
endocannabinoids, and the transgenic triad model can then be used to provide information about
the functional in vivo activity of both AEA, 2-AG, as well as other endocannabinoids, such as
noladin ether (Hanus et al, 2001), or hemopressin (Heimann et al, 2007). Importantly, CB1 KO
mice distinguish between CB1 and non-CB1 actions of these and other ligands.
With the ongoing discovery of clandestinely synthesized cannabinoids, a need exists to
rapidly assess these compounds for their in vitro and in vivo potency and efficacy. The
procedures outlined here provide a systematic, high throughput approach to screen the huge
variety of novel structures available. A library of compounds already exists to conduct structure
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activity relationships for the novel backbone structures being produced. Many changes in
structure are small, such as fluorination or chlorination, which result in a decrease in
susceptibility to be detected and to evade scheduling. Interestingly this has resulted in SAR
relationships to reduce detection, but the pharmacological implications of these changes have not
yet been investigated. For instance, UR-144, XLR-11, and A-834,735 are structurally related
CB1 ligands produced by Abbott Laboratories, and each possesses a heat degradant in which the
tetramethylcyclopropyl ring opens. This change renders them much more efficacious to stimulate
GTPS binding, but this does not capture the entire biochemical chain of events from receptor
binding to behavior that would be assessed in the CB1 transgenic triad. It is unknown why this
change results in such a large increase in efficacy, but the degree to which it relates to efficacy
for a variety of biochemical assays would be interesting to study alongside the triad. Many
synthetic cannabinoids agonists have nanomolar affinity for CB2 as well as CB1, and as a result a
similar approach using CB2 transgenic mice (Buckley et al, 2000) may also be used for CB2
relevant endpoints including inflammatory or neuropathic pain and the loss of potency in CB2
HET mice. The feasibility of cumulative dosing is an empirical question that can be answered
systematically to determine the effect of repeated testing and repeated injections versus
cumulative treatment with a potentially therapeutic ligand.
As discussed above, ICSS might not be well-suited to measure cannabimimetic abuserelated effects. CPP and SA are likely not good candidates either, but the drug discrimination
procedure provides an alternative option. While not strictly an abuse liability assay,
cannabimimetic agents such as nabilone (Lile et al, 2011) substitute for THC in humans, and
many cannabimimetic agents display substitution for THC (Wiley et al, 2014, 2015), and vice
versa (Järbe et al, 2012, 2014). Importantly, this substitution occurs in a CB1-dependent manner
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for humans (Huestis et al, 2001), non-human primates (McMahon, 2006), and rodents (Järbe et
al, 2011). Therefore, drug discrimination represents one of the better options to assess the
subjective effects of putative cannabinoids and by proxy their abuse liability. Although CB1 KO
mice would be unlikely to acquire a cannabimimetic agent as a discriminative stimulus, CB1 WT
and HET mice likely would providing the unique opportunity to assess the effect of receptor
density on the discriminative properties of cannabimimetic agents. The intensity of the CB1
stimulus may also be controlled by varying the training dose of the cannabimimetic agent and
looking at differences in potency to substitute for the training drug in CB1 WT and HET mice.
Utilizing a very high efficacy CB1 ligand such as A-834,735D, one could fade the training dose
of the test drug, and at each level of the training drug a selection of agonists which vary in
efficacy could be assessed. The hypothesis that very high efficacy drugs would maintain their
potency better than low-efficacy drugs at low training is testable, and results would permit
inferences into the mechanisms underlying substitution. Consistent with the anatomical
distribution of CB1 expression, generalization from cannabimimetic agents appears to be a
centrally mediated phenomenon (Järbe et al, 2011), and as a result the cannabinoid abuse
liability of these agents may be inferred. Another alternative approach would be to use THC as
the discriminative stimulus, providing a low efficacy ligand to fade, and assess the maintenance
of potency by high efficacy cannabinoid ligands in HET mice.
The effects of SCs upon dependence-related phenomenon are not well-characterized. One
approach to explore this aspect of their pharmacology is to conduct rimonabant-precipitated
withdrawal studies and vary ligands based upon efficacy. Receptor occupancy seems to drive
tolerance in the case of opioids (Pawar et al, 2007), though similar studies have not yet been
conducted for cannabinoids, and the relationship between efficacy and the severity of withdrawal
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has not yet been explored. Utilizing the cumulative dosing triad as a guide for efficacy and
potency determinations, one could compare the impact of repeated administration of these drugs
on adaptive changes at the CB1 receptor. From there, the dose-response relationship of
rimonabant to precipitate spontaneous signs of cannabinoid withdrawal (e.g., paw flutters and
head shakes) may reveal differences among the agonists differing in efficacy. It remains
unknown whether repeated administration of highly efficacious SCs would result in a greater
magnitude of observed withdrawal signs. In this design, the use of CB1 KO mice will be critical
to control for potential off-target effects that might occur with high doses of SCs given
repeatedly. Other aspects of withdrawal could be captured with measures of anxiety-like
phenotypes (e.g. marble burying or elevated plus maze) or assays of learning and/or memory
(e.g. Morris water maze or object recognition tasks).
SC will likely continue to be a public health problem for years to come, and so long as
clandestine chemists synthesize novel cannabimimetic agents there will be a need to assess both
their basic pharmacological properties as well as potential abuse-related effects. Though overall
use seems to be declining, severe health complications associated with SC abuse continue to
arise (Debruyne and Le Boisselier, 2015). Here, we utilized CB1 transgenic mice to elucidate
differences in efficacy in an in vivo model of cannabimimetic activity, while utilizing ICSS as an
assay of abuse liability. Overall, this in vivo approach effectively stratified agonists of varying
CB1 efficacy that showed a strong positive relationship with efficacy in the in vitro model of
cannabimimetic activity, and would have excellent utility to assess CB1 efficacy of emerging
SCs, endogenous cannabinoids, and potential cannabinoid-based medications.
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